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Abstract
Critical Physicochemical Properties for Nanoparticle Toxicity:
Impact of Surface Coating and Size on Particle-Induced Cell Transformation and
Inflammatory Response
Tiffany G. Kornberg
Nanoparticles, which measure 100 nm in at least one dimension, have surged in
development, production, and use for a wide range of applications. However, the rapid pace of
development for these emerging materials with unclear/unknown toxicity profiles makes it
difficult to adequately assess health risk associated with exposure. One critical obstacle
which limits scientific research to fill these critical knowledge gaps is the lack of accurate and
predictive models for nanotoxicology studies, particularly those which involve occupationally
relevant exposure scenarios (pulmonary exposure to low dose of particles in the circulating
air). Typically, animal models are used to assess potential systemic toxicity. However, the time,
cost, and resource heavy methods are insufficient due to the sheer number of new nanoparticles
being produced and used each day. Cell culture-based systems have been suggested as a more
rapid alternative which could be used to predict and rank potential toxicity of such emerging
materials. However, the translation of an existing in vivo study to an in vitro model requires
additional parameters to be considered for experimental design, and a lack to do so may
contribute to the discrepancies and lack of clarity in the existing nanoparticle toxicity literature.
The key objective for my dissertation work was to illustrate how the better integration of in
vitro and in vivo may be used to evaluate potential toxicity of two nano-metal oxides with unclear
toxicity profiles: iron oxide nanoparticles (IONP) and cerium oxide nanoparticles (CONP), as well
as how alterations in specific physicochemical properties may contribute to severity of the
pulmonary adverse outcomes they may induce.
Some studies report IONP to be biologically benign, whereas others have linked
IONP exposure to cancer-related adverse outcomes, including genotoxicity, neoplasticlike cell transformation, and tumor promotion in vivo. To assess this potential toxicity, a
specific IONP (nFe2O3) was evaluated in a physiologically relevant low dose/long term in vitro
exposure model to identify its general toxicity and potential carcinogenic capacity, as well as how
alterations in particle surface chemistry (with the addition of an amorphous silica coating) may
impact overall toxicity. Results were compared to previously published in vivo data which showed
nFe2O3 would promote tumor formation in mice.
CONP has a similarly unclear toxicity profile, with some studies suggesting CONP may
reduce oxidative stress, whereas others show this particle to induce robust oxidative
stress and inflammatory response. The chemical composition and valence state of CONP is
known to be a critical component to its toxicity, and the inability to control for this in
previous studies likely obscured any other physicochemical properties which may also play a
role. Therefore, we evaluated size dependent toxicity of CONP using chemically identical particles,
including their ability to induce inflammation, pro-fibrotic, and potential systemic toxicity within
an occupationally relevant in vivo exposure model. Corresponding dose was used in an in
vitro model system for a better understanding of potential mechanism underlying these
outcomes, as well as to illustrate the potential use of an in vitro/in vivo integrated model
system.

Overall, my dissertation study results showed that an occupationally relevant low dose/long term
exposure to IONP would induce neoplastic-like cell transformation in human bronchial epithelial
cells, which was dramatically reduced with the alteration of its surface chemistry with an
amorphous silica coating; Alteration of CONP size affected its inflammatory and pro-fibrotic
response in male C57BL/6J mice, with smaller sizes inducing a robust and sustained
inflammatory response, while larger sizes induced a milder response but with increased fibrotic
potential.
These results clearly show the impact of specific physicochemical properties on
overall toxicity profile, as well as the importance of careful physiologically relevant model design
for better in vitro to in vivo translation, with the ultimate goal of protecting those at risk of
exposure to these new materials with unclear/unknown toxicity profiles.
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Chapter 1: Introduction
1-1. Nanoparticles: general
Nano-sized particulates, which measure 100 nm or less in at least one dimension, are known to
be incidentally released from industrial anthropogenic activities such as mining or welding. More
recently, it has been discovered that when particles are specifically engineered to be on the nanoscale, they can take on unique properties which allow them to be utilized in a wide range of
technological applications. For example, carbon based nanomaterials are lightweight but have
enhanced tensile strength for use in building materials1,2. Cerium-oxide nanomaterials are being
pursued as diesel additives to reduce emissions and improve fuel economy3. Nano-sized iron oxide
has paramagnetic or super-paramagnetic properties, which allow for their utilization in MRI
imaging techniques and targeted drug delivery systems4.
This knowledge has led to a surge in development of a rapidly expanding cohort of different
types of nano-materials, with exciting potential for incorporation into consumer products,
building materials, advanced biomedical treatment techniques, and more. In fact, even though
nano-enabled products have only entered the marketplace within the last few decades, the nanotechnology market in the United States is expected to reach or exceed $125 billion by the year
2024 5.
However, the unique properties of engineered nanomaterials, as well as the rapid surge in
their production and use, has led to increased risk of exposure for certain populations. In
particular, workers involved in the manufacture and incorporation of particles at the beginning of
their life cycle, or the processing and recycling of these materials towards the end of their lifecycle,
may be at greatest risk of pulmonary exposure to particles which have a poorly understood
toxicity profile. The expansion and development of new types of particles is occurring so rapidly
that traditional methods of toxicity assessment are unable to sufficiently assess potential risk,
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leading to critical knowledge gaps as to any potential hazards which may be associated with these
new and emerging materials.
In general, it is believed that nanoparticles are able to induce more toxicity on a per mass basis
than their fine (100-2500 nm6) sized counterparts, largely due to an increase in surface area7. This
increased surface area is also known to affect bio-distribution8, particle translocation9, and
particle uptake/elimination10, all which may also impact overall toxicity8. Other properties, such
as surface charge/functionalization, particle shape, aspect ratio, and dissolution, may also affect
toxicity11. How or which specific physicochemical properties may contribute to particle-induced
adverse outcomes are somewhat unclear from the existing literature, and if better understood,
could be used to inform particle design and overall reduce risk for those who may be exposed.
For a better understanding of the potential hazards associated with engineered nanomaterials,
my dissertation focused on two key nano-metal oxides, which have potential applications in a
wide variety of fields, as well as known risk of exposure for vulnerable workers.
1-1a. Iron Oxide Nanoparticles
Fine or micron size iron oxide has been used in a wide array of applications, including
medicine, electronic tape, tattoo inks, and catalysts12,13. Specific types of iron oxide (Fe2O3 and
Fe3O4) can be purposefully engineered to be less than 100 nm in diameter, and possess unique
paramagnetic or superparamagnetic properties at sizes of 10 nm or less. Because of this, iron
oxide nanoparticles (IONP) are being incorporated into a wide range of consumer products and
industrial applications including: biomedical (cell labeling, targeted drug delivery platforms, novel
imaging techniques), electronics (circuitry, data storage), transportation (brake systems), and
cosmetics (pigments)14,15.
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IONP are also being developed for use in targeted cancer treatments, MRI imaging
techniques, and as environmental catalysts16, and can also be incorporated into thermoplastics or
other types of materials17. However, despite these surges in production and use of IONP, their
potential toxicity or its underlying mechanism remain unclear and poorly understood.
There have been a number of epidemiological studies which focused on adverse outcomes
in workers who were exposed to fine sized iron oxide. Iron oxide particulates as a mixture of fine
or unknown size are incidentally released from industrial applications such as iron ore mining and
pyrite production, as well as industries which use iron oxide as a pigment or polishing agent, or
involve the mechanical alteration of iron containing products18. These processes release iron
oxide particulates into the circulating air, becoming an exposure risk for workers, including
miners, foundry workers, smiths, and metal grinders7,13. Pulmonary exposure to high levels of iron
is also known to occur via polluted air 19, which has the potential to affect an even larger cohort of
people. More recently, workers involved in the manufacture of Fe2O3-containing materials in
China were shown to be exposed to low levels of Fe2O3 in the circulating air20. Workers in a similar
type of manufacturing plant in Russia had elevated oxidative stress and inflammatory biomarkers
following exposure to a similarly low level of a mostly nano-sized iron oxide aerosol21.
In general, studies have shown the potential for IONP to induce pulmonary adverse
outcomes, including inflammation22–27, pulmonary fibrosis28,29, and genotoxicity in the lung30,31, as
well as extra-pulmonary effects due to particle translocation28,29,32. Furthermore, both iron oxide
and IONP have been tangentially linked to cancer development. Some studies have shown that
iron ore miners, who are known to be exposed to iron oxide via the circulating air, have elevated
risk of lung cancer as compared to a non-mining population33–36. However, confounding factors in
these studies made it difficult to distinguish iron oxide specific effects. Some researchers have
suggested that iron itself plays a critical role in the induction of cancer-related adverse outcomes,
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as well, especially for those who may be exposed to high levels of this metal particulate via
polluted air37. However, due to the limited amount of information available on IONP-specific
toxicity, no exposure limit recommendations specific to the nano/ultra-fine form of iron oxide can
be made. Instead, IONP are currently regulated based on exposure limits and recommendations
for fine sized iron oxide. The National Institute for Occupational Safety and Health (NIOSH) and
the American Conference of Governmental Industrial Hygienists (ACGIH) have a recommended
exposure limit of 5 mg/m3, while the Occupational Safety and Health Administration (OSHA) has a
permissible exposure limit of 14 mg/m3 38. These relatively high exposure limits across agencies
show iron oxide (and, by extension, IONP) is largely considered a “nuisance dust,” meaning the
iron oxide particulate itself is considered non-toxic for humans. This is despite some
epidemiological evidence that associates the inhalation of iron oxide particulates with adverse
respiratory outcomes in exposed workers18,33,39,40. However, the majority of these studies
involved concurrent exposures to other carcinogens, which made it difficult to distinguish iron
oxide specific effects and overall obscuring iron oxide specific toxicity.
1-1b. Cerium Oxide Nanoparticles
Nano-sized cerium oxide (nCeO2) has also become a particle of interest across a wide
spectrum of industries and applications. nCeO2 has been utilized as a glass polishing agent3, in
development for biological and medical fields41, and as a diesel additive to reduce emissions42,43.
Its role as a diesel fuel catalyst indicate an increased exposure risk to aerosolized exhaust particles
for the general public. Several studies have been able to identify high levels of cerium exposure in
populations in close proximity to motor vehicles or major roadways3,44.
However, despite the relatively widespread use of cerium oxide and nCeO2, there is still very
limited toxicity information available. nCeO2 has a somewhat controversial toxicity profile, with
4|Kornberg

some studies suggesting that it has the potential to induce systemic oxidative stress45, whereas
others suggest this particle may actually protect against oxidative stress46,47. The transitional
nature of nCeO2 valence state48 is a key factor in the discrepancies of observed adverse outcomes.
Some workers who are exposed to fine or nano-size cerium oxide via the circulating air were
shown to develop a pulmonary disease known as “cerium pneumoconiosis,” although concurrent
exposures to other types of earth metals during these exposures prevented a cerium oxide-specific
effect from being conclusively shown3. Other studies also indicate nCeO2 exposure may induce
functional changes in alveolar macrophages49, resulting in pulmonary inflammation41,49, fibrosis50,
and chronic lung injury51. However, this has also not been conclusively shown, and no underlying
mechanisms outside of oxidative stress have been suggested or thoroughly explored in the
existing literature.
Cerium and cerium oxide (>100 nm) are also perceived as “non-toxic” particles, as indicated by
the lack of clear exposure limits or recommendations by either OSHA or ACGIH52, although rare
earth oxides have an ACGIH established exposure limit of 15 mg/m3 53. Similar to IONP, there are
also no nano-specific exposure limits for cerium oxide, most likely due to the lack of available
literature on its potential toxicity.
Both CONP and IONP have unclear toxicity profiles with minimal exposure limits or
recommendations, which ultimately fail to protect at risk workers. The discrepancies and lack of
clarity as to actual particle-induced adverse outcomes in the existing literature is likely due to
critical issues in how nanoparticle toxicity is currently evaluated, as well as the sheer number of
different iterations for each of these particles (including changes in surface coating,
functionalization, size, etc.), which prevent adequate assessments from being made for each one.
1-2. Current Methods for Chronic Nanoparticle Toxicity Assessment
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A critical issue for IONP, CONP, and other types of emerging nano-materials is their unknown
toxicity profile. Most nanoparticles are regulated based on exposure limits associated with their
fine sized counterparts until more definitive conclusions about nano-specific toxicity can be made.
The most common techniques to assess new/unknown materials involve whole animal models
and short term/high dose toxicity54. However, these animal studies are both time and resource
heavy, which makes it difficult to keep pace with the rapid development of new and unique types
of nanomaterials using traditional methods55. Long term or chronic animal studies – which are
necessary to better understand particle-induced chronic diseases– are cost prohibitive, preventing
researchers from fully studying these potential adverse outcomes with relation to nanoparticles.
Furthermore, the sheer number of new types of nanoparticles being produced and used each day
make it impossible to adequately test each one using traditional in vivo methods within a
reasonable amount of time.
To address this, some scientists have utilized cell culture methods to better assess potential
nanoparticle toxicity in a more rapid and cost-effective way56. However, this approach can be just
as flawed. For in vitro model systems, there are a number of additional parameters which must be
taken into account in order to ensure results are going to be accurate and predictive of an in vivo
or human response. For example, thorough particle characterization, calculated delivered dose,
cell type used, potential assay interference, and human relevance must all be considered to ensure
results from an in vitro assay can be translated or extrapolated to a human-relevant exposure
scenario57.
One of the most common occupational exposure scenarios involves the inhalation of a low
dose of particles in the circulating air over an extended period of time. This type of chronic
exposure is more likely to result in chronic disease outcomes such as cancer development or
pulmonary fibrosis58. Extended exposure to particle may result in chronic and continuous cell
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injury and induce damage without immediately pathological adverse effects59. Over time, chronic
cell injuries and responding adaptations may accumulate to result in devastating consequences for
workers exposed in these types of scenarios. However, the extended period of time involved in the
development of these types of diseases makes them difficult to study at a pace on par with the
development of new materials.
OECD guidelines for the assessment of chronic conditions require an extended period of time
to conduct the study. For carcinogenesis, as an example, there is one recommended in vivo test
from OECD, and requires two species (usually rodent) with data collected over the animal’s
lifespan (typically 2-3 years)60. These time and resource heavy methods are unable to totally
address the need for carcinogenic assessment of emerging materials. In fact, due to the sheer
number of new materials being produced and used each day, it is becoming increasingly urgent
that more rapid and cost-effective methods are developed to assess the potential for new
materials to induce these types of chronic conditions.
To at least partially accommodate this, OECD has also recommended in vitro cell
transformation assays, which may be conducted on a shorter term basis, and can be used to
predict particle-induced carcinogenicity in vivo61. However, with the development of cell culturebased systems, there are a number of additional parameters which must be accounted for to
ensure accurate and predictive results. When these are not taken into consideration, the result is a
lack of clarity as to actual particle toxicity. There are clear discrepancies in the existing IONP and
CONP literature, and this lack of clarity is not unique to these two nano-metal oxides. Many other
types of nanomaterials have similarly unknown or unclear aspects to their potential toxicity,
particularly for particle-induced chronic disease states. Overall, this reveals the critical need for
better methods of toxicity evaluation for new and emerging materials. More rapid assays need to
be available, but must also be accurate and predictive of an in vivo or human response.
7|Kornberg

1-3. Emerging Techniques for Nanoparticle Toxicity Assessment
There are several critical issues which need to be addressed with the design of in vitro
screening techniques, so these assays can be better utilized to protect those at risk of exposure to
new/emerging materials while keeping up with the rapid pace of nanoparticle discovery and
development56. Tiered toxicity screening for nanoparticles is reliant on a true integration of in
vitro and in vivo techniques. If better, more accurate, and more predictive in vitro models can be
developed which will represent an in vivo or human response, these assays can be used to screen a
large number of particles relatively quickly. This would allow scientists to select the most
potentially hazardous ones for further, more in-depth study, and prioritize compounds for future
animal studies57.
However, this type of approach only works if the in vitro models used are accurate and
predictive of an in vivo or human response. Many traditional in vitro techniques give accurate
toxicity results for fine/micron sized materials. However, the unique properties of nano-sized
particles which allow them to be utilized in so many novel applications may also have a unique
impact on obscuring results from these already established in vitro models. As such, there are a
number of additional parameters which must be taken into consideration when designing and
implementing an in vitro exposure for nanoparticle toxicity, specifically.
The first of these is thorough particle characterization. Although primary particle size as a dry
powder should remain the same as long as particles are generated from the same source and in
the same manner, the dispersion of particle in any kind of dosing medium will have a dramatic
impact on particle agglomerate size and shape. Depending on particle zeta potential, and media
protein content and viscosity, particle aggregation and agglomeration may change drastically. If
particles agglomerate in an unexpected way, it may obscure actual particle-induced toxicity. For
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example, if a particle agglomerate was recognized by the cell as a larger structure than the
primary particle size suggests, this would drastically impact observed results62. Therefore,
thorough particle characterization, including hydrodynamic diameter, zeta potential, and surface
area of agglomerates in the cell culture media are all necessary for an in vitro exposure.
Particle dissolution will also have a critical impact on overall toxicity. If a particle readily
dissolves in water or the dosing medium, it is likely that the cells may never come in contact with
the particle itself, making it difficult to determine a particle specific effect as compared to an ionic
compound effect. Therefore, it is important to determine particle dissolution in its storage
medium (e.g. water), delivery media (e.g. cell culture media), and once inside the cell, if possible
(e.g. phagolysosome-like buffer). For IONP, in particular, the rate of dissolution is known to have
an impact on IONP induced adverse effects, and varies quite a bit based on the type of particle
generated and the specific medium used63.
Particle deposition rate will dictate the dose which is actually delivered to cells in an in vitro
model system. If the calculated delivered dose varies significantly from the known administered
dose, this could also obscure particle toxicity. In fact, many new types of nanomaterials, including
clays, thermoplastics, and other platelet shaped particulates, are buoyant, and may never actually
deposit onto cells. More recently, particle deposition rate has been modeled using the Distorted
Grid (DG) dosimetry modeling system64–66, which takes into account specific factors such as
particle effective density, media protein content, and media viscosity, to calculate delivered dose.
Another parameter which could also have an impact on results in an in vitro model system is
cell type. For example, in the lung, response to foreign particle exposure relies on chemical
interactions and communications between a vast array of cell types. Due to the complexity of this
system, it can be difficult to replicate using cell culture models. There are several types of in vitro
model systems which have been used in an attempt to replicate this, including mono-culture (one
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cell type), co-culture (two cell types), multicellular spheroid model systems, and even “organ-ona-chip” methods67. Although each of these model systems has clear advantages and disadvantages,
one of the most necessary criteria that should be taken into consideration is the use of a relevant
cell type, including disease state, species, and location in the body, in relation to the specific
toxicity endpoints which are being studied. This is highly dependent on the overall goal of a study.
For example, if the goal of a study is to assess IONP response in a healthy individual, only cell lines
derived from a healthy individual should be used. If the goal of a study is to assess IONP impact on
a particular endpoint, it is important to fully consider which cell types may be involved in that
specific process, and which ones will allow for the most relevant assessment of a human
response68.
Finally, potential assay interference is a critical factor which must be considered for
nanoparticle toxicity studies. Assay interference is relatively common for these types of particles
due to their small size and pigmented properties. For example, Kain, et al.69 noted that a specific
IONP caused observable DNA damage when it was measured via the comet assay, but not when
formamidopyrimidine DNA glycosylase (FPG) sites were used as an indicator instead. The authors
attributed this to IONP interference with FPG, leading to inaccurate results. If particle interference
is not known, measured, and accounted for, this could obscure actual particle-induced toxicity. In
fact, several different types of IONPs have been shown to interact with the components of
cytotoxicity assays70 and cytokine secretion assays71, as well as likely interfere with other types of
assays which have not yet been reported. To counteract this, proper control experiments are
necessary to account for potential particle interference72.
Overall, the goal for any in vitro model system, particularly within the context of a tiered
toxicity screening approach, is to design the model in such a way that it will be representative of
an actual in vivo or human exposure, so that results may be extrapolated to more complex model
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systems. If an in vitro experiment is unable to relate to a physiologically relevant in vivo or human
exposure, it is unnecessary, and may critically contribute to the lack of cohesion in IONP and other
nanoparticle toxicity literature.
1-4. Dissertation
The main objective of my dissertation was to assess toxicity of two types of metal oxide
nanoparticles (nFe2O3 and nCeO2) within the context of physiologically relevant in vitro and in vivo
model systems, as well as how the alteration of specific physicochemical properties may impact
their toxicity. For my dissertation, I hypothesized that changes in specific physicochemical
properties of nFe2O3 (surface coating/chemistry) or nCeO2 (size) would impact their pulmonary
toxicity.
Based on this, my dissertation is divided into key chapters centered around these topics. First,
I delve into what is known about IONP toxicity based on the current literature, and how assay and
model development may impact the uncertainty in its toxicity profile. Then, I utilize these
concepts in a low dose/long term in vitro exposure model, to look at the impact of nFe2O3 on
neoplastic-like cell transformation as a precursor to cancer-related adverse outcomes, as well as
the use of an amorphous silica coating to alter particle surface chemistry, and how that may affect
its toxicity. Next, I utilize nCeO2 within an occupationally relevant in vivo exposure model to
evaluate size dependent effect on pulmonary inflammation, pro-fibrosis, and systemic toxicity, and
compare results to corresponding in vitro studies. Finally, I focus on the potential mechanism
underlying nFe2O3-induced cell transformation with preliminary data and supporting literature, to
suggest potential future directions for this research.
The underlying concept of my dissertation research was to demonstrate examples of in vitro
and in vivo model system integration, and to utilize these for a better understanding of particle11 | K o r n b e r g

induced chronic diseases, such as pulmonary fibrosis or carcinogenesis. A more thorough
integration of cell culture and whole animal model-based techniques would allow for better
assessment of particle toxicity at a pace in concordance with the recent surge in production and
use of nanoparticles in general. For my project, I showed this integration for nFe2O3 by comparing
results to recently published in vivo work which utilized identical or very similar particles. I
showed this integration for nCeO2 within my study, by directly comparing in vivo and in vitro
response using corresponding doses.
To ensure the translational quality of my research, I carefully considered some critical
parameters in model development, as have been previously alluded to. For my in vitro studies,
particle agglomeration and deposition were carefully calculated, and delivered dose was based on
translated occupationally and physiologically relevant doses. Cell type was selected to adequately
represent the type of occupational exposure I was trying to model, and cells were exposed at a low
dose continuously over an extended period of time to better represent chronic exposure
conditions in humans. Potential particle interference was carefully accounted for, and measured
end points were chosen based on relevant OECD guidelines. For my in vivo work, an
occupationally relevant dose was carefully selected, and scaled to a comparable in vitro model
system, again with cell type and experimental design selected to best represent a real-world
exposure scenario.
Overall, the goal of this project was to assess the potential for two different nano-metal oxides
(nCeO2 and nFe2O3) within the context of physiologically relevant in vitro and in vivo models to
induce chronic disease outcomes, as well as how alterations in specific physicochemical properties
may impact this toxicity. The overall impact of this work was to better demonstrate how the
integration of in vitro and in vivo models may be used to better guide tiered toxicity screening
approaches for future materials with unclear or unknown toxicity profiles.
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Chapter 2: Potential Toxicity and Underlying Mechanisms Associated with
Pulmonary Exposure to Iron Oxide Nanoparticles: Conflicting Literature and
Unclear Risk.
Chapter Introduction:
IONP toxicity is a poorly understood topic. As design and production of these particles
increases, so does risk of exposure for workers involved in their manufacture and processing. The
controversial and unclear nature of IONP toxicity makes it difficult to set exposure limit
recommendations. The goal of this review paper was to highlight what is already known about
IONP toxicity, identify critical knowledge gaps in IONP literature, and address ways in which assay
development can be used to generate more accurate and predictive toxicity information for IONP,
all of which could be applied to other types of nano-metal oxides, as well.
Adapted from: T. Kornberg et al., “Potential Toxicity and Underlying Mechanisms Associated with
Pulmonary Exposure to Iron Oxide Nanoparticles: Conflicting Literature and Unclear Risk,”
Nanomaterials, vol. 7, no. 10, p. 307, Oct. 2017.
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Abstract:
Fine/micron-sized iron oxide particulates are incidentally released from a number of
industrial processes, including iron ore mining, steel processing, welding, and pyrite production.
Some research suggests that occupational exposure to these particulates is linked to an increased
risk of adverse respiratory outcomes, whereas other studies suggest that iron oxide is biologically
benign. Iron oxide nanoparticles (IONPs), which are less than 100 nm in diameter, have recently
surged in use as components of novel drug delivery systems, unique imaging protocols, as
environmental catalysts, and for incorporation into thermoplastics. However, the adverse
outcomes associated with occupational exposure to IONPs remain relatively unknown. Relevant in
vivo studies suggest that pulmonary exposure to IONPs may induce inflammation, pulmonary
fibrosis, genotoxicity, and extra-pulmonary effects. This correlates well with in vitro studies that
utilize relevant dose, cell type(s), and meaningful end points. A majority of these adverse outcomes
are attributed to increased oxidative stress, most likely caused by particle internalization,
dissolution, release of free iron ions, and disruption of iron homeostasis. However, because the
overall toxicity profile of IONPs is not well understood, it is difficult to set safe exposure limit
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recommendations that would be adequate for the protection of at-risk workers. This review article
will focus on known risks following IONPs exposure supported by human, animal, and cell culturebased studies, the potential challenges intrinsic to IONPs toxicity assessment, and how these may
contribute to the poorly characterized IONPs toxicity profile.
2-1. Introduction
The field of nanotechnology is expanding rapidly as scientists and engineers continue to
develop innovative applications using nano-scaled materials. For example, iron oxide nanoparticles
(IONPs) have been developed for use in targeted cancer treatment, new imaging techniques, and as
environmental catalysts due to their unique paramagnetic properties 16. They can be incorporated
into thermoplastics and other materials due to their pigmented properties, as well

17.

Iron oxide

particulates (both fine/micron- and ultra-fine/nano-sized) are known to become aerosolized
during anthropogenic activities related to the iron and steel industries, as well as during the
nanoparticle manufacturing process, where they may represent a significant portion of the
circulating air for industrial workers [3, 4]. However, the actual adverse outcomes to human health
induced by iron oxide particulate exposure remain highly controversial. The most common adverse
health outcomes induced by iron oxide include permanent discoloration of the eyes, siderosis, and
pneumoconiosis

38.

Some epidemiology studies also indicate adverse respiratory outcomes and

increased risk of lung cancer following inhalation of iron oxide particulates in an occupational
setting [3, 5–7], whereas other researchers report iron oxide particulates to be biologically benign
34,39,40,74–76.

The exact mechanisms underlying iron oxide particulate-induced adverse outcomes are

poorly understood, but most research suggests they are related to the physicochemical properties
of the iron or iron oxide metal compounds, and are largely due to iron oxide-induced or catalyzed
oxidative stress.
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Iron is a transition metal, meaning it exists in several different valence states, and can form
compounds with other elements such as oxygen. Iron oxides come in three main oxidative states:
FeO, Fe2O3, and Fe3O4. FeO (wustite) makes up a significant component of the earth’s mantle and
may have electrical conducting properties 12. It is also used as a pigment for tattoo inks

13,

and is

involved in the forge welding process. Fe2O3 (hematite) is ferromagnetic, and has two common
structural forms. α-Fe2O3 is rhombohedral and is the most common type of iron oxide mined during
the iron ore mining process

77.

At high temperatures, α-Fe2O3 is converted to the gamma form

(maghemite), which has a cubic structure. γ-Fe2O3 becomes superparamagnetic at sizes of 10 nm or
less, making it relatively popular for biomedical applications. Fe3O4 (magnetite) is ferrimagnetic
and was a primary component in rudimentary forms of the compass

78.

On the nano-scale, Fe3O4

will take on paramagnetic or superparamagnetic properties, which also allow it to be utilized in a
broad range of applications.
Examples of applications that rely on micron/fine-sized iron oxide include: medicine, electronic
tape, pigments, and catalysts. Both γ-Fe2O3 and Fe3O4 can be purposefully engineered to be less than
100 nm in diameter, and possess unique paramagnetic or superparamagnetic properties at sizes of
10 nm or less. Because of this, IONPs are being incorporated into a wide range of consumer products
and industrial applications 14, including biomedical (cell labeling, targeted drug delivery platform,
and novel imaging techniques), electronics (circuitry, data storage), transportation (brake systems),
and cosmetics (Figure 2-1).
Although IONPs are involved in a broad range of applications, their toxicological profile remains
unclear. This review will first focus on what is known of IONPs toxicity based on representative
human, in vivo, and in vitro-based studies. Representative epidemiology studies will be used to
highlight potential adverse outcomes induced by IONPs exposure based on fine/micron-sized iron
oxide reports (summarized in Table 2-1), followed by in vivo and in vitro studies to better ascertain
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IONPs-induced adverse outcomes, as well as the potential underlying mechanism. Then, intrinsic
issues with IONPs toxicity assessment will be addressed, and further clarified how these issues may
contribute to the lack of certainty regarding IONPs-induced adverse outcomes. This review is not
meant to be a comprehensive review of IONPs toxicity literature, but rather a critical evaluation of
the literature that does exist, and why so much of it appears to be conflicting.
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Figure 2-1. IONPs Uses by Humans and Potential Exposure Sources. IONPs are currently being
used in a wide range of fields, including biomedical, electronic, transportation, environmental,
materials, cosmetics, and more. Currently, biomedical uses for IONPs, including cancer therapy,
MRI contrast agents, and targeted drug delivery systems may involve injection into humans.
Cosmetics products may involve dermal application. IONPs use in propellants, or as pigmented
components of coatings/paints may result in pulmonary exposure. However, adverse outcomes
resulting from these exposures remain largely unknown.
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2-2. Potential Toxicity of IONPs Based on Human Studies
2-2a. Mining/Industrial Applications—Fine/Unknown-Sized Iron Oxide
Human exposure to iron oxide particulates, especially for miners and industrial workers, has
been relatively well studied. There are a wide range of industries that involve worker exposure to
fine/micron-sized iron or iron oxide particulates. These include iron ore mining and pyrite
production, as well as industries which use iron oxide as a pigment or polishing agent, or which
involve the mechanical alteration of iron containing products 18. These processes release iron oxide
particulates into the circulating air, becoming an exposure risk for workers, including miners,
foundry workers, smiths, and metal grinders [7, 12]. An occupational exposure is more likely to be
continuous or extended 73, thus potentially leading to exacerbated risk of chronic health conditions.
However, iron or iron oxide dusts often contain quartz or silica

34,

as well as mixtures of other

workplace particulates (e.g., welding), which make it difficult to distinguish iron oxide-specific
effects. Furthermore, the size of the iron oxide released during these processes often varies greatly.
Therefore, the actual adverse outcomes induced by iron oxide particulates in these settings remain
controversial and unclear.
Iron ore mining is known to release iron oxide dust, and many researchers have focused on this
occupation to elucidate the potential adverse outcomes associated with iron oxide particulate
exposure. Boyd et al. 33 found that underground iron ore miners had an almost 75% increased risk
of lung cancer related death as compared to local, non-mining subjects. The authors attributed these
deaths to the potentially carcinogenic effect of iron oxide. Studies which followed iron ore miners
in both Finland 79 and China 36 reported similar outcomes. A lack of ventilation during the mining
process, which leads to increased particulate exposure 36, was used as additional evidence that the
iron oxide particulates released during the mining process were most likely responsible for
subsequent lung cancer-related deaths. However, these three studies also note that an excessive
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amount of radon daughters, as well as the inability to fully characterize particulate size and
composition in the circulating air, made it difficult to conclusively attribute the observed increased
risk of lung cancer to iron oxide exposure, specifically.
Currently, the Occupational Safety and Health Administration (OSHA) has a permissible
exposure limit of 14 mg/m3 for fine iron oxide over the course of an 8 hour workday. The National
Institute for Occupational Safety and Health (NIOSH) set a recommended exposure limit (REL) of 5
mg/m3 for iron (in iron oxide) over a 10 hour work day, while the American Conference of
Governmental Industrial Hygienists (ACGIH) recommended 5 mg/m3 limit for the respirable
fraction of iron oxide over an 8 hour workday 38. However, there is currently no separate REL for
IONPs due to lack of toxicity and hazard assessment, which may put vulnerable workers at risk of
IONPs-induced adverse outcomes. This has become a more critical problem recently, due to the
rapid development and projected influx of IONPs-based applications.
2-2b. Ultrafine and Nano-Sized Iron Oxide
IONPs are currently being incorporated into a wide range of consumer products. As applications
for IONPs expand, there is an increasing concern for potential toxicity induced by these materials,
especially for those who would be exposed in an occupational setting. It is generally believed that
decreasing particle size leads to increasing toxicity on a per mass basis due to increased particle
surface area and number [22, 23]. Therefore, IONPs may have increased potential to induce adverse
health effects as compared to their fine/micron-sized counterparts. However, there is currently
very little known about these potential risks. The limited human data on IONPs toxicity largely
focuses on either occupational exposures to particulate mixtures, which are known to include iron
or iron oxide (such as welding, iron smelting, or steel processing), or workers in IONPs
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manufacturing facilities. Representative studies are presented below, and are summarized in Table
2-2.
There are a large number of mixed particulate exposures that contain iron or iron oxide
particulates, including certain types of welding fumes. Andujar et al. 81 used a cohort of 21 welders
to assess welding fume exposure as a potential cause for observed lung changes in patients. The
authors collected lung samples from 21 welders who had worked for an average of 27 years each,
and compared the tissue to similarly obtained lung samples from 21 matched controls. The welders
were shown to have increased fibrotic lesions and elevated lung iron levels as compared to nonwelders. This was shown in conjunction with iron oxide, manganese oxide, and chromium oxide
particulates internalized within alveolar macrophages. When the authors synthesized
representative nanoparticles (including Fe2O3 and Fe3O4) and used them to treat human
macrophages in vitro, the IONPs were found to induce pro-inflammatory cytokine secretion 81. This
directly implicates iron oxide as being a driver for an inflammatory response, which when
dysregulated or dysfunctional, can be known to contribute to pulmonary fibrosis as was observed
in these welders.
IONPs are also specifically engineered for a wide range of consumer products and applications,
leading to the recent increase of IONPs manufacturing facilities. Unfortunately, due to the relatively
high exposure limit recommendation for fine iron oxide, along with the greater toxic potential of
nano-sized particulates in general, these types of facilities have the potential to provide much better
evidence for IONPs-specific-induced adverse effects. Xing et al.

20

assessed the concentration of

airborne nanoparticles in a factory which manufactured Fe2O3-based materials via chemical
synthesis. Air sampling locations were chosen based on proximity to one of four major steps
involved in this synthesis process, and included two packaging locations, a powder screening
location, and a material feeding area. The authors found a significantly higher amount of Fe 2O3
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between 10 and 1000 nm in diameter in these four locations as compared to both indoor and
outdoor background particulate levels. They reported an average (across all four sites) of three fold
increased number of particles, two fold increase in mg/m3 particle concentration, and almost two
fold increase in total particle surface area as compared to background particulate levels. Total
exposure ranged from 0.04 to 0.28 mg/m3 depending on site, which is much lower than the
previously described OSHA permissible exposure limit (14 mg/m3 for fine iron oxide over an 8-h
work day). However, the authors did not assess if any adverse health outcomes were reported in
these exposed workers.
Pelclova et al. 21 assessed workers known to be exposed to an iron oxide aerosol (80% of which
was less than 100 nm in diameter) in a nanoparticle manufacturing facility. Median mass exposure
concentrations were 0.083 mg/m3, or 66,800 particles/cm3 (lower than the OSHA permissible
exposure limit, but roughly similar to the Xing et al.

20

reported exposure) with an average of 10

years exposure per worker. Workers were evaluated at the end of a work shift, and were found to
have elevated oxidative stress and inflammatory biomarkers in exhaled breath condensate and
urine, indicating the potential for IONPs to induce adverse outcomes with a long-term occupational
exposure. A caveat to this study, however, is the transient nature of oxidative stress biomarkers in
the urine. A more thorough evaluation of these workers, as well as a larger sample size, would be
necessary to definitively illustrate the potential systemic oxidative stress response induced by
IONPs occupational exposure, and to better link this response to subsequent adverse health
outcomes.
Overall, these studies provide direct evidence that workers involved in the IONPs synthesis or
manufacturing process are exposed to IONPs in an occupational setting, and that this exposure can
lead to oxidative stress and inflammation over an extended period of time. Due to the limited
amount of information available, however, no exposure limit recommendations for IONPs have
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been made, and both its full toxicity profile and the underlying mechanisms of action are still poorly
understood.
2-3. Toxicity of IONPs—In Vivo Studies
In vivo toxicity testing is currently the primary source of information to establish potential risk
following particle exposure. The observed animal response can be extrapolated to risk of adverse
outcomes in humans, and is used to help establish or support safe exposure limit recommendations.
The most common route of IONPs exposure in an occupational setting is via inhalation. However,
very few in vivo studies have been done which assess this route for IONPs-induced toxic effects.
Furthermore, the resulting data often show conflicting results, or are otherwise inconclusive. The
studies which do report adverse outcomes following IONPs pulmonary exposure reveal subsequent
inflammation 22–27, pulmonary fibrosis [31, 32], genotoxicity [33, 34], and extra-pulmonary effects
28,29,32,

almost all of which are attributed to IONPs-induced excessive oxidative stress.

Representative studies are presented below, and are summarized in Table 2-3.
2-3a. Inflammation
The inhalation of a foreign particle will likely induce an inflammatory response immediately
following exposure. This allows lung immune cells to identify and remove foreign material from the
lung, in an attempt to minimize tissue injury and damage. If the particle persists and inflammation
becomes prolonged, it may become dysfunctional and can ultimately lead to development of
fibrosis, cancer, or other adverse outcomes [38, 39]. IONPs have been shown to induce an acute
inflammatory response in both rats and mice, which in some cases may become prolonged or
chronic 23. IONPs may also modulate a pulmonary allergic reaction [29, 30].
Park et al. 22 exposed ICR mice via a single intratracheal instillation to Fe3O4 (5.3 nm primary
particle size) at the dose of 250, 500 μg/kg, or 1 mg/kg (about 0.005 to 0.02 mg/mouse), and
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assessed the inflammatory response up to 28 days post exposure. The authors reported an initial,
acute inflammatory response one day post exposure, and lower but still significantly elevated
inflammatory cytokine levels up to 28 days post exposure, indicating both acute and prolonged
IONPs-induced inflammatory responses. The authors also reported an increase in the expression of
genes related to inflammation and tissue damage (including heat shock proteins and matrix
metalloproteinases) throughout the study’s time course, as well as significant formation of micro
granulomas—a potential precursor to fibrosis. These adverse effects were primarily attributed to
excessive oxidative stress, as indicated by a significant reduction in glutathione (GSH) in the lavage
fluid.
This same group also evaluated Fe2O3 particles (209.4 nm agglomerates) with a needle-like
shape in ICR mice. Mice were administered the particles via a single intratracheal instillation (0.5,
1, or 2 mg/kg, or about 0.01 to 0.04 mg/mouse). The authors were able to show that the particles
remained in the lung even 90 days post exposure, with many particles having been engulfed by
alveolar macrophages. A failure to completely remove foreign particles from the lung has the
potential to contribute to a chronic or dysregulated inflammatory response. The highest dose used
in this study led to significant infiltration of inflammatory cells into the lung (neutrophils and
lymphocytes), as well as a dose dependent increase in lactate dehydrogenase activity (LDH),
increase in chemokine secretion, and increase in antigen presentation related protein expression.
Overall, the authors concluded that IONP exposure induced a Th1 polarized immune response in
the lungs 23.
Sadeghi et al. 24 dosed Wistar rats with 20 or 40 mg/kg Fe2O3 (20 nm) via repeated intratracheal
instillations (either 7 or 14 times, once every other day). The authors found signs of pulmonary
inflammation and injury, including pulmonary emphysema, and an increased presence of
neutrophils, eosinophils, and lymphocytes. The authors also noted elevated hepatic enzymes in the
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blood serum, which is indicative of hepatic cell injury and liver damage. They attributed this to
excessive oxidative stress, as indicated by an increase in free radicals and a reduction in GSH in the
lung tissue.
Srinivas et al.

25

exposed Wistar rats via head and nose only inhalation (4 hour continuous

exposure) to Fe3O4 (15–20 nm) at a reported actual aerosol concentration of 640 mg/m3 based on
mass median aerodynamic diameter and geometric standard deviation within respirable range—
much higher than the OSHA permissible occupational exposure limit. Lung burden following
exposure was not measured. The authors assessed lung injury and inflammation up to 14 days postexposure, and showed that IONPs were able to induce acute cytotoxicity and inflammatory
responses, as indicated by increased LDH, neutrophil infiltration, and pro-inflammatory cytokines
in both lavage fluid and blood. The inflammatory response was sustained out to 14 days post
exposure, although it decreased in severity in a time dependent manner. Once again, the authors
attributed these adverse outcomes to excessive oxidative stress, as indicated by a significant
reduction in GSH and antioxidant enzyme activities within this same time frame 25. However, due to
the excessive concentration used in this study, the observed response may have been due to
overloading the lungs with particle, which would compromise normal pulmonary clearance
mechanisms.
IONPs may also have the capacity to alter a typical immune response. Ban et al.

26

compared

nano (35 nm) and sub-micron (147 nm)-sized Fe2O3 particles at 100, 250, or 500 μg/mouse. The
animals were exposed via intratracheal instillation both before and after sensitization with
ovalbumin (OVA), and the Th2 immune response was assessed. The authors found that the allergic
response induced by OVA was inhibited with the middle or high doses of IONPs, but was actually
enhanced at the lowest dose used for treatment, whereas the submicron-sized particles at the
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lowest dose had no effect at all. The authors were only able to conclude that the pulmonary immune
response is sensitive to IONP exposure.
Gustafsson et al.

27

used a similar Fe2O3 particle (30 nm) in conjunction with the OVA

sensitization model to further elucidate how IONPs may alter the immune response. In this case, the
authors showed that intratracheal instillation of Fe2O3 alone (2.5 mg/kg body weight) induced a
pulmonary inflammatory response in non-sensitized or OVA challenged Balb/c mice, as indicated
by an increase in neutrophils, eosinophils, and lymphocytes in the airways. However, OVAsensitized and challenged mice exposed to IONPs had a decreased inflammatory response. The
authors attributed this to excessive cell death in already inflamed airways and in the lung draining
lymph nodes (LDLN), most likely caused by excessive reactive oxygen species (ROS) generation in
the resulting pro-oxidative environment.
Overall, these studies clearly indicate that IONPs have the capacity to induce lung inflammation
and injury in both mice and rats, and that this is most commonly attributed to IONPs-induced
oxidative stress.
2-3b. Pulmonary Fibrosis
Chronic inflammation has the potential to lead to pulmonary fibrosis, which is characterized by
an increase in proliferation and collagen production by alveolar fibroblasts. This can be triggered
by inflammatory cytokines such as TGF-β, and will normally occur following a foreign particle
exposure or other type of lung injury to help initiate lung healing

86.

However, excessive or

dysregulated fibrosis may lead to irreversible lung scarring, and have an impact on overall
breathing capacity and oxygen intake. Based on the known capacity for IONPs to induce a
pulmonary inflammatory response that has the potential to become chronic, it would seem logical
that these particles may also have some sort of fibrotic capacity. Although very few studies exist,
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those summarized below show a clear potential fibrotic capacity of IONPs. Furthermore, these
studies largely agree on oxidative stress and particle overload as being primary instigators of this
potential adverse outcome.
Zhu et al. 82 used a single intratracheal instillation of Fe2O3 particles (22 or 280 nm) to expose
Sprague Dawley rats to 0.8 and 20 mg/kg body weight and assessed subsequent adverse outcomes.
One day post-exposure, the animals showed a peak in inflammation, as indicated by an increase in
immune cell infiltration. By day 30, the animals exhibited markers of pro-fibrosis and lung
emphysema, an increase in microvascular permeability, cell lysis, and other indicators of lung
injury. The authors noted particle overloaded alveolar macrophages, and, again, attributed the
observed adverse outcomes to an IONPs-induced oxidative stress response.
Szalay et al. 83 used a single intratracheal instillation in Wistar rats (1 or 5 mg/kg body weight)
of Fe3O4 (<50 nm diameter) and assessed potential fibrotic capacity of these particles. The authors
reported a weak pulmonary fibrosis 30 days post exposure, but found no changes in extrapulmonary organs.
A caveat to both of these studies, however, is that IONPs fibrotic capacity was only assessed up
to 30 days post exposure, while most in vivo studies assess fibrotic outcomes after a longer time
period. Therefore, while the above studies clearly demonstrate the pro-fibrotic capacity of IONPs,
later time points are necessary to determine this more conclusively. Not only are there very few
chronic in vivo IONPs studies, but the ones available do not include pulmonary fibrosis as a
measured endpoint. This represents a clear and significant knowledge gap in the IONPs toxicity
profile.
2-3c. Genotoxicity and Carcinogenic Potential
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The potential genotoxicity of IONPs is also inconclusive. Some studies report no genotoxic effect
of IONPs

87,

although study design issues make it difficult to conclusively determine this

88.

Furthermore, there are very few papers that assess this end point at all. This is likely due to a
combination of factors, including the extended period of time it may take for tumors to develop in
an in vivo model system, as well as the perceived benign quality of iron oxide dust

89.

However,

pulmonary response after an extended period of time is a major concern for workers in an
occupational setting who may be exposed to a particle over months or years, but may not experience
cancer-related symptoms until much later. As mentioned previously, some studies involving fine or
unknown-sized iron oxide particulates show an association between iron oxide exposure and lung
cancer development in miners and other industrial workers. An overload of free iron in the lungs
(siderosis) is also known to be associated with increased risk of cancer development 90. Genotoxicity
is often a crucial first initiating step in cancer development, and is an important endpoint that can
be used to evaluate carcinogenic potential in vivo.
Totsuka et al.
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used an intratracheal instillation of Fe3O4 (10 nm primary particle size) to

expose both ICR and gpt delta mice at 0.05 or 0.2 mg per animal. Three hours post-exposure, the
ICR mice showed signs of significant lung damage

30,

and 24 hours post exposure they had

significantly increased formation of DNA adducts (DNA covalently bound to carcinogenic
compound) with elevated etheno-deoxycytidine (ϵdC) levels. ϵdC is an indicator of inflammation
and oxidative stress 31. Eight weeks post-exposure, the gpt delta mice had increased gpt mutations
(another indication of DNA damage), lipid peroxidation-related DNA adducts, inflammatory cell
infiltration, and the formation of focal granulomas 30. These results clearly indicate the potential for
IONPs to induce genotoxicity, even within a very short time frame, and at a relatively low dose.
Genotoxicity is generally believed to be a significant driver of tumor development. However,
there have been no in vivo studies that assess the actual carcinogenic potential of these particles.
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Even older in vivo cancer studies, which utilized an unknown or unreported-sized iron oxide, are
scarce. Campbell et al. 91 exposed groups of 8–10 mice to 0.5 g Fe2O3·H2O for six hours a day, five
days a week, over an entire year to mimic an occupational exposure scenario. At 800 days post
exposure, the iron oxide-exposed mice had significantly increased formation of primary lung
tumors as compared to control animals. However, the iron oxide particles were not characterized,
and their actual size is unknown. Particularly with regards to IONPs, the potential carcinogenicity
has not been well explored, and indicates a very clear knowledge gap in IONPs-induced adverse
effects.
2-3d. Extra-Pulmonary Effects
IONPs, due to their small size, may be able to translocate to other organ systems following
pulmonary exposure either as intact particles or as its solubilized constituents. Radioactively
labeled IONPs have been shown to enter the circulating blood stream less than 10 minutes following
a pulmonary exposure
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and ultimately end up in organs which play a role in the mononuclear

phagocyte system, including the liver, spleen, and kidney. This may lead to extra-pulmonary effects
via the same or different mechanisms as IONPs pulmonary adverse effects. Once at these secondary
sites, IONPs may dissolve, or may accumulate as whole particles and induce tissue damage.
Furthermore, IONPs have been shown to activate or alter components of the blood such as platelets
92,

and as was previously alluded to, may activate the immune system as well [29,30].
Al Faraj et al.

29

used magnetic resonance imaging to document superparamagnetic Fe2O3

translocation after an intrapulmonary administration. The particles (129.3 nm) were coated with
polyethylene glycol and had either positively- or negatively- charged functionalization groups to
enhance biocompatibility. After intrapulmonary administration into Balb/c mice at a calculated
dose of 0.8 mmol iron/kg body weight, the authors looked for nanoparticles in several major organ
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systems at two hours, one day, two days, one week, two weeks, and one month post-exposure. They
showed rapid movement of the particles to the liver at one day post-exposure, but this hepatic iron
was almost completely cleared by later time points. The authors also showed that inflammatory
biomarkers, lipid peroxidation, and DNA damage all increased with IONPs exposure as compared to
non-treated control animals. Although previous studies showed that IONPs may persist in the lungs,
this study indicates that if the particle translocates to a secondary site, it may be more rapidly
cleared from there.
Wang et al. 32 used intratracheal instillation of 30 nm Fe2O3 into Wistar rats (twice per day for
3 consecutive days at 8.5 mg/kg body weight) and evaluated particle persistence in the lung, as well
as translocation to, and persistence in, the liver. They showed significant increase in overall iron
content in both the lung and the liver, as well as clear indications of IONPs-induced lung and liver
tissue damage, as determined via histopathology. The authors do not, however, assess the source of
the elevated iron in the lung and liver. It could be from IONPs translocation, dissolution, and release
of free iron ions, or may be due to IONPs sequestration of iron from the mitochondria or other
organelles, leading to a cellular compensatory response.
Overall, the existing in vivo literature shows that pulmonary exposure to IONPs may lead to lung
inflammation, injury, and immune modulation, with some studies also suggesting pro-fibrotic or
fibrotic potential. There are conflicting studies as to the mutagenic potential of IONPs, with only one
study showing actual tumor development (using an unreported size iron oxide). IONPs have also
been shown to rapidly enter the circulatory system, potentially inhibiting platelet activation 92, as
well as traveling to other major organ systems and causing tissue damage at these secondary sites.
Although in vivo studies provide information on potential IONPs-induced adverse outcomes,
there are also several significant knowledge gaps, including fibrotic potential and carcinogenic
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capacity. This lack of information makes it difficult to evaluate risk to a human population, and
prevents a clear understanding of the IONPs toxicological profile.
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Table 2-1. Referenced iron oxide (unknown or unreported size) human studies.
Reference
33

79

36

Exposure
Particulates
Iron oxide dust with
10–12% silica content,
radon

Size

Adverse Outcomes

Unknown

70% increased lung cancer
mortality rate

Boyd

6000 underground and surface
hematite iron ore miners (UK)

Siew

Employed males 1906–1945
(Finland)

Iron fumes/dust,
welding fumes

Unknown

Underground iron ore miners and
surface workers (Longyan and
Taochong, China)
Hematite miners decreased
1932–1953 (West Cumberland,
UK)

3.8 mg/m3 total
airborne dust, 28%
iron content

Unknown

Ferric oxide with 10–
12% silica content

Unknown

Chen

Faulds &
Stewart

34

Cohort

Increased risk of lung cancer
following exposure to one or both
types of particulates
Increased incidences of nonmalignant respiratory disease and
lung cancer
Almost 5 fold increased incidences
of lung carcinomas at time of death
(attributed to silica content)

32 | K o r n b e r g

Table 2-2. Referenced iron oxide nanoparticle human studies.
Reference

81

21

Cohort

Andujar

21 welders, average
27 years exposure

Pelclova

14 workers in iron
oxide pigment
production facility,
average 10 years
exposure

Exposure
Particulates
Iron oxide,
manganese
oxide,
chromium
oxide

Size

Adverse Outcomes

Unknown/notreported

Fibrotic lesions, elevated iron load. In vitro
treatment with representative nanoparticles caused
increased secretion of pro-inflammatory cytokines.

Iron oxide
80% measured
(primarily α- particles less than 100
Fe2O3)
nm in diameter

Elevated oxidative stress and inflammatory
biomarkers in exhaled breath condensate and urine.
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2-4. Toxicity of IONPs—In Vitro Studies
Clearly, there is a critical need for a more complete toxicological profile of IONPs. In tandem,
there is a dramatic increase in sheer number of new types of other nanomaterials, with similar
knowledge gaps as to their unique potential to induce adverse outcomes. Overall, it is becoming
increasingly urgent that more rapid methods are developed to better assess potential toxicity of
these emerging materials, while concurrently maintaining robust and rigorous scientific methods
to ensure these models are relevant and predictive of an in vivo and human response. In order to do
this, many researchers are pushing for better in vitro model development, which would allow for a
useful tiered hazard assessment of nanomaterials, in general.
There are many advantages to using in vitro model systems for toxicity assessment. In addition
to the potential for more rapid toxicological evaluation, these models can also provide more
information on the potential mechanism or mode of action of particle-induced toxicity. However,
this can only be done if these in vitro model systems are predictive and representative of a human
exposure and response. The overall goal with these systems, in the context of a tiered toxicity testing
approach, is to utilize in vitro methods to rapidly screen a large number of nanomaterials for specific
end points or adverse outcomes, also known as a high-throughput screening approach. These
results can then be used to prioritize the most potentially hazardous materials for further in vivo
studies.
However ideal this situation may seem, there are several issues with nanoparticle in vitro
toxicity testing, which prevent this from being fully realized, and the study of IONPs in vitro toxicity
is representative of these issues. Some studies report essentially no cytotoxic effect with exposure
93–95,

whereas others report major dysfunction in macrophages

96

and mitochondria

97,

and even

DNA damage 69,98,99 induced by these particles. This lack of agreement is likely due to overall issues
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with in vitro model system experimental design and exposure conditions, and ultimately prevents
them from being useful for hazard assessment purposes. In order to better utilize cell culture
systems as even an initial screening tool, these major issues must be recognized and systematically
addressed.
In the following section, this review will first discuss important considerations when
developing an in vitro model system, including dose, particle agglomeration, particle uptake, cell
type, and relevant end points, which may all have an impact on observed adverse outcomes. Next,
this review will use these established criteria to critically examine the existing IONPs in vitro
literature, and will highlight occupationally relevant IONPs in vitro studies which appear to
correlate well to previously discussed in vivo results. All referenced in vitro studies are summarized
in Table 2-4.
2-4a. Issues with In Vitro Model Systems
2-4a.i. Particle Dose
An issue common to both in vitro and in vivo experimental design is the use of a relevant dose.
With in vivo studies, based on mode of exposure and observed particle deposition, the delivered
dose can be determined and compared to actual human burden to ensure dose relevancy. With in
vitro studies, however, there are several other factors which will influence how much of the
administered dose is actually delivered to the cells, and in what time frame that exposure may occur.
Furthermore, a confounding factor specific to IONPs and other emerging nanomaterials is the lack
of knowledge of what constitutes an occupationally relevant dose. There are, currently, only two
studies which show actual human exposure to IONPs in an occupational setting (0.04–0.28 mg/m3
20

or 0.083 mg/m3 21) and a much higher OSHA permissible exposure limit (14 mg/m3 over 8 h 38).
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Because the OSHA permissible exposure limit is likely to be the worst case exposure scenario,
some researchers have focused on this dose specifically, and used it to better assess the translation
from occupationally relevant animal exposure to in vitro model system. For example, Teeguarden
et al. 100 exposed Balb/c mice to a 12.8 nm Fe3O4 particle via inhalation. Mice were exposed to 19.9
mg/m3 particle over 4 h, which is less (80 mg·h/m3) than the OSHA permissible exposure limit for
fine-sized Fe2O3 particles (14 mg/m3 over 8 h or 112 mg·h/m3). After this inhalation exposure, the
authors assessed target tissue dose in the bronchial region (about 1 μg/cm2), and the alveolar
region (0.003–0.13 μg/cm2) of the lung. Based on these results, it would seem reasonable that an in
vitro model system using cells derived from the bronchial region of the lung would require a higher
dose of particle than cells derived from the alveolar region of the lung in order to obtain results that
would be most representative for the deposited dose used in an in vivo exposure.
Although their findings have not necessarily been taken into account with other in vitro studies,
this paper is an important guideline to use when evaluating in vitro studies and determining their
potential relevance to an occupational exposure scenario.
2-4a.ii. Particle Aggregation, Agglomeration, and Assay Interference
Even if particle deposition is taken into account, the administered in vitro dose may still not be
representative of the delivered dose that reaches the cells. Agglomerate size, liquid media density,
media protein content, and other factors will affect particle settling rate and dosimetry. This, in turn,
may affect the administered to delivered dose ratios, and may have a major impact on subsequent
adverse outcomes 66.
In fact, particle aggregation and agglomeration have already been shown to play a major role in
the severity of IONP-induced adverse outcomes. As previously mentioned, it is generally accepted
that smaller particles are able to induce more toxicity on a per mass basis due to increased surface
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area and particle number [22, 23]. However, if these particles agglomerate in an unanticipated way,
the observed adverse outcomes may be different than predicted. This would especially be the case
if the agglomerate was recognized by the cell as a larger structure than the primary particle size
suggests. This may not only lead to inaccurate toxicity assessment, but may also obscure potential
size dependent particle toxicity.
For example, Karlsson et al. 94 showed no size-dependent toxicity when comparing “nano” and
“sub-micron”-sized Fe2O3 and Fe3O4 particles—even with a relatively high dose (40 μg/cm2)
administered to A549 cells. This is most likely due to particle agglomerate size. The primary particle
size of the “nano” Fe2O3 was 30–60 nm, but once in suspension become about 1600 nm, making it
very similar in size to the 150–1000 nm “sub-micron” Fe2O3. Similarly, the “nano” Fe3O4 had a
primary particle size of 20–40 nm, but became greater than 200 nm as an agglomerate in
suspension, again making it almost the same size as the 100–500 nm “sub-micron” Fe3O4 used. In
fact, other researchers have shown that the agglomerate size of Fe3O4 (12.1 nm primary particle
size) will vary significantly (199–453 nm) based on FBS content and overall density of the dosing
media 101.
Additionally, the pH of the dosing media may have an impact on IONPs capacity to generate ROS
102. The pH dependent dual enzymatic activity of IONPs may also obscure results if the dosing media

used is not physiologically relevant. It is, therefore, critical that IONPs—and other nanomaterials,
as well—are fully characterized in the media or vehicle that will be used for treatment.
Another factor that may interfere with perceived IONPs-induced adverse outcomes is assay
interference. This is relatively common due to the small size and pigmented properties of IONPs.
For example, Kain et al. 69 noted that Fe3O4 particles (20–40 nm primary particle size, agglomerates
> 200 nm) caused DNA damage in Beas-2B cells after 4 hours of exposure to 20 μg/cm2 when this
damage was measured via the comet assay, but that no oxidative DNA damage could be detected
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when formamidopyrimidine DNA glycosylase (FPG) sites were used as an indicator instead. The
authors attributed this to IONP interference with FPG, leading to inaccurate results. Overall, the
authors concluded that multiple methods should be used to verify results if particle interference is
unknown with a particular assay. In fact, many different types of IONPs have been shown to interact
with the components of cytotoxicity assays 70 and cytokine secretion assays 71, and likely interfere
with others which have not yet been reported.
2-4a.iii. Relevant Cell Type
In the lung, response to foreign particle exposure relies on chemical interactions and
communications between a vast array of cell types. Due to the complexity of this system, it can be
difficult to replicate this using cell culture models. There are several types of in vitro model systems
that have been used, including mono-culture (one cell type), co-culture (two cell types),
multicellular spheroid model systems, and even “organ-on-a-chip” methods. Although each of these
model systems has clear advantages and disadvantages, one of the most necessary criteria that
should be taken into consideration, is the use of a relevant cell type, including relevant disease state,
species, and location in the body. This is also highly dependent on the overall goal of a study. For
example, if the goal of a study is to assess IONPs response in a healthy individual, only cell lines
derived from a healthy individual should be used. If the goal of a study is to assess IONPs impact on
a particular endpoint, it is important to fully consider which cell types may be involved in this
process, and which will allow for the most relevant assessment of a human response.
It is also important to consider the species of origin to determine if a cell line is going to be
useful for a particular study. Although in vivo studies are typically used to establish potential risk
following exposure to humans, and a good indicator of the success of an in vitro study is its
correlation to in vivo results, it is also crucial to consider the differences between human and animal
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response with IONPs exposure. A mouse cell line is likely to be the best predictor of an in vivo mouse
response, but a human cell line may be more predictive of a human response. Therefore, it is
exceedingly important to consider mouse compared to human response both when designing cell
culture-based systems, and for in vivo and in vitro experimental design.
It is also important to match organ location of a cell line used in vitro to the exposure scenario
and end point being studied, so as to ensure the most predictive and relevant results. The same cell
type from the same species but originating from two different organ systems may have an extreme
impact on response following IONPs exposure. For example, mouse alveolar macrophages are
known to have relatively low lysosomal activity as compared to mouse peritoneal macrophages.
Park et al.

103

showed that this difference has a subsequent impact on IONPs-induced adverse

outcomes. The authors exposed murine alveolar macrophages at a range of doses from about 1.89
to 15 μg/cm2 of Fe2O3 (102 nm in cell culture media). After 24 hours and at the highest dose used,
they found a 40% decrease in cell viability, a 25% decrease in ATP production, and a 2 fold increase
in both ROS and nitric oxide production as compared to non-treated controls. However, during a
previous study which used the same nanoparticle but different cell line (mouse peritoneal
macrophages) the authors saw a 20% decrease in cell viability, 40% decrease in ATP production, a
5 fold increase in ROS, and a 2.5 fold increase in nitric oxide as compared to non-treated controls
104.

They concluded that this difference between studies was most likely due to the differences in

lysosomal activity and other characteristics which differentiate mouse alveolar macrophages from
mouse peritoneal ones.
Clearly, the use of a relevant cell type is crucial for relevant and predictive results. However,
very few IONPs studies utilize an in vitro model that is well matched to a specific end point and
exposure scenario. This is likely a major contributor to the lack of cohesion or agreement on IONPsinduced adverse outcomes based on in vitro studies.
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2-4b. Underlying Mechanisms of IONPs-Induced Adverse Effects
By limiting IONPs literature to those studies which utilize relevant parameters based on the
discussion above, in vitro IONPs studies appear to correlate well to observed in vivo outcomes. In
vitro, IONPs have been shown to induce oxidative stress and a decrease in cell viability, as well as
genotoxicity and neoplastic-like cellular transformation. These may all be components of, or
precursors to, inflammation, pulmonary fibrosis, and potential carcinogenic capacity.
Oxidative stress and cell viability are basic assessments of potential particle toxicity, and also
provide information as to the potential inflammatory capacity of a particle. Bhattacharya et al.
showed that a dose of 2 μg/cm2 (roughly comparable to Teeguarden et al.

100

98

established IONPs

deposition in the bronchial region) of Fe2O3 (50 nm) induced a 15% decrease in cell viability, as well
as elevated ROS generation in human bronchial fibroblasts (IMR-90). A study done with a less
relevant, but still of human lung origin, cell line showed similar results with Fe 3O4 (174 nm
agglomerate). At about 3.03 μg/cm2, Dwivedi et al. 97 showed that IONPs induced a decrease in cell
viability and indications of oxidative stress, including an increase in lipid peroxidation and a
decrease in GSH in A549 cells.
As with in vivo work, one area in which in vitro nanotoxicology is generally lacking is in the
assessment of carcinogenic potential of emerging nanomaterials. The major difficulty with this
particular endpoint is that cancer is a multi-step, multi-cellular process that usually occurs over
extended time periods. Therefore, acute in vitro exposures are unable to provide sufficient
information about this particular area. However, there is some in vitro support for IONPs-induced
genotoxicity, and the potential development of a cancer-like phenotype.
IONPs have been shown to cause DNA damage using relevant experimental parameters as
described above. Bhattacharya et al. 98 showed 10 and 50 μg/cm2 doses of Fe2O3 (50 nm) can cause
double stranded DNA breaks (as measured via the comet assay) in both IMR-90 and Beas-2B cell
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lines. Watson et al.

105

also showed the potential genotoxicity of IONPs using a novel CometChip

assay, which functions similarly to the comet assay, but also takes into consideration potential
particle interference as described above. Using this innovative platform, the authors showed that
Fe2O3 (19.7 nm primary particle size, 934–1444 nm agglomerates) induced significant double
stranded DNA breaks as compared to non-treated control cells, at doses of about 3.03 μg/cm2.
IONPs-induced genotoxicity, as shown in both of these studies, may lead to neoplastic-like cellular
transformation, which has been separately shown to be induced by IONPs exposure.
Sighinolfi et al. 99 used Fe3O4 particles (161 nm) in the Balb/3T3 cell transformation assay at a
dose of about 2.76 μg/cm2. This assay measures cellular transformation in mouse fibroblast cells
and compares transformation rate induced by the particles to that of known tumor promoters. The
authors found that IONPs exposure induced toxicity after 72 hours, and was also able to promote
tumoral foci, although they could not initiate them. These tumoral foci appeared to develop in
conjunction with large IONPs agglomerates, and the authors noted that these agglomerates could
potentially serve as a scaffold for foci engraftment 99. It should be noted, however, that since most
tumors are of epithelial origin, the use of fibroblasts in this example to assess the tumorigenic
potential of a particle should be taken with caution.
Our research group developed an epithelial cell-based assay by using primary small airway
epithelial cells to assess the capacity of Fe2O3 (12 nm primary particle size) to induce a neoplasticlike cellular transformation 106. In this study, a low-dose sub-chronic exposure model (0.6 μg/cm2
continuously for 10 weeks) was used to mimic an occupationally relevant exposure scenario. After
10 weeks, the IONPs treated cells underwent a significant and dramatic neoplastic-like cellular
transformation, as indicated by an increase in cell proliferation, formation of attachmentindependent colonies, and immortalization. Overall, there is early evidence to suggest that IONPs
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can induce genotoxicity, and may cause a neoplastic-like cellular transformation under
occupationally relevant exposure conditions.
A critical question underlying the IONPs toxicity profile is the mechanism behind IONPsinduced adverse effects. By again limiting literature to studies that utilize relevant parameters, as
discussed above, IONPs-induced oxidative stress appears to be a critical component of observed
adverse outcomes both in vitro and in vivo. A proposed mechanism to this is heavily reliant on
particle uptake, dissolution, and release of free iron ions into the cell’s catalytically active labile iron
pool (Figure 2-2a). If IONPs are engulfed via phagocytosis, they will end up inside a phagosome.
These phagosomes can then fuse with a lysosome, so the resulting acidic environment will degrade
its contents. IONPs, however, may instead dissolve, releasing free iron ions (Fe2+) into the cell’s
cytoplasm

107.

This catalytically available iron

108

can then participate in the Fenton reaction and

generate ROS 109, an excess of which can ultimately induce DNA damage, lead to an inflammatory
response, and/or carcinogenic related outcomes. In fact, Malvindi et al. 110 were able to show that
Fe3O4 (32 nm) induced adverse effects on A549 cells (3 μg/cm2), which included decreased cell
viability and increased LDH, ROS, and DNA damage. However, these outcomes were largely ablated
with the use of an iron chelator. This clearly indicates that a primary source for IONPs-induced
damaging effects may be due to excessive free iron ions causing an oxidative stress response.
Furthermore, Park et al. 103 were able to show that the difference in solubility between Fe3O4
and Fe2O3 nanoparticles could be linked to the severity of subsequent adverse outcomes—less
soluble Fe2O3 also had a less severe impact on murine alveolar macrophages as compared to the
more highly soluble Fe3O4. Additionally, Freyria et al.

95

clearly connected the mild solubility and

poor reactivity of α-Fe2O3 to the almost negligible adverse outcomes observed following exposure,
which included no cytotoxicity, necrosis, DNA damage, nor nitrate release in several cell types,
regardless of particle size (87, 238, or 1100 nm) or high dose used (20–100 μg/cm2). Overall, these
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studies clearly show the demonstrable link between IONPs dissolution and subsequently observed
adverse outcomes.
Other studies also suggest that IONPs may be involved in the sequestration of iron from
mitochondria or other organelles, causing cellular compensation and prompting an influx of free
iron ions into the cell’s labile iron pool

111.

Again, this would result in an overall excess of

catalytically available iron, which can then participate in the Fenton reaction, and lead to increased
ROS production within the cell as previously discussed. Overall, both proposed mechanisms remain
largely unstudied, likely due to difficulty in differentiating the source of this catalytically available
iron, as well as the complex network of proteins that are involved in maintaining the cellular iron
homeostatic balance (Figure 2-2b).
Iron homeostasis is carefully regulated within a cell, particularly because iron is the major
oxygen carrier in humans and is crucial for electron transfer and normal cellular functions.
Catalytically active iron, which is diffusible and able to participate in redox reactions, is localized
within a cytosolic labile iron pool 90. Due to the sheer amount of available and inhalable iron in the
atmosphere, the lung relies on the protein Divalent Metal Transporter 1 (DMT1), which is involved
in the import of free iron into the cell. There, it can then be sequestered in the iron storage protein
Ferritin (FTH) to limit its capacity to generate free radicals. Free iron may also be bound to the
transferrin protein, which can then be imported into the cell via the transport protein CD71.
Ultimately, iron may be exported out of the cell via Ferroportin (FPN) or a ZRT-IRE like protein
(ZIP14)

112.

Expression levels of DMT1, FPN, and ZIP14 have all been shown to increase with an

influx of iron content 113–115 to help combat potential toxicity associated with excessive free iron.
Generally, the lung and other organs are well equipped to deal with potential iron overload,
which is suggested by the complex network of proteins involved in maintaining iron homeostasis.
However, if IONPs are able to disrupt this careful balance—either through directly dissolving and
43 | K o r n b e r g

releasing iron into the catalytically active labile iron pool, or by affecting iron stores within the
mitochondria or other organelles—IONPs have the potential to overload this protective pathway,
leading to an overall excess of iron in the catalytically active labile iron pool. This iron overload has
been linked to increased pathogenesis of atherosclerosis

115,

and increased iron levels in the lung

are also associated with increased rates of lung pneumonia and lung infection 116. Furthermore, the
excessive oxidative stress may induce mitochondrial damage, which could then have deleterious
effects on the cell, including increased induction of autophagy [75, 76], as well as overall respiratory
disease and pulmonary dysfunction [77, 78].
Based on this proposed mechanism of action and published literature, the key to IONPs-induced
adverse outcomes appears to be largely reliant on particle dissolution and release of free iron ions.
If this aspect can be affected by altering IONPs design, it may be possible to design a less hazardous
IONPs which retains the properties necessary for its inclusion in biomedical or other applications.
This would be a core component of a “safe by design” hazard reduction or prevention strategy.
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Table 2-3. Referenced iron oxide nanoparticle in vivo studies.
Study

Animal

Particle

Primary
Particle Size

22

Park

ICR mice

Fe3O4

5.3 nm

23

Park

ICR mice

Fe2O3

10 nm
(209.4 nm
agglomerate)

24

Sadeghi

Wistar
rats

Fe2O3

20 nm

25

Srinivas

Wistar
rats

Fe3O4

15–20 nm

82

83

Zhu

Szalay

Sprague
Dawley
rats

Wistar
rats

Fe2O3

Fe3O4

Dose
0.25, 0.5, 1
mg/kg
body
weight
0.5, 1, 2
mg/kg
body
weight
20 or 40
mg/kg
body
weight
640
mg/m3

Mode/Duration
of Exposure

Time
Points

Adverse
Outcomes

Intratracheal
instillation

1, 7, 14, 28
days

Inflammation

Intratracheal
instillation

90 days

Inflammation, Th1
polarized immune
response

Intratracheal
instillation (7 or 14
times, once every
other day)
Inhalation, 4 h
continuous

1 day post
exposure
set
completion
1, 2, 14
days

Inflammation, liver
damage
Inflammation

22 or 280
nm

0.8 or 20
mg/kg
body
weight

Intratracheal
instillation

1, 30 days

Inflammation, profibrosis, longer
prothrombin and
activated partial
thromboplastin
times

<50 nm

1 or 5
mg/kg
body
weight

Intratracheal
instillation

1, 3, 7, 14,
30 days

Weak fibrosis
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30

Totsuka

ICR or gpt
delta mice

Fe3O4

10–100 nm

0.05 or 0.2
mg/animal

Intratracheal
instillation

3 h, 8 wks

Ishino

ICR mice

Fe3O4

10–100 nm

0.2
mg/animal

Intratracheal
instillation

1 day

Unknown

0.5 g for
8–12
animals

Inhalation, 6 h/day
continuous, 5
days/week, 1 year

Up to 800
days (or
death of
animal)

31

91

Campbell

28

29

Zhu

Mice
(strain
unknown)

Sprague
Dawley
rats

Al Faraj

Balb/c
mice

Wang

Wistar
rats

32

Fe2O3·H2O

59Fe2O3

Fe2O3

Fe2O3

22 nm

4
mg/animal

Intratracheal
instillation

Daily, up to
50 days

129.3 nm

0.8 mmol
iron/kg
body
weight

Intrapulmonary
administration
(once or three
times on
consecutive days)

2 h, 1 or 2
days, 1 or 2
weeks, 1
month

30 nm

8.5 mg/kg
body
weight

Dry powder nasal
spray, twice daily
for three days

Up to 36 h

DNA damage in
lungs, DNA adduct
formation,
inflammation, focal
granuloma
formation
DNA adducts
(elevated ϵdC)
Primary lung
tumors
IONPs can pass
into systemic
circulation, and is
distributed to
mononuclear
phagocyte rich
organs
Particle
translocation to
liver, lipid
peroxidation, DNA
damage,
inflammation
biomarkers
Severe lung and
liver tissue damage
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26

Ban

27

Gustafsson

100

Teeguarden

Balb/c
mice

Fe2O3

35 or 147
nm

100, 250,
or 500
μg/mouse

Intratracheal
administration
(four times) with or
without OVA
sensitization

Intratracheal
instillation with or
without OVA
sensitization

1, 2, 7 days
post
exposure

Inhalation, four
hour continuous

Up to 7
days

Balb/c
mice

Fe2O3

30 nm

2.5 mg/kg
body
weight

Balb/c
mice

Superparamagnetic
IONPs

12.8 nm

19.9
mg/m3

24, 48 h
after
completion
of exposure
set

Inhibition of OVAinduced allergic
response at high
dose, enhancement
with low dose
Decreased
inflammation with
IONP and OVA
attributed to
excessive cell death
in inflamed airways
and lung draining
lymph nodes
Particle deposition,
interstitial
inflammation,
macrophage
infiltration
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Table 2-4. Referenced iron oxide nanoparticle in vitro studies.
Study

101

Watanabe

A549

Particle Type

Agglomerate
Size in Dosing
Media

Particle
Dose
(μg/cm2)

Adverse Outcomes

Magnetic
Fe3O4

10 nm

197 nm

0.303–30.3
μg/cm2

Cell membrane damage,
increased ROS and oxidative DNA
damage, decreased GSH,
increased CD44+ fraction and
HO-1 expression

Fe2O3: 1600 nm,
150–1000 nm
Fe3O4: >200 nm,
100–500 nm
Fe2O3: 102nm
Fe3O4: 26nm

40 μg/cm2

Cytotoxicity, mitochondrial
damage, DNA damage

Karlsson

A549

Fe2O3, Fe3O4

Fe2O3:
29 nm,
<1 μm
Fe3O4:
20–30
nm, 0.5
μm

104

Park

Murine
peritoneal
macrophages

Fe2O3

NR

102 nm

1.95–15
μg/cm2

Cytotoxicity, decreased ATP
production, increased ROS, nitric
oxide, TNF-α secretion

69

Kain

Beas2B

Fe3O4

20–40
nm

<200 nm

20 μg/cm2

DNA damage

98

IMR-90,
Beas2B

Fe2O3

NR

50 nm

2–50
μg/cm2

Dwivedi

A549

Fe3O4

36 nm

174 nm

3.03–15
μg/cm2

Cytotoxicity, DNA damage,
increased ROS
Cytotoxicity, increased ROS,
decreased GSH and
mitochondrial membrane
potential

Sighinolfi

Mouse
fibroblasts

Fe3O4

20–50
nm

161 nm

2.76 μg/cm2

94

Bhattacharya
97

99

Cell Type

Primary
Particle
Size

Promote tumoral foci, scaffold
for foci engraftment
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106

Stueckle

pSAEC

Fe2O3

19 nm

341.56 nm

0.6 μg/cm2

Increased formation of
attachment independent colonies

110

Malvindi

A549

Fe3O4

32 nm

107 nm

3 μg/cm2

Cytotoxicity, increased LDH,
ROS, DNA damage

Freyria

A549,
murine
alveolar
macrophages

Fe2O3

87 nm,
238 nm,
1100 nm

69 nm, 357 nm,
888 nm

1–100
μg/cm2

No effect on LDH, DNA damage,
apoptosis/necrosis, extracellular
nitrite

NR

156–1250
μg/cm2

With coating: reduced
cytotoxicity, decreased
deformation of mitochondrial
membranes, ROS production,
decreased particle degradation
and more controlled release of
iron ions
With coating: slower
metabolism/particle excretion,
less iron ion release in acidic
environment

No effect on cell viability, cell
injury/damage

95

[89] Shukla

A549

Fe3O4,
chitosan
oligosaccharide
coating

6 nm

[85] Tian

Human
mesenchymal
stem cells

Fe3O4, silica
coating

8 nm

NR

100 μg
Fe/mL
(unable to
determine
equivalent
μg/cm2
dose)

[88] Guldris

Rat
mesenchymal
stem cells

Superparamagnetic
IONPs, PAA
coating

7 nm

18, 35 nm

Up to 62.5
μg/cm2
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2-5. “Safe by Design” IONPs Hazard Reduction Strategies
“Safe by design” hazard reduction strategy is the idea that if a nanoparticle can be designed in
a way which both enhances its properties utilized for specific applications while simultaneously
reducing its toxicity, this may have overall positive outcomes on worker-related safety concerns. It
most often involves the alteration of one or more physicochemical properties of the particle to help
alleviate its toxicity without compromising its intended purpose. Dissolution rate, surface coating,
and functionalization can all be altered, and have all been shown to have an effect on overall IONPsinduced adverse outcomes. IONPs dissolution, which appears to be a key component of subsequent
adverse outcomes, can be alleviated primarily by altering particle surface coating and
functionalization, as will be discussed below.
2-5.a. Alterations in IONPs Physicochemical Properties May Reduce Hazard
2-5a.i. Particle Surface Coating and Functionalization
Nanoparticle surface coating and functionalization are major components of nanoparticles
which allow them to be used for specific applications. The surface coating can be altered to increase
biocompatibility

121,

to enhance paramagnetic or superparamagnetic properties for clinical and

therapeutic applications [80, 81], or to enhance catalytic properties [82, 83]. An increase in coating
thickness (and subsequent overall nanoparticle size) will increase relaxation times, allowing for
better imaging results 126. Surface modifications, such as lipids or polymers, have also been shown
to stabilize nanoparticles in suspension, and could potentially control in vivo translocation [79, 80].
In tandem, a change in surface coating or functionalization has also been shown to reduce particle
dissolution rate, and may reduce or prevent IONPs-induced adverse outcomes by acting as a “shield”
to prevent or delay particle dissolution in the lysosome [85, 86].
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Particle surface coating and availability of surface binding sites have been shown to affect Fe2O3
particle (31 nm)-induced cytotoxicity in both Beas-2B and A549 cells

129.

Furthermore, other

researchers have shown that different IONPs coating types (dextran, amino-alcohol glucose
derivative, or citrate) will affect Fe2O3 (7 nm primary particle size) dissolution rate in a coating
dependent manner once in an acidic, lysosome-like environment 127. The addition of a polyacrylic
acid (PAA) coating onto superparamagnetic IONPs (7 nm) also reduced the leaching of iron in a
neutral pH cell culture media 130. In this case, PAA-coated IONPs were also less likely to aggregate,
and did not induce any significant cytotoxicity when used to treat rat mesenchymal stem cells.
Shukla et al. 131 evaluated chitosan oligosaccharide coated Fe3O4 particles (6 nm). This coating
is known to increase hydrophilicity and biocompatibility for use in a wide variety of biomedical
applications. Even at very high doses (about 156–1250 μg/cm2), the authors found reduced
cytotoxicity (as measured via MTT assay and cell staining), decreased deformation of mitochondrial
membranes, and decreased ROS production in A549 cells with the coated nanoparticles as
compared to uncoated. Furthermore, TEM-EDX elemental analysis revealed that the coated
nanoparticles underwent less degradation in the cells and had a slower release of iron ions.
Tian et al. 128 examined silica-coated and uncoated Fe3O4 particles (8 nm) in a lysosomal model
system, and found that fewer Fe3+ ions were released with the coated nanoparticles as compared to
uncoated ones. Furthermore, these coated particles were taken up by human mesenchymal stem
cells at a similar rate to uncoated particles but were metabolized and excreted more slowly. This
could potentially be of positive benefit for the particles to be better utilized in a biomedical setting.
Polymer functionalization may also have a direct impact on IONPs-induced toxicity. For
example, Cochran et al.

132

utilized a poly (trolox ester) coated iron oxide nanoparticle. The poly

(trolox ester) was specifically designed to release trolox locally to help combat IONPs-induced prooxidant effects. Their results showed that human endothelial cells (HUVECs) treated with about
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9.375 μg/cm2 IONPs had significantly decreased cell viability and increased ROS generation than
non-treated control cells. However, cells treated with a poly (trolox ester) coated iteration of the
same nanoparticle showed similar viability and ROS generation as the non-treated control cells. The
authors conclude that the addition of a polymer coating may be able to directly counteract IONPsinduced oxidative stress related adverse outcomes. A major caveat with particle coating and
functionalization toxicity assessment, however, is that there are an infinite number of coatings and
functionalization combinations which could be used with IONPs, not all of which may be relevant
for human health. Furthermore, there are many coatings that may impart novel function while
reducing toxicity, but haven’t been developed or investigated yet.
Overall, these studies highlight that particle dissolution as related to surface coating and
functionalization may play a major role in determining in vitro adverse outcomes following IONPs
exposure. An alteration in these physicochemical properties could be used to help alleviate this
toxicity, as well as to potentially enhance other properties that allow for IONPs use in a broad range
of applications.
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(a)

(b)

Figure 2-2. (a) Proposed mechanism behind IONPs-induced iron homeostasis disruption
and subsequent adverse outcomes. If IONPs are engulfed by the cell via phagocytosis and
end up in a phagosome, this membrane bound vesicle will then fuse with the lysosome,
creating an acidic environment for degradation. However, once in this acidic environment,
IONPs will instead dissolve, releasing free iron ions into the cell’s catalytically active labile
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iron pool. This may ultimately result in increased and excessive ROS generation, and
subsequent adverse outcomes. Dissolved particle may also affect iron stores in
mitochondria and other organelles (not shown). (b) Maintenance of iron homeostasis via
iron import proteins, iron storage proteins, and iron export proteins. In order to maintain
appropriate iron levels within a cell, a complex network of iron-related proteins are
involved in iron import, storage, and export. Example proteins for these processes (DMT1,
CD71; ferritin; SLC40A1, respectively) are shown). Free Fe2+ in the labile iron pool is
necessary for cellular function, but too much can cause an excess of reactive oxygen species
generation via participation in the Fenton reaction. The labile iron pool is carefully
maintained using iron storage mechanisms via ferritin. In pathologic conditions, increased
iron in LIP will generate an excess of free hydroxyl radicals and induce adverse outcomes
within the cell.
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2-6. Summary
Currently, prevailing information on the toxicity of IONPs suggests potential risk associated
with exposure, including inflammation, fibrosis, genotoxicity, and extra-pulmonary effects, all of
which have been attributed to increased oxidative stress following exposure. The majority of this
literature correlates particle internalization, dissolution, and subsequent release of free iron ions to
be the primary source for these adverse outcomes. Some emerging studies show promise in the
alteration of physicochemical properties of these nanoparticles (particularly surface coating and
functionalization) to help prevent or reduce this toxicity. However, there is still little concurrence
on its actual effectiveness, or the resulting impact on nanoparticle function. Therefore, more
research involving long term in vivo exposure to assess particle distribution, and in vitro work that
utilizes relevant parameters (such as dose, cell type, and relevant end points), must be conducted
to better ascertain the risk associated with IONPs exposure. Furthermore, there is a major
knowledge gap as to which physicochemical alterations could affect bioactivity and toxicity
following exposure, and which ones could be altered to reduce this toxicity. Without this
information, it is exceedingly difficult to make accurate recommendations for safe exposure limits.
Despite this, IONPs continue to be incorporated into consumer products and can be released during
the manufacturing process, or throughout its lifecycle, becoming a source of potential hazard for atrisk workers. Therefore, there is a critical need to better characterize the IONPs toxicity profile, and
to establish more robust in vitro and in vivo toxicity assessment, so as to better assess risk for a wide
range of nanomaterials and to protect at-risk workers.
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Chapter 3: Iron oxide nanoparticle-induced neoplastic-like cell
transformation in vitro is reduced with protective amorphous silica coating.
Chapter Introduction:
The overall goal for this research project was to assess the potential for a specific IONP
(nFe2O3) to induce neoplastic-like adverse outcomes within the context of a physiologically
relevant low dose/long term exposure. This research also showed how the alteration of particle
surface coating, via the addition of an amorphous silica coating, may impact observed adverse
outcomes.
Adapted from: T. Kornberg et al., “Iron oxide nanoparticle-induced neoplastic-like cell
transformation in vitro is reduced with protective amorphous silica coating,” Chemical Research in
Toxicology. Accepted 23 October, 2019.

56 | K o r n b e r g

Iron oxide nanoparticle-induced neoplastic-like cell
transformation in vitro is reduced with protective
amorphous silica coating.
Tiffany G. Kornberg†,§ *, Todd A. Stueckle§, Jayme Coyle§, Raymond Derk§, Philip Demokritou║, Yon
Rojanasakul†, Liying W. Rojanasakul†,§*
†

Department of Pharmaceutical and Pharmacological Sciences, School of Pharmacy, West Virginia
University, Morgantown, WV 26506.

§

Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for
Occupational Safety and Health, Morgantown, WV 26505.
║Center

for Nanotechnology and Nanotoxicology, Department of Environmental Health, T.H. Chan
School of Public Health, Harvard University, Boston, MA 02115

57 | K o r n b e r g

ABSTRACT
Iron oxide nanoparticles (IONP) have recently surged in production and use in a wide variety of
biomedical and environmental applications. However, their potential long-term health effects, including
carcinogenesis, are unknown. Limited research suggests IONP can induce genotoxicity and neoplastic
transformation associated with particle dissolution and release of free iron ions. “Safe by design” strategies
involve the modification of particle physicochemical properties to affect subsequent adverse outcomes,
such as an amorphous silica coating to reduce IONP dissolution and direct interaction with cells. We
hypothesized that long-term exposure to a specific IONP (nFe2O3) would induce neoplastic-like cell
transformation, which could be prevented with an amorphous silica coating (SiO2-nFe2O3). To test this
hypothesis, human bronchial epithelial cells (Beas-2B) were continuously exposed to 0.6 µg/cm2
administered dose of nFe2O3 (~0.58 µg/cm2 delivered dose), SiO2-nFe2O3 (~0.55 µg/cm2 delivered dose),
or gas metal arc mild steel welding fumes (GMA-MS, ~0.58 µg/cm2 delivered dose) for 6.5 months. GMAMS are composed of roughly 80% iron/iron oxide and were recently classified as a total human
carcinogen. Our results showed that low-dose/long-term in vitro exposure to nFe2O3 induced a time
dependent neoplastic-like cell transformation, as indicated by increased cell proliferation and attachment
independent colony formation, and which closely matched that induced by GMA-MS. This transformation
was associated with decreases in intracellular iron, minimal changes in reactive oxygen species (ROS)
production, and the induction of double stranded DNA damage. An amorphous silica-coated but otherwise
identical particle (SiO2-nFe2O3) did not induce this neoplastic-like phenotype or changes in the parameters
mentioned above. Overall, the presented data suggests the carcinogenic potential of long term nFe2O3
exposure and the utility of an amorphous silica coating in “safe by design” hazard reduction strategy,
within the context of a physiologically relevant exposure scenario (low-dose/long-term), with model
validation using GMA-MS.
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3-1. INTRODUCTION
Nano-sized materials, which are specifically engineered to be 100 nm or smaller in at least one
dimension, have emerged as novel solutions to critical issues in areas such as medicine, biotechnology,
and transportation. Of these, iron oxide nanoparticles (IONP) have been investigated as unique
components of MRI imaging techniques
135

133

, and incorporation into thermoplastics

, targeted drug delivery systems

17,136

134

, environmental catalysts

, food products137, and toners for printing equipment

138

.

IONP, as well as many other types of nano-metal oxides, have also grown in interest, production, and
utilization for consumer products including agriculture and food applications

139–141

. This surge may

translate to increased risk of exposure for those involved in particle manufacture and use across its life
cycle. However, potential adverse health outcomes following extended periods of exposure to IONP
remain unclear.
One of the most common routes for human exposure is the inhalation of particulates in the
circulating air, which usually occurs at low doses over long periods of time. This type of exposure can
have distinct adverse outcomes for vulnerable populations. Chronic pulmonary exposure to metal-oxide
particulates has been associated with cancer development in miners, welders, and other types of industrial
workers 142. However, potential cancer-related outcomes induced by IONP, as well as other types of nanometal oxides, remain poorly understood. For IONP, the current standard is to regulate exposure based on
fine sized (100 – 2500 nm6) iron oxide exposure limits, even though evidence suggests that nano-sized
particulates may pose a greater risk with exposure on a per mass basis than their fine-sized counterparts
7,80

.
As a further complication, fine sized iron oxide has an unclear and controversial toxicity profile.

Some researchers suggest this particulate to be essentially benign

34,39,40,74–76

, whereas others associate

exposure with adverse pulmonary outcomes, including increased risk of lung cancer in iron ore miners
33,36,79

. Similarly, IONP-induced adverse health outcomes are also largely unclear. It is known there is

some risk of occupational exposure to IONP

20,21

, with unknown or unreported adverse outcomes. In
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laboratory settings, some researchers report no effect following IONP exposure

93–95

, whereas others

indicate that IONP or IONP-containing materials may induce genotoxicity 30,31,98,143, neoplastic-like cell
transformation 99,144, in vivo tumor formation 145,146, and neurotoxicity 147 .
Gas metal arc welding fumes (GMA) have recently been re-classified as a Group 1 total human
carcinogen 148. GMA generated from mild steel welding (GMA-MS) contain roughly 80% iron/iron oxide
particulates which fall within the nano-size range. GMA-MS exposure is associated with fibrotic lesions
and elevated lung iron levels in humans

81

, as well as lung tumor development

145,146

and lung cancer

progression 149. Although GMA-MS contains largely insoluble iron, it still provides a useful reference for
potential IONP-induced adverse outcomes, particularly those related to the induction or promotion of lung
cancer.
The aims of this study were to assess the potential for IONP to induce neoplastic-like cell
transformation within the context of an occupationally relevant sub-chronic in vitro exposure model (low
dose/long term), and to examine the potential protective qualities of an amorphous silica coating under
these conditions. GMA-MS particles were used as a positive control, as they have been previously shown
to promote carcinogenic outcomes in vivo

145,146

. Particle induced changes in intracellular iron, ROS

production, and DNA damage associated with the cell transformation were also evaluated throughout the
long term exposure.

3-2. EXPERIMENTAL METHODS
3-2a. Particle Generation, Preparation, Characterization, and Dosimetry
nFe2O3, SiO2-nFe2O3, and SiO2 were generated at Harvard University Center for Nanotechnology
and Nanotoxicology (Boston, MA) using the VEGNES-FSP system 150. Briefly, this flame spray pyrolysis
synthesis platform involves the dispersion of organometallic precursors (iron) and their combustion to
form nFe2O3. Immediately following combustion, particles were sprayed with SiO2 vapor to form a nanothin amorphous silica coating

150,151

, before collection on Teflon filters. Particles were then extracted as
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powders for subsequent experiments. Gas metal arc mild steel welding fumes (GMA-MS) were generated
at the Lincoln Electric Co. (St. Louis, MO), and provided by Dr. James M. Antonini from CDC/NIOSH
(Morgantown, WV). These fumes were generated in a fume chamber by a skilled welder, and particulates
were collected on filters for use in this study 152. Aeroxide TiO2 (80:20 anatase/rutile structure, Evonik)
was supplied from the Degussa Corporation (Parsippany, NJ) and provided by Dr. Tina Sager from
CDC/NIOSH (Morgantown, WV)

153

. TiO2 particulates were sieved at a vibration amplitude of 50, and

then filtered three times using Teflon filters (1.18 mm, 250 nm, and 45 nm). Only particles which were
able to pass through all three filters were used for treatments. TiO2 was used as a reference particle control,
as the same particle is the source material for NIST Standard Reference Material for TiO2 154.
Partial particle characterization in pristine powder phase was previously determined as described
for nFe2O3, SiO2-nFe2O3, and SiO2 (dXRD, SSA, and iron/iron oxide content) 150, TiO2 (dXRD)153, and GMAMS (iron/iron oxide content)152. dXRD of GMA-MS was calculated based on representative SEM images.
Particles were suspended in sterilized MilliQ water at a concentration of 1 mg/mL in sterilized glass test
tubes. Particle suspensions were sonicated with a cup horn sonicator (Sonics Vibra Cell, Newton, CT)
based on sonicator efficiency and calculated critical energy needed to generate stable particle
agglomerates (nFe2O3/SiO2-nFe2O3: 242 J/mL, SiO2: 161 J/mL, TiO2: 161 J/mL, GMA-MS: 242 J/mL)
65,155,156

, and were then serially diluted in BEGM for subsequent treatment. Fresh particle stock

suspensions in water were prepared every four weeks and sonicated a maximum of eight consecutive times
in water, with hydrodynamic diameter (dH) in medium determined separately for each sonication.
Hydrodynamic diameter (dH) and zeta potential (ζ) for all particles following suspension in MilliQ
water, sonication, and serial dilution in complete cell culture medium was determined by dynamic light
scattering (DLS, ZetaSizer Nano ZS, Model Zen3600, Malvern, Surrey, United Kingdom) using
previously described methods65,156. Zeta potential was determined using the ZetaSizer Nano Series Dip
Cell (Model Zen1002, Malvern, Surrkey, United Kingdom). For scanning electron microscopy (SEM)
with energy dispersive x-ray (EDX), particles in cell culture medium were further diluted in filtered

61 | K o r n b e r g

distilled water (1:10) and agitated manually to maintain dispersion. Following this, particles were vacuum
filtered onto a polycarbonate filter, which was then mounted on an aluminum stub and sputter coated with
gold palladium. SEM images were taken on a Hitachi S4800 field emission scanning electron microscope
(Hitachi, Tokyo, Japan) at magnifications of 15,000, 25,000, or 50,000X. For transmission electron
microscopy (TEM), one drop of diluted particle sample was placed on a formvar-coated 200 mesh copper
grid and evaporated overnight before imaging on a JEOL 1400 transmission electron microscope (JEOL,
Tokyo, Japan).
Particle release of free iron in H2O, culture medium (BEGM), and phagolysosome-like buffer was
assessed using Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) at CDC/NIOSH
(Cincinnati, OH; calculated limit of quantification: 0.0566 ug/mL). Particles were serially diluted in 1 mL
water, BEGM, or phagolysosome-like buffer (prepared as previously described

157

) at the concentration

of 20 µg/mL, then stored in 37°C incubator to replicate cell culture conditions. Particle-free vehicle
controls were also prepared and stored. 72 hours later, particle suspensions were centrifuged (13,000 rpm
for 10 minutes) and filtered (0.2 µm PTFE, ThermoFisher), and the resulting supernatant was assessed for
soluble iron content via ICP-OES. Percent dissolved particle was calculated based on beginning mass of
particle and mass of detectable soluble iron.
Volume weighted size distribution and effective density of particle suspensions in medium
(calculated as previously described

158

) were incorporated into distorted grid (DG) fate and transport

modeling algorithm in MatLab v.2006b developed at Harvard University 65,66,159 to assess cell deposited
dose metrics as a function of exposure time.

3.2b. Cell Culture and Exposure
Naïve Beas-2B cells (ATCC) were cultured in serum-free BEGM (basal medium with 1%
penicillin/streptomycin, 0.4% bovine pituitary extract, 0.1% hydrocortisone, human epithelial growth
factor, epinephrine, transferrin, insulin, retinoic acid, and triiodothyronine) from Lonza (Walkersville,
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MD) for a minimum of two passages before beginning exposures. Cells were passaged according to the
ATCC guidelines. For acute exposures, Beas-2B were seeded at 10,000 cells per well in a 96-well plate
(Corning). 24 hours post-plating, medium was aspirated out and replaced with specific particle treatments,
or particle-free vehicle control, which were prepared as described above, and serially diluted in BEGM to
appropriate doses. Administered doses ranged from 0.2 µg/cm2 (0.66 µg/mL) to 2.0 µg/cm2 (6.6 µg/mL)
for acute studies, and a sub-toxic dose was selected for sub-chronic treatment based on these results and
previous literature 100.
For sub-chronic exposures, Beas-2B (passage 3) were seeded at 50,000 cells/well in six-well plates
(Corning), with four biological replicates per treatment group, from which at least three biological
replicates were used for any subsequent assay. At 24 hours post-seeding, the medium was aspirated out
and replaced with specific particle treatments, prepared as described above. All particle treatments were
administered at 0.6 µg/cm2 (2.88 µg/mL). Particle-free vehicle exposed cells served as passage controls.
Medium with particle treatments was replaced every three to four days. When cells were approximately
80-90% confluent (roughly once a week), cells were washed, trypsin/EDTA released from plate, and
random selection of cells were re-plated at seeding density of 50,000 cells/well in 75% of total volume.
Particle treatments were added directly to these wells approximately 3 hours later in the remaining 25%
volume. Remainder of cells from each passage/re-plating were used for cell transformation and ROSrelated assays, or frozen back for future studies.

3-2c. Particle Uptake
Beas-2B (passage 3) were seeded at 50,000 cells/well in six-well plates (Corning) and exposed to
specific particle treatment 24 hours later as described above. Medium with particle treatment was replaced
three days later. When cells were 80-90% confluent (one week later), cells were washed, passaged, and
prepared for transmission electron microscopy (TEM) as previously described

160

. Briefly, cells were

suspended in Karnovsky’s fixative and pelleted, then fixative was removed and replaced with 4% agarose.
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After congealment, excess agar was trimmed away and fresh Karnovsky’s fixative was added overnight.
The pellet was rinsed (8% sucrose-0.9% sodium chloride buffer), then osmium teroxide was added. En
bloc staining was done using 1% tannic acid and 0.5% uranyl acetate. The pellet was dehydrated using a
graded series of ethanol, then cells were embedded in epoxy resin and polymerized. Blocks were sectioned
at 70 nm onto 200 mesh copper grids and stained (4% Uranyl Acetate and Reynold’s Lead Citrate).
Imaging was done at 1,500 to 3,000X or 10,000 to 50,000X magnification on a JEOL 1400 transmission
electron microscope (JEOL, Tokyo, Japan).

3-2d. Reactive Oxygen Species Production
For acute (18, 24 hours) and sub-chronic exposures (48, 62, 69, 76, 97, 104, 118, 125, 132, 145,
195 days continuous exposure), treated Beas-2B cells were seeded at 10,000 cells/well in a clear bottom
black 96-well plate (Corning), stained with 10 µM DCF-H and 1 µM Hoescht-33342 (Sigma-Aldrich, St.
Louis, MO), and incubated at 37°C for 30 minutes. Cells were washed once with BEGM, and imaged in
warm PBS at 20X magnification, with 9 image sites per well. Imaging using DAPI and FITC filters were
analyzed using high content screening on an ImageXpress Micro XLS apparatus with MetaXpress v5.3
software (Molecular Devices, San Jose, California). Using the MultiWavelength Application Module in
MetaXpress, minimum/maximum cell diameters and minimum intensity thresholds were used to identify
each nucleus (DAPI) and intracellular ROS (FITC). Masks were applied to positively identify cells for
each imaged site. Only FITC masks containing a nucleus were included in the analysis. Integrated intensity
of fluorescent signal from each cell (evaluated using cell mask) was calculated and averaged for
quantification. 10 µM H2O2 treatment was used as a positive control for ROS detection, and particle only
controls were used to verify there was minimal particle interference (data not shown).
3-2e. Cell Proliferation
Acute and sub-chronic exposures were done at previously indicated time points. Treated Beas-2B
cells were plated at 10,000 cells/well in a 96-well plate with at least four technical replicates per biological
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replicate and treatment group. At appropriate time points, cells were incubated with WST-1 reagent
(Sigma Aldrich, St. Louis, MO) at a 1:10 dilution for two hours, then absorbance at 450 nm was measured
using a spectrophotometer (SpectraMax, Molecular Devices, San Jose, California), according to
manufacturer’s instructions.

3-2f. Attachment Independent Colony Formation
Soft agar colony assay was conducted as previously described 144 at 55, 83, 111, 138, 174, and 202
days of continuous exposure. Briefly, 0.5% w/v agar medium was prepared and plated in six-well plates
(1.25% Difco agar, 15% v/v fetal bovine serum, and growth supplements at concentrations consistent with
complete cell culture medium in 2X MEM). After the base layer was solidified, cells were suspended in
33% agar at 1x104 cells/well and slowly layered onto precast agar in triplicate six-well plates. Plates were
stored in 37°C incubator for 14 days, and colonies were digitally photographed under light microscopy
(1.25X). Five representative pictures from each well were taken, totaling 15 pictures per biological
replicate. Only colonies >50µm in diameter were included in counts, which were done manually using
ImageJ Grid and CellCounter plugins.

3-2g. Intracellular Iron and Lysosome Counts
At select time points during sub-chronic exposure (91, 132, and 202 days), treated cells were
seeded at 10,000 cells per well in a 96-well clear bottomed black plate (Corning). When cells were at least
70% confluent, Beas-2B were fluorescently stained with 1 µM PhenGreen SK, 1 µM Deep Red
LysoTracker, and 1 µM Hoechst 33342. Plates were incubated at 37°C for 30 minutes. Cells were washed
once and imaged in warm Fluorobrite clear DMEM (ThermoFisher) at 20X magnification for intracellular
iron, then 40X magnification for lysosome counts, with 9 imaging sites per well for each. Imaging (DAPI,
FITC, and Cy5 filters) and analysis were done using ImageXpress apparatus and MetaXpress software as
described above. Using this program, individual intracellular lysosomes were identified using
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minimum/maximum diameter masks, counted using the TransFlour HT module, and averaged per cell for
each image site and treatment group. Integrated intensity of PhenGreen fluorescent signal from each cell
was calculated using cell mask and averaged for quantification of intracellular iron. PhenGreen fluorescent
signal from acute intracellular iron studies was measured using Varioskan Lux fluorescent plate reader
(excitation: 492 nm, emission: 517 nm). PhenGreen fluorescent signal is quenched upon binding to free
iron ions. Therefore, inverse of integrated intensity of fluorescent signal was calculated using non-treated
control cell fluorescence as threshold (F0/F), as has been previously described161. Iron specificity of
PhenGreen was assessed using FeSO4 as a positive control, and pyridoxal isonicotinoyl hydrazine (PIH,
Sigma-Aldrich) as an intracellular iron chelation control).

3-2h. γH2AX Assay for DNA damage
Treated Beas-2B cells from sub-chronic exposure (91, 132, and 202 days) were seeded at 10,000
cells per well in a 96-well clear bottomed black plate (Corning). When cells were at least 70% confluent,
the Beas-2B were fixed in 4% paraformaldehyde, permeabilized with 0.25% Triton-X, and then washed
with PBS, all at ambient room temperature. 48 hours later, cells were incubated with 0.5% phosphorylatedγH2AX primary antibody (1:250, Cell Signaling, Danvers, MA) for one hour, washed in PBS, and
fluorescently tagged using AlexaFlour-555 secondary antibody (1:500) and 1µM Hoechst 33342. Imaging
(at 20X magnification) and analysis were performed using the ImageXpress apparatus and MetaXpress
software as described above. Minimum/maximum cell diameters and minimum intensity thresholds were
used to identify each nucleus (DAPI) as described above. Average nuclear intensity of top 3% of nontreated cells was used as threshold for positive or negative scoring of all cell treatments, to determine
percentage of cells with positive γH2AX damage. 10 µM H2O2 treatment was used as a positive control
(data not shown).

3-2i. Statistical Analyses
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Data represents mean ± standard error of the mean (SE) from three or more biological replicates
and four or more technical replicates per biological replicate. Samples were normalized to non-treated
control for each biological replicate, then combined for all figures. Following normalization, samples were
analyzed using a two-way ANOVA with Tukey’s post-hoc test for multiple comparisons to determine
significance. Statistical significance is indicated in each figure as *p < 0.05, **p < 0.01, ***p < 0.001, and
****p<0.0001. All statistical analyses were performed using GraphPad Prism Software (La Jolla, CA).

3-3. RESULTS.
3-3a. Particle Characterization
First, particles were evaluated for agglomerate hydrodynamic diameter and zeta potential
following preparation and sonication in sterilized water, then serial dilution in complete cell culture media
(BEGM), using DLS (Table 3-1). All test particles had roughly similar primary particle diameters (dXRD
ranging from 15-45 nm), and zeta potentials (ranging from -15.63 to -8.84 mV) in BEGM, but with diverse
agglomerate hydrodynamic diameters, ranging from 1114 nm (GMA-MS) to 2570 nm (nFe2O3).
Dispersed particle agglomerates were visualized using TEM (Figure 3-1A) and SEM (Figure 31B). SEM-EDX (Figure 3-1C) indicated an amorphous silica coating on SiO2-nFe2O3, and also showed
that GMA-MS particulates were primarily comprised of insoluble iron and small amounts of other metals.

3-3b. Acute Cytotoxicity Assessment
Next, the acute bio-effect of particle treatments (nFe2O3, SiO2-nFe2O3, GMA-MS, SiO2, and TiO2)
was evaluated. Reactive oxygen species (ROS) production and proliferative capacity were used as basic
indicators of particle-induced changes in cell activity (Figure 3-2). Beas-2B cells were exposed to a range
of administered doses (0.2 – 2.0 µg/cm2) of particle treatments for up to 24 hours, and ROS production
and cell proliferation were assessed. For ROS production, treated Beas-2Bs showed a dose response for
all particle treatments, with the greatest ROS response overall at 18 hours post-exposure (Figure 3-2A).
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2.0 µg/cm2 administered dose of nFe2O3, GMA-MS, and TiO2 all induced significantly elevated ROS
production compared to non-treated controls at 18 hours post-exposure, with GMA-MS and TiO2 exposed
cells retaining this elevated ROS at 24 hours. There was no significant cell death induced by any particle
treatments, and higher doses of SiO2 and the lowest dose of TiO2 induced significantly elevated
proliferation at 24 hours post-exposure (Figure 3-2D). Intracellular iron was evaluated using the
fluorophore PhenGreen SK and iron chelator PIH). In Beas-2B cells, the majority of iron is sequestered,
and not catalytically active. PIH as a chelator, and PhenGreen as a fluorescent marker, actively target
chelatable iron within the cell’s catalytically active labile iron pool

162

, as is indicated with FeSO4

treatment, which was used as a control. There were no significant changes in intracellular iron across
particle treatments at 18- or 24-hours post-exposure (Figure 3-3). Cells exposed to higher doses of GMAMS (0.6 or 2.0 µg/cm2 administered dose) showed a trend of elevated intracellular iron at 24 hours postexposure. Overall, the acute treatment data supported 0.6 µg/cm2 as a sub-toxic dose for sub-chronic
treatment.
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Table 3-1. Colloidal/physicochemical characterization of dispersed nanoparticles after one sonication.a

ENM

dXRD
(nm)

SSA
ζ
(mV), Iron/Iron
Oxide
(m2/g) [measured
Content
pH]
(%)

dH (Z avg., nm)

PDI

ρENM
(g/cm3)

ρEV ( g/cm3)

nFe2O3

19.6

42

-8.63 [7.55]

100

2570

0.43

5.242

1.534

SiO2-nFe2O3

21.3

49

-13 [7.54]

66

1895

0.28

5.242

1.273

SiO2

19

147

-15.63 [7.58]

0

1774

0.16

2.648

1.08

Gas Metal Arc Mild
Steel Welding
Fumes

1545

nd

-10.49 [7.53]

80

5.7

2.362

TiO2

23

nd

4.26

1.391

-8.56 [7.59]

0

1114

2085

0.28
0.17

a

Primary particle size as determined by X Ray diffraction (dXRD), surface area (SSA), hydrodynamic diameter (dH), zeta potentials (ζ), iron/iron
oxide content, polydispersity index (PDI), raw material density (ρENM), and agglomerate effective density (ρEV) of all particle treatments in
complete cell culture media (BEGM). nd: no data.
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Figure 3-1. Representative SEM and TEM images of particle treatments. Particle agglomeration in
complete cell culture medium was visualized using A) transmission electron microscopy (TEM), B)
scanning electron microscopy (SEM), and C) SEM-Energy Dispersive X-Ray Spectroscopy (SEMEDX). For TEM, magnification ranged from 15,000 to 50,000X.
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Figure 3-2. Acute particle-induced changes in ROS production (DCF assay) at A) 18 and B) 24 hours, and WST metabolism at C) 18 and D)
24 hours post-exposure. Doses refer to administered dose. Error bars indicate mean ± SE (n=3). *p<0.05, ****p<0.0001 from non-treated
control (NT).
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Figure 3-3. Acute particle-induced changes in intracellular iron (PhenGreen fluorescence) at A) 18 and
B) 24 hours. Doses refer to administered dose. Error bars indicate mean ± SE (n=4). Cross hatches
indicate addition of 100 µM pyridoxal isonicotinoyl hydrazine (PIH, iron chelator). In Beas-2B cells, the
majority of iron is sequestered, and not catalytically active. PIH as a chelator, and PhenGreen as a
fluorescent marker, actively target chelatable iron within the cell’s catalytically active labile iron pool162,
which is why it had minimal effect on acutely treated Beas-2B, with the exception of FeSO4 treatment.
F0/F: inverse integrated intensity of fluorescent signal. *p<0.05 from same particle treatment without
PIH chelation.
72 | K o r n b e r g

3-3c. Sub-Chronic Cell Transformation
Based on previous in vitro and in vivo research, and results from the above acute experiments, an
administered dose of 0.6 µg/cm2 (2.88 µg/mL) was selected for the sub-chronic exposure. A recent study
by Teeguarden et al. 100 exposed Balb/c mice to a similarly sized iron oxide (Fe3O4) particle via inhalation
at 19.9 mg/m3 over 4 hours (80 mg*h/m3), which is slightly lower than the OSHA permissible exposure
limit (PEL) for fine sized Fe2O3 particles (14 mg/m3 over 8 hours or 112 mg*h/m3). Following the
exposure, target tissue dose in the bronchial region was calculated to be about 1 µg/cm2. Previous research
by our group144 also indicated that at 0.6 µg/cm2 administered dose, nFe2O3 induced a neoplastic-like cell
transformation in primary human small airway epithelial cells. Therefore, in the present study, Beas-2B
cells were exposed to this low dose (0.6 µg/cm2) of nFe2O3, SiO2-nFe2O3, GMA-MS, or particle controls
(TiO2, SiO2) continuously for 6.5 months, and assessed throughout for indications of neoplastic-like cell
transformation, particularly at time points surrounding two, four, and six months. Uncontrolled
dysregulated cell proliferation is a classic hallmark of cancer

163

or

. Therefore, this was used as an initial

indicator of potential cell transformation throughout the exposure period (Figure 3-4). Beginning at 97
days (~3.25 months) of continuous exposure, nFe2O3 exposed cells had a trend of decreased proliferation,
which began to increase at 118 days, as compared to non-treated controls. By 125 days (~4.5 months), the
nFe2O3 exposed cells had almost a two-fold significant increase in proliferation as compared to nontreated control cells. Elevated proliferation was maintained through the rest of the exposure period (6.5
months). GMA-MS exposed cells followed a similar trend for this parameter, with significantly elevated
proliferation (~1.25 fold) by 145 days (~5 months) of exposure, which was maintained through the rest of
the exposure period, as compared to non-treated controls. However, SiO2-nFe2O3 exposed cells had no
significant changes in cell
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proliferation throughout the entire exposure period. TiO2 exposed cells began to exhibit significantly
decreased proliferation at 97 days of continuous exposure, which gradually increased until it became
significantly elevated at 145 days. This elevation was maintained through the rest of the exposure period.
SiO2 exposed cells had significantly elevated cell proliferation at 125 days continuous exposure, which
then returned to be roughly similar to that of non-treated control cells by the end of the exposure period.
Attachment independent colony formation is an indicator of neoplastic-like cell transformation
because abnormal or neoplastic cells can continue to proliferate without attachment to a solid surface164.
This was assessed using soft agar colony formation assay throughout the sub-chronic exposure period
(Figure 3-5). At 55 days (~2 months) of continuous exposure, there were no significant changes in colony
formation across treatment groups. nFe2O3 and GMA-MS exposed cells had a significant increase (1.2
and 1.4 fold) in colony number at 83 days (~2.75 months) post-exposure, which was ablated by 111 days
(~3.7 months). Colony number then became significantly elevated again (1.6 fold) at 138 days (~4.5
months) as compared to non-treated control cells, which was maintained through the remainder of the
exposure period (202 days, ~6.5 months). TiO2 exposed cells had a significant 1.3-fold increase in colony
formation at 111 and 138 days, which then returned to be roughly similar to that of non-treated control
cells by 174 days exposure and remained at baseline levels through the end of the exposure period. SiO2nFe2O3 and SiO2 exposed cells had no significant changes in attachment independent colony formation
throughout the exposure period.
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Figure 3-4. Cell proliferation throughout sub-chronic exposure to 0.6 µg/cm2 administered dose of specific particle treatment (~0.58 µg/cm2
nFe2O3, ~0.54 µg/cm2 SiO2-nFe2O3, ~0.57 µg/cm2 GMA-MS, ~0.24 µg/cm2 SiO2, or ~0.57 µg/cm2 TiO2 delivered dose). There were no
significant changes in activity of non-treated control cells (Figure 3-S1), so fold change as compared to non-treated cells was calculated for
each time point separately. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as compared to non-treated control cells at the same time point.
Error bars indicate mean ± SE (n=4).
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Figure 3-5. Attachment independent colony formation throughout sub-chronic exposure to 0.6 µg/cm2
administered dose of specific particle treatment (~0.58 µg/cm2 nFe2O3, ~0.54 µg/cm2 SiO2-nFe2O3,
~0.57 µg/cm2 GMA-MS, ~0.24 µg/cm2 SiO2, or ~0.57 µg/cm2 TiO2 delivered dose). A) Quantification
of attachment independent colonies followed by representative images of colonies from B) 83 days, C)
138 days, and D) 202 days of continuous exposure. There were no significant changes in the activity of
non-treated control cells (Figure 3-S2), so fold change as compared to non-treated cells was calculated
for each time point separately. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as compared to nontreated control cells at the same time point. Error bars indicate mean ± SE (n=4).
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3-3d. Sub-Chronic Exposure-Induced Changes in Cell Response
Sub-chronically exposed cells were assessed for changes in intracellular iron, lysosome counts,
ROS production, and DNA damage at key points during the sub-chronic exposure period. Intracellular
iron and lysosome counts were evaluated using PhenGreen SK and LysoTracker fluorescent staining and
high content image analysis (Figure 3-6). At all three measured time points (91, 132, and 202 days
continuous exposure), nFe2O3-exposed cells had significantly decreased intracellular iron as compared to
non-treated control cells (~70%, 55%, and 90% of non-treated control cells at 91, 132, and 202 days
continuous exposure, respectively). GMA-MS-exposed cells had significantly decreased intracellular iron
at 91 days continuous exposure only (~70% that of non-treated control cells), then returned to be similar
to non-treated control cells at 132 days, which was maintained through the end of the exposure period.
GMA-MS exposed cells also had significantly fewer average lysosomes per cell than non-treated controls
at 202 days continuous exposure, but all other treatment groups showed no significant changes in this
parameter at this or any other time points measured.
ROS production was also assessed throughout the sub-chronic exposure period (Figure 3-7). At
the first measured time point for this parameter (48 days/1.5 months continuous exposure), all treatment
groups had significantly decreased ROS as compared to non-treated controls. nFe2O3 exposed cells
showed a trend of increased ROS production at 104, 125, and 145 days, which then decreased to become
less than that of production by non-treated control cells by the end of the exposure period. Both GMAMS and SiO2-nFe2O3 exposed cells had slight and sometimes significantly decreased ROS production
throughout the entire sub-chronic exposure period compared to non-treated controls. SiO2 and TiO2
exposed cells had no significant changes in ROS production throughout the exposure period, with the
exception of the first time point measured (48 days).
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Figure 3-6. Intracellular iron and lysosome response during the sub-chronic exposure. A)
Quantification of intracellular iron fluorescent signal, B) representative images of 20X fluorescent
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staining, C) average lysosome count per cell, and D) representative images of 40X fluorescent staining.
Images were taken at key time points during sub-chronic exposure to 0.6 µg/cm2 administered dose of
specific particle treatments (~0.58 µg/cm2 nFe2O3, ~0.54 µg/cm2 SiO2-nFe2O3, ~0.57 µg/cm2 GMA-MS,
~0.24 µg/cm2 SiO2, or ~0.57 µg/cm2 TiO2 delivered dose). For images, blue: nuclear staining; green:
intracellular iron staining, red: lysosome staining. **p<0.01, ***p<0.001, ****p<0.0001 as compared to
non-treated control cells. Error bars: mean ± SE (n=3). F0/F: inverse integrated intensity of fluorescent
signal.
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Figure 3-7. ROS production throughout sub-chronic exposure to 0.6 µg/cm2 administered dose of specific particle treatments (~0.58 µg/cm2
nFe2O3, ~0.54 µg/cm2 SiO2-nFe2O3, ~0.57 µg/cm2 GMA-MS, ~0.24 µg/cm2 SiO2, or ~0.57 µg/cm2 TiO2 delivered dose). There were no
significant changes in ROS production of non-treated control cells (Figure 3-S3), so fold change as compared to non-treated cells was
calculated for each time point separately. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 as compared to non-treated control cells at the same
time point. Error bars indicate mean ± SE (n=4).
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Genomic instability and DNA damage are known to be key events associated with carcinogenesis
165

. There are several types of DNA damage which have been implicated in carcinogenesis adverse

outcome pathways, such as double stranded DNA damage, which is known to have a critical impact on
cell phenotype

166,167

. To assess double stranded DNA damage of the transformed cells, γH2AX

fluorescence was evaluated at key time points during the sub-chronic exposure period (Figure 3-8) as an
indicator of double stranded DNA breaks168. At 132 days (~4.5 months) of continuous exposure, there
were significantly more nFe2O3-exposed cells that were γH2AX positive as compared to SiO2-nFe2O3
treated cells. By 202 days continuous exposure, nFe2O3 exposed cells had significantly elevated γH2AX
as compared to both non-treated and SiO2-nFe2O3 treated cells. GMA-MS cells also showed significant
DNA damage at 202 days continuous exposure as compared to non-treated control cells.

3-3e. Particle Dosimetry
A critical issue with in vitro nanoparticle exposures is the difficulty in ascertaining accurate
dosimetry. Particle agglomeration and settling rate will impact how the known administered dose may
compare to actual delivered dose, while particle uptake may play a key role in the induction of adverse
outcomes. First, previously calculated particle agglomeration (Table 3-1) and measured particle density
were used to calculate particle settling rate. Raw particle density is known to related to effective density
in cell culture medium, and effective density is a key factor in the calculation of in vitro particle deposition
rate 158.
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Figure 3-8. Double stranded DNA damage (p-γH2AX) at key points during sub-chronic exposure to 0.6
µg/cm2 of selected particle treatments (~0.58 µg/cm2 nFe2O3, ~0.54 µg/cm2 SiO2-nFe2O3, ~0.57 µg/cm2
GMA-MS, ~0.24 µg/cm2 SiO2, or ~0.57 µg/cm2 TiO2 delivered dose). A) Quantification of integrated
intensity of fluorescent signals, representative images of fluorescent staining at B) 91 days, C) 132 days,
and D) 202 days continuous exposure. *p<0.05 as compared to non-treated control cells at the same time
point. #p<0.05 as compared to SiO2-nFe2O3 exposed cells at same time point. Error bars indicate mean ±
SE (n=3).
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These values, along with hydrodynamic diameter, were used to model particle deposition (Table 3-S1).
All particles except for SiO2 had greater than 90% particle deposition (average fraction deposited) within
the first 24 hours following treatment, whereas SiO2 had roughly 70% deposition (average fraction
deposited) by 24 hours following exposure (0.6 µg/cm2 administered dose or ~0.42 µg/cm2 delivered
dose). During the sub-chronic exposure period (6.5 months), particle suspensions in water were freshly
prepared every four weeks, and were sonicated before each exposure (every 3-4 days), followed by
dilution in BEGM to 0.6 µg/cm2 administrated dose. With repeated sonications (≤8 times), all particles
decreased in average agglomerate hydrodynamic diameter, but deposition remained >86% (>0.52 µg/cm2
delivered dose for sub-chronic exposures), with the exception of SiO2. For SiO2, agglomerate size and
deposition decreased roughly 7-fold over the course of eight repeated sonications.
Qualitative particle uptake by Beas-2B cells was evaluated using TEM (Figure 3-9) following
one week of continuous exposure, with two consecutive particle treatments. All particle treatments
except SiO2 were clearly shown to be taken up by cells, and were shown encased in membrane bound
organelles which were likely endosomes or phagolysosomes.
Particle dissolution of nFe2O3, GMA-MS, and SiO2-nFe2O3 was assessed in sterilized MilliQ water
(pH 6.40), BEGM (pH 7.46), or a phagolysosome-like buffer (pH 4.55) over 72 hours by ICP-OES (Figure
3-10). In both water and BEGM, SiO2-nFe2O3 had the greatest iron release as compared to other particle
treatments. In phagolysosome-like buffer, GMA-MS had the greatest iron release, while nFe2O3 had the
least. However, overall particle dissolution was relatively minimal, with the maximum dissolution at only
1.2% over 72 hours.
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Figure 3-9. Representative transmission electron microscopy (TEM) images of Beas-2B uptake of
particles following one week of continuous exposure (two consecutive particle treatments). Arrows refer
to location of higher magnification images.
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Figure 3-10. Particle dissolution following 72 hours suspension in sterilized water (pH 6.40), complete
cell culture medium (BEGM, pH 7.46) or phagolysosome-like buffer (pH 4.55) by ICP-OES. Error bars
indicate mean ± SE (n=3). Limit of quantification: 0.0283 µg/mL; Limit of detection: 0.0089 µg/mL,
with a maximum of 1.5% dissolved particle measured over 72 hours.
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3-4. DISCUSSION
Within the context of a sub-chronic in vitro exposure model, the present study showed a particle
type and time dependent neoplastic-like cell transformation.

Long-term exposure to 0.6 µg/cm2

administered dose (~0.58 µg/cm2 delivered dose) of nFe2O3 induced neoplastic-like transformation in
Beas-2B cells beginning at 4-4.5 months, which was associated with decreases in intracellular iron,
minimal changes in ROS production, and significantly elevated cell proliferation, colony formation, and
double stranded DNA damage. The observed response was similar to that of GMA-MS exposed cells (0.6
µg/cm2 administered dose, ~0.57 µg/cm2 delivered dose). Conversely, Beas-2B cells exposed to
amorphous silica coated nFe2O3 particles (SiO2-nFe2O3, 0.6 µg/cm2 administered dose, ~0.54 µg/cm2
delivered dose) did not undergo a neoplastic-like transformation, nor exhibit significant changes in any of
the above measured parameters.
Acute assessment of cytotoxicity and ROS production (Figure 3-2) showed that nFe2O3, GMAMS, and TiO2 exposure induced significantly elevated ROS production at 18 hours, which was maintained
through 24 hours for GMA-MS and TiO2 treatments, at the highest dose used (2.0 µg/cm2). However, this
influx did not have a significant impact on acute cytotoxicity or cell proliferation for nFe2O3 or GMAMS. There were also no significant changes in intracellular iron (Figure 3-2) across particle treatment
groups, although GMA-MS induced a trend of increased intracellular iron at 24 hours post-exposure at
both 0.6 and 2.0 µg/cm2 administered dose.
Based on the presented acute response, and previous cell transformation data

169

, a sub-toxic

administered dose (0.6 µg/cm2) was selected for sub-chronic exposure. This dose was also lower than the
calculated target tissue dose of IONP in the bronchial region of the lung (1 µg/cm2 100) with exposure to
the OSHA PEL (14 mg/m3 over 8 hours). Such occupationally relevant low dose/long term exposure is
more physiologically representative of occupational and environmental exposure conditions as compared
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to a high dose/acute exposure scenario, and may be more likely to contribute to human development of
chronic conditions 170.
Throughout the sub-chronic exposure period, cells were assessed for neoplastic-like
transformation, using cell proliferation (Figure 3-4) and attachment independent colony formation (Figure
3-5) as primary indications. Uncontrolled or dysregulated cell proliferation can indicate some type of
abnormal cell phenotype

171

, while soft agar colony formation assay is the recommended technique by

OECD to assess continued proliferation when cells are plated in non-adherent conditions
hallmark of abnormal or cancer-like phenotype in cells

171

164

, which is a

. Both nFe2O3 and GMA-MS exposed-cells

followed a similar trend of decreased proliferation at roughly 3-3.5 months, which became significantly
elevated by 4.5-5 months, and was maintained through the rest of the 6.5-month exposure period. The
initial lower proliferation observed in the first few months of exposure may have indicated some type of
chronic cell injury or stress, leading to cell adaptation, and ultimately resulting in significantly elevated
proliferation and overall cell transformation by the end of the exposure period. The 4.5-5-month time
point, when elevated cell proliferation was first observed, coincided with significant elevation of
attachment independent colony formation, again indicating particle-induced cell transformation by nFe2O3
and GMA-MS. For nFe2O3 exposure, this trend has been previously reported

144

, and at the time was

suggested to be attributable to chronic particle injury, which may have resulted in chronically stressed
cells and resulting adaptations.
TiO2 exposure induced a similar trend in cell proliferation as GMA-MS and nFe2O3, but without
a sustained neoplastic-like transformation. TiO2 exposed cells also showed increased attachment
independent colony formation at 4.5-5 months, but this effect was gone by the end of the exposure period,
even though cell proliferation remained elevated. This suggested that TiO2 may have the potential to
induce cell transformation, but a more transient kind. This is mirrored in the current literature, which has
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shown TiO2 exposure to be associated with in vitro cytotoxicity 172,173 and in vivo tumorigenesis only at
high doses 174.
nFe2O3 and GMA-MS-induced cell transformation was hypothesized to be reliant on particleinduced changes in intracellular iron, ROS production, and double stranded DNA damage. It is generally
believed that if a particle is engulfed by the cell via phagocytosis or endocytosis, the resulting phagosome
will fuse with a lysosome for degradation. Once in this acidic environment, iron-containing particles may
dissolve and release free iron ions into the cell’s labile iron pool. This increase in catalytically available
iron can participate in the Fenton reaction and generate ROS 107,109, which is known to induce DNA lesions
108

, and may ultimately result in the observed neoplastic-like phenotype predicted with sub-chronic nFe2O3

or GMA-MS exposure. Therefore, this proposed mechanism was evaluated using changes in intracellular
iron, ROS production, and double stranded DNA damage at key points during the sub-chronic exposure
for nFe2O3, SiO2-nFe2O3, or GMA-MS exposed cells, which, to our knowledge, has not been previously
reported for any of these particles. However, our data showed that nFe2O3 and GMA-MS induced
decreased intracellular iron and minimal changes in ROS production, but still induced significant double
stranded DNA damage. Therefore, the observed sub-chronic effects were likely not due to an influx of
intracellular iron, but rather some kind of alternative mechanism. The minimal changes in ROS production
observed by nFe2O3 and GMA-MS exposed cells align with some previous literature, which has shown
human lung adenocarcinoma cells to have minimal oxidative stress response with IONP exposure, even
though the exposure still resulted in increased DNA damage

175

. Cadmium, a heavy metal which is a

known carcinogen, induced decreased oxidative stress 176 and minimal changes in related gene expression
177

with low dose/long term exposure, as well. For cadmium, adaptation and tolerance to oxidative stress

were believed to be critical mechanisms involved in its overall toxicity and carcinogenic capacity

178

.

Arsenic, another heavy metal, was reported to have a similar effect. Arsenic-transformed Beas-2B cells
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exhibited a decrease in ROS generation, which was posited to be responsible for observed increases in
cell growth and colony formation 179.
However, the underlying mechanism of carcinogenic agent-induced cell transformation is not
totally understood. The results presented here, as well as similarly conducted low dose/long term exposure
studies suggest other mechanisms involved in the nFe2O3-induced cell transformation and DNA damage
beyond the hypothesized intracellular iron-ROS-DNA damage pathway, such as direct nanoparticle
surface interaction with exposed cells, cellular uptake efficiency, and intracellular distribution of the
engulfed particles, which we are currently investigating in our lab.
Sub chronic GMA-MS exposure induced a similar response in cells compared to nFe2O3 treatment.
Previous GMA-MS in vivo pulmonary exposure has shown minimal inflammatory or oxidative stress
response, and no changes in iron homeostasis markers
genotoxicity 181 and tumor formation

146

180

, even though long term exposure did induce

. This aligns with the presented in vitro GMA-MS induced cell

transformation, which occurred without direct increases in intracellular iron or ROS production. GMAMS exposed cells also had a decreasing average number of lysosomes per cell over time (Figure 3-6C),
suggesting cellular changes in autophagy, which have been previously shown to act as a protective
mechanism in some types of particle-induced cell transformation 182. Autophagy dysfunction as a potential
underlying mechanism is also under further investigation in our lab.
As was hypothesized, compared to nFe2O3 treatment, SiO2-nFe2O3 exposed cells did not show any
significant changes in cell proliferation or attachment independent colony formation throughout the subchronic exposure period, and also did not exhibit any significant changes in intracellular iron, ROS
production, or DNA damage. This suggested the protective capacity of the amorphous silica coating by
reducing overall cell-interaction with nFe2O3. Many researchers have shown the utility of using a surface
coating to alter particle function 121–123. Previous studies have also shown the potential for an amorphous
silica coating to reduce or postpone inflammatory outcomes in vivo with other types of nano-metal oxides
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183

, but this has not been previously shown for SiO2-nFe2O3 within the context of a low dose/long term in

vitro exposure model, as is presented here. One caveat to this, however, is that the persistence of an
amorphous silica coating is unknown. With the present repeated/continuous exposure model, fresh particle
with intact amorphous silica coating was used for treatment. However, other in vivo studies which utilized
an identical coating on a cerium oxide nanoparticles showed this coating may only last up to ten days in
an animal lung 50.
A complicating factor for in vitro nanotoxicology is the lack of information regarding dosimetry.
In the present study, when able to do so, we evaluated how the known administered dose compared to the
actual delivered dose of test particles. If known administered dose and calculated delivered dose to the
cells vary significantly, this may be able to account for unexpected observed cell response. Particle
characterization was done in the present study via DLS (Table 3-1), SEM-EDX, and TEM (Figures 3-1,
3-9) in conditions that replicated those of exposure. Delivered dose of each particle in complete cell culture
medium (BEGM) was calculated using the Distorted Grid (DG) dosimetry model. Due to the extended
exposure period (6.5 months), particle suspensions in MilliQ water were freshly prepared every four
weeks, and sonicated before each particle treatment (every 3-4 days). This repeated sonication (≤8 times)
affected average agglomerate hydrodynamic diameter for particle treatments. However, regardless of
hydrodynamic diameter, all test particles except amorphous SiO2 had > 86% deposition within the first 24
hours after exposure (Table 3-S1). Previous research has shown that particle settling rates are dependent
on a complex interplay of each particle’s effective density, protein corona formation, and medium
composition and viscosity184. The cell culture medium used in this study (BEGM) was serum-free and had
low density/viscosity. This, combined with the relatively high effective density of the metal-oxide
particles resulted in rapid particle deposition regardless of agglomerate size or number of sonications.
Amorphous SiO2, however, had a much lower effective density, as well as steadily decreasing agglomerate
size with repeated sonications, which resulted in the observed low deposition (≤70% after 24 hours). Cells
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treated with amorphous SiO2 did not receive a similar deposited dose as compared to other particle
treatments; therefore, no definitive conclusions about the potential toxicity of amorphous SiO2 can made
compared to other treatments used in the present study. Information about amorphous SiO2 toxicity can
be inferred from previous research, which has shown the overall benign49,185 or protective183,185–188
qualities of amorphous SiO2, especially when used as a coating for other types of metallic nanoparticles.
Furthermore, in the present study, SiO2 coated nFe2O3 had similar deposition to its uncoated counterpart
(nFe2O3), resulting in the direct contact of cells with amorphous SiO2, but did not induce neoplastic-like
cell transformation, which may further support the potentially protective/benign qualities of amorphous
SiO2. However, this example clearly emphasizes the importance of thorough particle characterization
before exposure begins, to ensure consistent dosing each time.
3-5. CONCLUSIONS
Sub-chronic in vitro exposure to nFe2O3 (~ 0.58 µg/cm2 delivered dose, for 6.5 months) induced a
neoplastic-like cell transformation in human lung bronchial epithelial cells (Beas-2B), as characterized by
elevated cell proliferation, increased attachment independent colony formation, and induction of DNA
damage. An amorphous silica coated but otherwise identical nFe2O3 particle (SiO2-nFe2O3, ~0.54 µg/cm2
delivered dose) had markedly diminished neoplastic-like cell transformation, as indicated by no significant
changes in any of the parameters described above.
GMA-MS sub-chronic exposure (~0.57 µg/cm2 delivered dose) induced a neoplastic-like cell
transformation in Beas-2B cells similar to that induced by nFe2O3 exposure, which was also associated
with the induction of double stranded DNA damage, but overall decreased ROS production and no
significant changes in intracellular iron. Overall, this suggests that ROS may play a limited and not-critical
role in particle-induced neoplastic-like transformation in vitro or carcinogenesis in vivo.
This study provides support for physicochemical property-dependent modes of toxicity for nanometal oxide induced carcinogenic potential, and helps establish “safe by design” hazard reduction
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strategy for emerging nanotechnology. Furthermore, this study gives evidence for the utility of a lowdose/long-term in vitro exposure model to assess risk of cancer-related outcomes for occupationally
relevant nano-metal oxide exposures.
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Supplemental Information:
Table 3-S1: Particle dosimetry with repeated sonications.b
nFe2O3

SiO2-nFe2O3

GMA-MS

SiO2

TiO2

#
dH
Avg.
Avg.
dH
Avg.
Avg.
dH
Avg.
Avg.
dH
Avg.
Avg.
dH
Avg.
Avg.
Sonic. (h, Z Fraction Fraction (h, Z Fraction Fraction (h, Z Fraction Fraction (h, Z Fraction Fraction (h, Z Fraction Fraction
avg.) Dep.
Dep.
avg.) Dep.
Dep.
avg.) Dep.
Dep.
avg.) Dep.
Dep.
avg.) Dep.
Dep.
(2hr)

(24hr)
1895

(2hr)

(24hr)

0.600

0.921

1114

(2hr)

(24hr)

0.712

0.938

1774

(2hr)

(24hr)

0.333

0.704

2085

(2hr)

(24hr)

0.773

0.973

1

2570

0.799

0.979

2

1569 0.774

0.972

1570 0.639

0.939

1239 0.781

0.969

1078 0.174

0.570

2007 0.773

0.973

3

1758 0.785

0.975

1539 0.607

0.927

1119 0.773

0.965

760

0.101

0.451

1309 0.680

0.949

4

1550 0.762

0.969

1311 0.560

0.907

1123 0.763

0.961

590

0.016

0.114

1507 0.712

0.957

5

1541 0.713

0.954

1287 0.571

0.917

1185 0.780

0.969

729

0.031

0.179

1164 0.615

0.927

6

1343 0.701

0.951

1150 0.499

0.884

844

0.714

0.943

555

0.015

0.100

1441 0.782

0.975

7

1428 0.763

0.970

1392 0.601

0.923

1244 0.781

0.970

588

0.017

0.118

1947 0.785

0.976

8

1603 0.766

0.970

1149 0.467

0.865

1047 0.770

0.966

513

0.015

0.096

1440 0.705

0.956

b

Particle size measured using dynamic light scattering (DLS), and incorporated into distorted grid (DG) fate and transport modeling algorithm.
Each repeat sonication was conducted 3-4 days following previous one. Avg: Average. Dep: Deposition. Sonic: sonications.
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Figure 3-S1. Non-treated cell proliferation throughout sub-chronic exposure, using raw absorbance of
WST1 assay as a measurement. There were no significant differences in activity across the exposure
period.
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Figure 3-S2. Attachment independent colony formation of non-treated control cells throughout subchronic exposure, shown in raw colony counts. There were no significant differences in this parameter
throughout the exposure period.
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Figure 3-S3. ROS production of non-treated control cells throughout sub-chronic exposure, shown in
raw fluorescent units. There were no significant changes in this parameter throughout the exposure
period.

97 | K o r n b e r g

Chapter 4: nCeO2 Induces Size Dependent Changes in Inflammation, Fibrotic
Potential, and Hematopoietic Outcomes with In Vivo Pulmonary Exposure.
Chapter Introduction:
The overall goal of this research project was to show how the alteration of size as a
physicochemical property may play a role in nCeO2-induced pulmonary inflammation/fibrosis and
hematopoietic changes. This study was done in the context of an occupationally relevant in vivo
exposure model, with corresponding in vitro studies completed to show the translation and
integration of these two types of techniques.
Adapted from: T. Kornberg, D. Davidson, et al., “nCeO2 Induces Size Dependent Changes in
Inflammation, Fibrotic Potential, and Hematopoietic Outcomes with In Vivo Pulmonary Exposure,”
In Review.
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Abstract:
Nano-sized CeO2 (nCeO2) particles have steadily increased in production and use as glass
polishing agents, diesel additives, and in other applications. However, there is limited information
as to their potential pulmonary toxicity, especially how specific physicochemical properties of
nCeO2 may impact particle-induced adverse outcomes. It has been generally suggested that smaller
particles may induce more toxicity on a per mass basis due to increased surface area, but this has
not been clearly shown with nCeO2. Therefore, the overall goal of this paper was to evaluate
potential size dependent toxicity of nCeO2 using chemically identical particles in an in vivo model
system with an occupationally relevant dose, and further support this work using a comparable in
vitro exposure model. Following oral-pharyngeal aspiration to small (9.5 nm), medium (23.7 nm),
or large (119 nm) nCeO2, male C57BL/6J mice were evaluated for markers of inflammation,
pulmonary fibrosis, and systemic toxicity at days 1, 7, 28, and 84 post exposure. Results from this
study showed that nCeO2 induced a modest size dependent systemic and inflammatory response in
vivo, with small nCeO2 (which had 13 times greater surface area than large nCeO2) causing a more
robust and prolonged response of inflammatory cells and platelet activation, whereas both medium
and large nCeO2 induced a more moderate inflammatory response with increased fibrotic potential.
A limitation of this study, however, is that a majority of mice were shown to have blocked airways
following exposure, likely due to issues with particle dispersion, and may therefore have obscured
further size dependent effects.
The present data suggested that the alteration of a particle physiochemical property, such as
size, may alter nCeO2-induced bio- and toxic- effects. This could be used to inform future “safe by
design” hazard reduction strategy for nCeO2 or other nano-metal oxides, and overall reduce risk for
those who may be exposed.
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4-1. Introduction
Nano-scaled CeO2 (nCeO2) particulates have recently surged in use for a broad range of
applications, including as glass polishing agents189, diesel additives42,43, and for development in
biological and medical fields41. However, despite the influx in production and use of these particles,
there is still very limited toxicity information available. Most evidence suggests that nCeO2 has the
potential to induce functional changes in alveolar macrophages49, resulting in pulmonary
inflammation3 , fibrosis183, and chronic lung injury51, as well as systemic oxidative stress190. For
nCeO2, and other types of nanomaterials, it has been suggested that the alteration of specific
physicochemical properties may be used to alleviate particle-induced toxicity. Some of these
alterations, as part of a “safe by design” hazard reduction strategy, have already been shown to
impact nCeO2-induced toxicity. For example, a nano-thin amorphous silica coating can reduce
adverse outcomes following nCeO2 exposure both in vivo183 and in vitro185, and changes in surface
charge alterations have been shown to affect overall in vitro cytotoxicity as well191.
The physicochemical property of particle size may also play a critical role in particle-induced
toxicity. However, this relationship is poorly understood. Previous studies have suggested that
there may be a size dependent factor in toxicity for other types of nano-metal oxides7 largely due to
differences in surface area with the alteration of size. Some studies have shown that nano-CeO2 has
the potential to induce more severe adverse outcomes than “fine” sized CeO2 particulates (>100
nm)192. However, to our knowledge, there have been no studies which directly study the size
dependent effect of nCeO2 toxicity. Furthermore, while size-based conclusions on nCeO2 could be
assumed by widely surveying nCeO2 literature, these separate studies may not involve chemically
identical – or even similar – nCeO2 particles, thus obscuring any size dependent results.
Therefore, the overall goal of this study was to utilize chemically identical nCeO2 of various
sizes to better demonstrate potential nCeO2 induced size dependent toxicity within the context of a
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physiologically relevant in vivo exposure model. We hypothesized that the small nCeO2 particle
would induce a more robust inflammatory/pro-fibrotic response due to increased surface area as
compared to the medium or large nCeO2 particle. In order to assess this, male C57BL/6J mice were
exposed to low or high dose (7 or 70 µg/mouse) of small (9.5 nm), medium (23.7 nm), or large (119
nm) nCeO2 particles, with ultrafine TiO2 (23 nm) as a reference particle control. Following
pharyngeal aspiration, mice were sacrificed at 1, 7, 28, and 84 days post exposure, and end points
related to pulmonary inflammation, fibrosis, and blood platelet activation were assessed. Finally,
corresponding in vitro doses were used to evaluate markers of pulmonary fibrosis in normal human
lung fibroblasts, to better understand the potential mechanism underlying nCeO2 induced
pulmonary toxicity, and show the utility of an in vitro/in vivo integrated approach.
Results from the present study may lend to a growing body of knowledge as to the significant
role particle physiochemical properties may play in determining adverse outcomes. If these are
better understood, they may be utilized to inform future particle design, and ultimately reduce
severity of particle-induced adverse outcomes.
4-2. Methods
4-2a. In vivo assessment of size dependent CeO2 induced lung inflammation and fibrosis
4-2a.i. Particle generation and characterization:
nCeO2 (small, medium, and large) particles were generated at Harvard University Center for
Nanotechnology and Nanotoxicology (Boston, MA) using the VEGNES-FSP system150 as previously
described. Briefly, the flame spray pyrolysis (FSP) synthesis platform involves the dispersion of
organometallic precursors (cerium) and their combustion to form nCeO2. Particle size was
controlled via changes in the oxygen dispersion flow rate during particle generation193.
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Aeroxide TiO2 (80:20 anatase/rutile structure, Evonik) was supplied from the Degussa
Corporation (Parsippany, NJ) and provided by Dr. Tina Sager from CDC/NIOSH (Morgantown, WV).
TiO2 particles were sieved three times, and only particulates which were able to pass through all
filters (1.18 mm, 250 nm, and 45 nm) were used for treatments.
Particle characterization in pristine powder phase for all three sizes of nCeO2194, and TiO2153
were previously determined as described. For exposures, particles were suspended in sterilized
MilliQ water (pharmaceutical grade) at a concentration of 1 mg/mL in sterilized glass test tubes.
Particle suspensions were sonicated with a cup horn sonicator (Sonics Vibra Cell, Newton, CT)
based on sonicator efficiency and calculated critical energy needed to generate stable particle
agglomerates (CeO2: 242 J/mL, TiO2: 161 J/mL) as previously described65.
Particles were further diluted in MilliQ H2O for animal treatment, or complete Fibroblast
Growth Medium (FGM) for in vitro exposures. Following suspension in MilliQ water, sonication, and
serial dilution in complete cell culture media, hydrodynamic diameter (dH) was determined by
dynamic light scattering (DLS, ZetaSizer Nano ZS, Model Zen3600, Malvern, Surrey, United
Kingdom), and zeta potential (ζ) was determined using the ZetaSizer Nano Series Dip Cell (Model
Zen1002, Malvern, Surrey, United Kingdom).
4-2a.ii. Animal Exposures:
Three-week-old male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were
acclimated for three weeks in group housing before exposures began. Animals were provided
Harlan 7913 irradiated NIH-31 modified 6% feed and water ad libitum. Three mice were housed
per cage in temperature and humidity-controlled environment, and closely monitored for evidence
of fighting or lack of food access. All animal procedures used were reviewed and approved by the
National Institute for Occupational Safety and Health’s Animal Care and Use Committee. All methods
103 | K o r n b e r g

were performed in accordance with the relevant guidelines and regulations by AAALAC, and the
animal quarters used were AAALAC certified.
Six week old mice were anesthetized with isoflurane (Abbott Laboratories, Chicago, IL), then
exposed to low (7 µg/mouse) or high (70 µg/mouse) dose of small, medium, or large nCeO2, or TiO2
(n=12) via oral-pharyngeal aspirations, as previously described195. Sham control mice were dosed
with an equivalent volume of sterilized MilliQ water.
4-2a.iii. Blood platelet number and activity measurement
At 1, 7, 28, and 84 days post exposure, platelet activation was measured using a tail
nick assay, which uses time to clot after tail nick as an indication of platelet activity195.
An aliquot of whole blood was used for blood cell differential analysis using the ProCyte Dx
(IDEXX Laboratories, Westbrook, ME). Remainder of collected blood was centrifuged at 250 x g for
15 min (no brake). “Buffy” coat was collected and centrifuged at 3.2k rpm for 5 min to separate
platelets from platelet-poor plasma. Each fraction was collected, and platelets were lysed with RIPA
lysis buffer (ThermoFisher Scientific, Grand Island, NY), then stored at -80°C.
4-2a.iv. Collection of blood, bronchial alveolar lavage fluid, and lung tissue.
The subset of mice used for the platelet activation studies (n=6) were anesthetized and
euthanized with isoflurane. Immediately following last breath, blood was collected via cardiac
puncture195, with acid citrate-dextrose (ACD) used as an anticoagulant. This blood was processed
and used for blood cell differential analysis as described above.
Following blood collection (exsanguination used as secondary method for euthanasia),
transection of the abdominal aorta was performed, then whole lung was lavaged with cold, sterile,
phosphate buffered saline (PBS, ThermoFisher, Grand Island, NY). First lavage (0.8 mL) was
centrifuged at 1500 rpm for 5 min, and resulting supernatant was used for cytokine analysis. Three
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more lavages were performed, collected, and pooled with first lavage for cell differential analysis.
These bronchial alveolar lavage (BAL) cell pellets were re-suspended in PBS, counted, and fixed via
CytoSpin. Briefly, volume containing 1 x 104 cells from each animal was placed into centrifuge funnel
with glass slides, and spun at 800 x g for 5 min. Slides were air dried, fixed, and then stained using
HEMA 3 Giemsa staining kit (Fisher Scientific, Pittsburgh, PA).
Other subset of mice (n=6) were euthanized via intraperitoneal injection of >100 mg/kg
sodium pentobarbital followed by exsanguination. The left lung lobe was formalin-fixed, paraffin
processed, and embedded. 5 µm sections of lung tissue were prepared for hematoxylin and eosin (H
& E), picosirius red, and masson trichrome staining.
4-2a.v. Evaluation of Lung Inflammation, Injury, and Fibrosis
Collected BAL fluid was used to assess lung inflammation and injury via lactate
dehydrogenase (LDH) activity and inflammatory/pro-fibrotic cytokine profile. LDH activity was
measured using Cytotoxicity Detection Kit (Roche, MontClair, NJ) according to manufacturer’s
instructions.
Cell differentials and macrophage polarization were evaluated using flow cytometry, as
previously described196,197. Briefly, cell suspensions were prepared from BALF fluid, and Fc
receptors were blocked to reduce non-specific binding (CD16/32 antibody in Dulbecco’s phosphate
buffered saline with 5% fetal calf serum and 0.0005% sodium azide). For staining, CD45 was used
to identify leukocytes, which were further differentiated with CD170/Siglec F, CD11c, and Ly6G
staining markers. Macrophage polarization was determined using CD80, CD86, and MHCII staining.
Specific lymphocyte markers used were: CD19 for B cells, and CD3e for T cells. All antibodies
(BioLegend, San Diego, CA) were used per manufacturer’s instructions. After staining, suspensions
were fixed (BD CytoFix) for differential analysis of cell populations. Cell populations were evaluated
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and differentiated using a BD LSRII flow cytometer system (BD Biosciences). Analysis of flow
cytometry data was conducted using FlowJo v 7.6.5 software (Tree Star, Inc., Ashland, OR).
Cytokine profile was measured using custom Luminex cytokine panel (R&D Systems, Minneapolis,
MN) according to manufacturer’s instructions with cytokines: GM-CSF, CXCL-1, TNFα, IL-12p70,
MCP-1, IL-1b, MIP-2, VEGF, IL-6, IL-10, IL-13, MIP-1a, MMP-9, FGF-basic, Eotaxin, Osteopontin,
PDGF, as well as separate total TGFβ cytokine analysis with ELISA assay following manufacturer’s
protocol (R&D Systems). TGFβ was activated using concentrated hydrochloric acid.
Stained H & E slides were evaluated for inflammation and airway damage under polarized
light. Particle penetration and overall acute inflammatory response were evaluated by a trained
veterinary pathologist. Images were taken with an Olympus BX53 microscope and DP73 camera.
4-2b. In Vitro Mechanistic Studies of Size Dependent CeO2 Induced Lung Fibrosis
4-2b.i. Cell culture
Normal primary human lung fibroblasts (NHLF) were obtained from Lonza (Walkersville,
MD) and cultured in complete Fibroblast Growth Medium (FGM), which is composed of Fibroblast
Cell Basal Medium (FBM, Lonza) and all recommended growth supplements (0.1% each of insulin,
hFGF-β, and Gentamicin-1000; FGM-2 BulletKit, Lonza). Cells were cultured and maintained at subconfluent densities in a humidified incubator at 37°C with 5% CO2. For each experiment, cells were
seeded at density of 2.5 x 104 cells per well in a 24 well plate the day before treatments were
performed. Only cells at passage 5-10 were used.
4-2b.ii. Fibroblastic nodule formation and proliferation.
Glass coverslips were treated with poly-L-lysine (0.1 µg/mL), rinsed, and dried. Then, NHLF
were seeded onto the coverslips at a density of 2.5 x 104 cells per well in a 24 well plate, and allowed
to adhere overnight. For treatment, nanoparticles were sonicated as previously described, then
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serial diluted in FGM to the desired concentration (0.056 or 0.56 µg/mL ~ 0.014 or 0.14 µg/cm2).
Fibroblasts were incubated with nanoparticles for 48 hours and fixed in 4% paraformaldehyde and
permeabilized using phosphate buffered saline containing 0.25% Triton-X 100. Non-specific
binding was blocked with 2% normal donkey serum and cells were incubated with primary raised
against collagen I, followed by fluorescently conjugated secondary antibody. Cover slips were then
slowly washed and mounted on glass slides using ProLong Glod Antifade mountant with DAPI.
Fluorescent and brightfield images were captured using a Zeiss Axiovert 100 TV inverted
microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY). For nodule formation, two cover slides
from each culture were analyzed and counted for nodule formation, and data was pooled from three
independent replicates. For fibroblast proliferation, images were analyzed for total cell numbers via
ImageJ software (Bethesda, MD) by counting the total number of DAPI stained nuclei per 10X field.
Four fields were captured per coverslip in duplicate for each of the three independent replicates.
4-2.c. Statistical Analysis.
Data represents mean ± standard error of the mean (SE) from three or more biological replicates and
four or more technical replicates per biological replicate for in vitro studies, and six biological
replicates for the in vivo studies. Samples were normalized to non-treated control for each biological
replicate, then combined for all figures. Following normalization, samples were analyzed using a
two-way ANOVA with Tukey’s post-hoc test for multiple comparisons to determine significance.
When treatment groups had different degrees of variance, a Wilcoxon Chi-squared test was used
instead. Statistical significance is indicated in each figure as *p < 0.05, **p < 0.01, ***p < 0.001, and
****p<0.0001. All statistical analyses were performed using GraphPad Prism Software (La Jolla, CA).
Hierarchical clustering analysis was performed using JMP-SAS Version 13 (Cary, NC).
4-3. Results
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Basic physiochemical properties of all particle treatments were evaluated via BET and XRD
(Table 4-1). The three sizes of nCeO2 particles used, small (9.5 nm), medium (23.7 nm), and large
(119 nm), had surface areas which were inversely proportional to their primary particle size. The
small nCeO2 had the greatest surface area (144 m2/g), which was roughly 13 times greater than that
of large nCeO2 (11 m2/g). TiO2 primary particle size (23 nm) was comparable to that of medium
nCeO2, and therefore likely had similar surface area, although this was not reported. Particle
hydrodynamic diameter in the dosing media used (water) was also evaluated. In water, the small
nCeO2 had the greatest agglomerate size (371.6 nm), whereas the large nCeO2 had the smallest
agglomerate size (218.2 nm). Differences in polydispersity index (PDI) indicated that large nCeO2
had the most homogenous agglomerate population (0.12), whereas the larger agglomerate size
measured with small nCeO2 was relatively heterogenous in the dosing media used (0.5).
Following particle characterization, C57BL/6J mice were exposed to nCeO2 (small, medium,
or large) or TiO2 via oral-pharyngeal aspiration at a dose of 7 or 70 µg/mouse (0.35 or 3.5 mg/kg).
A dose of 7 mg/kg is roughly equivalent to a 40-year occupational exposure to diesel exhaust49, and
previous literature has shown doses as low as 0.15 mg/kg can induce pulmonary inflammation in
rats86. At 1, 7, 28, and 84 days post exposure, platelet activity was measured, then bronchial alveolar
lavage (BAL) fluid was collected and evaluated for markers of lung injury and inflammation.
LDH enzymatic activity was used as an initial indicator of lung injury or damage. There were
no significant changes in LDH activity across treatment groups throughout the exposure period
(Figure 4-1). However, overall LDH activity increased roughly 5-fold from days one through twentyeight to day eighty-four for all treatment groups.
Inflammatory cell infiltration and differentials were used to indicate the specific nature of
particle induced inflammatory response (Figure 4-2). The high dose of both small and medium
nCeO2, as well as the high dose of TiO2, induced significant neutrophil infiltration and decreased
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alveolar macrophages at one day post exposure. For high dose of small nCeO2 and TiO2, the
macrophage response was sustained through seven days, but resolved by 28 days post exposure.
BAL alveolar macrophages were further differentiated based on activity and polarization
(Figure 4-3). CD80 and CD86 are co-stimulatory molecules which, when bound to CD28, are heavily
involved in the regulation of T cell activation for subsequent immune response198. MHC II is also a
marker of macrophage activation, and is essential for both M1 (classically activated) and M2
(alternatively activated) macrophage polarization199.
The high dose of small nCeO2 induced significantly elevated MHC II and CD80 expression at
days 1, 7, and 28 post exposure. Mice exposed to the high dose of nTiO2 had significantly elevated
MHC II and CD80 at one day post exposure, with increased MHC II sustained through seven days.
The high dose of medium nCeO2 induced significantly elevated MCH II at seven days post exposure
only. There were no corresponding changes in CD86 across treatment groups at any time point
measured.
The specific nature of the inflammatory/pro-fibrotic response in the lung was analyzed using
collected BAL fluid to test for a panel of 16 cytokine markers: GM-CSF, CXCL-1, TNFα, IL-12p70,
MCP-1, IL-1b, MIP-2, VEGF, IL-6, IL-10, IL-13, MIP-1a, MMP-9, FGF-basic, Eotaxin, Osteopontin, and
TGFβ (Figure 4-4). The inflammatory cell response to particle exposure involves the release of
specific cytokines and mediators in a highly complex process to initiate and sustain the
inflammation. MIP-1a200 and GM-CSF201 are involved in initial monocyte recruitment and activation
into macrophages. IL-6 is further involved in macrophage activation and phenotype polarization
202,203.

Activated/polarized macrophages and other inflammatory cells will release TNF-α204, which

is an established marker of inflammation. These macrophages may also secrete MIP-2, which
mediates the neutrophil inflammatory response205. CXCL-1 production will stimulate the
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infiltration of neutrophils to the site of injury206, and these activated neutrophils can secrete MMP9 207, which is vital for extracellular matrix remodeling following lung injury208.
The high dose of small nCeO2 induced significantly upregulated MIP-1a, GM-CSF, CXCL-1, and
VEGF, and IL-6 at one day post exposure, with increased MIP-1a, GM-CSF, and CXCL-1 sustained
through seven days, and MIP-1a sustained through 28 days. At seven days post exposure, TNFα,
MIP-2, Osteopontin, TGFβ, and MMP9 were also up-regulated, with the increase in MMP-9 sustained
through 28 days post exposure. There were no significant elevations in any of these cytokines with
the high dose of small nCeO2 by 84 days post exposure.
Low and high doses of medium and large nCeO2, as well as high dose of nTiO2, induced
significantly elevated TGFβ at 28 days post exposure. The low dose of medium nCeO2 also induced
significantly up regulated IL-6 at this same time point. There were no other significant changes in
these parameters at any of the time points measured.
Time to clot was used as a measure of platelet activation (Figure 4-5). All particle treatments
induced significantly reduced bleed times at one- and seven-days post exposure. At day 28, only
mice exposed to the high dose of small nCeO2 or low dose of medium nCeO2 sustained the
significantly reduced bleed times. By day 84, there were no significant changes in bleed times across
treatment groups.
The inflammatory response indicated in the BAL fluid was further evaluated via the physical
characteristics of collected lung tissue (Figure 4-6). Particle penetration into the deep lung and
overall acute inflammatory response were evaluated by a trained veterinary pathologist. The high
dose of all treatment particles induced physical changes in the lung at one day post exposure. On
average, roughly half of treated mice were observed to have particle present in the deep lung, and
many had blocked airways. Other time points were not evaluated for histopathologic changes due
to issues with particle penetration and observed blocked airways of some animals. Histopathology
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slides were also stained with Sirius Red to evaluate collagen as a potential pro-fibrotic marker, but
showed no significant difference between treatment groups across time points (data not shown).
Despite the value of in vivo assessments for potential inflammation and fibrosis, there is a
critical need for more rapid and cost-effective in vitro methods to evaluate these types of end points.
In vitro model systems also allow for a better elucidation of the potential mechanism underlying
particle-induced pulmonary effects, if they can be adequate and predictive of an in vivo response.
Therefore, we translated our in vivo exposure model to a comparable in vitro system, for a better
determination of potential size dependent nCeO2 induction of inflammatory/pro-fibrotic outcomes.
Inhalation of foreign particle may result in direct exposure and stimulation of alveolar
fibroblasts209. Excessive proliferation, nodule formation, and collagen production by these cells may
ultimately induce fibrotic pathology. To assess this in vitro, normal human lung fibroblasts were
exposed to equivalent particle dose as the previous in vivo exposure, and fibroblast nodule
formation and proliferation were evaluated.
Low and high doses of medium and large nCeO2, as well as the low dose of TiO2, induced
significantly elevated fibroblast proliferation, but with no significant changes in nodule formation
(Figure 4-7).
4-4. Discussion
The overall goal of this study was to evaluate size dependent toxicity of nCeO2 on pulmonary
inflammation and systemic platelet response. The physicochemical properties of nCeO2, such as
surface coating or charge, have been previously shown to have an impact on subsequent adverse
outcomes48,183,185. Size, which is inverse of surface area, is generally known to play a role in severity
of particle-induced response for other types of nano-metal oxides7, but this has not been well
characterized for nCeO2. If specific properties, such as size/surface area, were identified which may
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have the greatest impact on nCeO2 toxicity, such information could be used to inform particle design,
and overall reduce risk for those who may be exposed.
All three sizes of nCeO2 used here (small: 9.5 nm, medium: 23.7 nm, large: 119 nm) induced
an inflammatory response; the small sized nCeO2 induced a more robust and prolonged response,
whereas medium and large sized nCeO2 induced a milder response with potential increased profibrotic capacity.
The overall cytotoxic response of three sizes of nCeO2 following in vivo exposure showed no
significant changes in LDH activity (Figure 4-2). However, LDH release is increased roughly fivefold from days 1 through 28 to day 84 post exposure. Previous studies have shown nCeO2 does not
induce a very robust LDH response, especially when particle dispersion is poor210.
Despite the low cytotoxic response, nCeO2 did induce a size dependent inflammatory
response as indicated in collected BAL fluid (Figure 4-3). Small nCeO2 induced acute neutrophil
infiltration, alveolar macrophage mediated inflammation, and platelet activation (Figures 4-3, 4-5).
Exposure to this particle also induced significant elevation of inflammatory cytokines related to
monocyte recruitment and activation (MIP-1a, GM-CSF), activated macrophages (TNFα, MIP-2), and
the infiltration and activation of neutrophils (CXCL-1, MMP-9) (Figure 4-5). This aligned with
previous literature, which has shown that nCeO2 of varying sizes (8-55 nm) can induce a robust
neutrophil response at early time points post exposure51,211,212. Previous research has also shown
the capacity for nCeO2 to induce a chronic pro-inflammatory response51,211,212, as well as elevation
of specific inflammatory markers (IL-12, IL-6, TGFβ) at higher doses213, or other types of
inflammatory markers (TNFα, IL-1β) at lower doses45, all of which aligned with the research
presented here. Clustering analysis of cytokines and treatment groups also revealed the high dose
of small nCeO2 induced a specific and unique inflammatory response at 1- and 7-days post exposure,
as compared to other particle treatment groups or H2O-treated control group.
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Small nCeO2 also induced significant changes in macrophage polarization, as indicated by
changes in markers MHC II and CD80, although these did occur without corresponding changes in
CD86 (Figure 4-4). Previous research has shown CeO2 exposure will activate M1 polarization in
alveolar macrophages49, although typically CD80 and CD86 work in a co-stimulatory manner 214,215,
which was not shown here. This suggested M1 polarization was at least partially induced by small
nCeO2 in a way other than this co-stimulatory mechanism, or that the negative population used to
evaluate CD86 was not sufficient. Small nCeO2-induced inflammatory response was sustained
through 28 days post exposure, and was resolved by 84 days post exposure.
Both the medium and large nCeO2 induced a milder inflammatory response, which was most
apparent at later time points (7 and 28 days). Medium nCeO2 induced significantly elevated MHC II
marker in alveolar macrophages at 7 days post exposure, and an overall influx of these
macrophages, as well as increased IL-6 and TGFβ expression, at 28 days post exposure, all of which
was resolved by 84 days. Although these particles did not induce a very robust inflammatory
response, both doses of medium and large nCeO2 induced significantly elevated fibroblast
proliferation in vitro (Figure 4-7), which is often involved in the development of pulmonary
fibrosis185. CeO2 has been generally considered to be a pro-fibrogenic agent, due to hypothesized
inflammasome activation and production of pro-fibrogenic growth factors 216,217. However, none of
the particle treatments used in the present study induced significant nodule formation, or in vivo
collagen production, both of which are also indications of fibrotic potential. Therefore, it was likely
that the fibrotic potential of medium and large nCeO2, while existent, was very mild in this mouse
model.
TiO2, which was used as a reference particle control, also induced a comparatively robust
inflammatory response, the majority of which was sustained through 7 days post exposure. TiO 2
exposure induced significant increases in expression of MHC II and CD80 macrophage markers one
113 | K o r n b e r g

day post exposure, with MHC II remaining elevated through day 7 (Figure 4-4). However, because
this response was not prolonged, and not coupled with an increase in CD86, this effect was likely
transient and not necessarily indicative of the overall inflammatory response. TiO2 also induced a
TGFβ mediated inflammatory response at 28 days post exposure (Figure 4-5), as well as significant
increase in overall alveolar macrophage number at day 84 (Figure 4-3). TGFβ has been linked to
pro-fibrotic outcomes218, which aligned with presented in vitro results (Figure 4-7), that showed
increased fibrotic potential in TiO2-exposed cells, as indicated by the observed increase in fibroblast
proliferation. Previous literature has associated in vivo TiO2 exposure with mild to moderate
pulmonary fibrosis219, although there have been no clear links with TiO2 exposure and development
of fibrosis in workers220.
Exposure to any treatment group caused significant platelet activation at one- and sevendays post exposure (Figure 4-5). A growing body of research has shown that platelets, which are
typically involved in a clotting response to injury221, may play a critical role in response to
pulmonary exposure to particles222. Macrophages can secrete a platelet activating factor223, which
will activate platelets for inflammatory response. Ultra-fine particles have been shown to enhance
peripheral thrombosis via platelet activation224, as can the rapid translocation of ultra-fine particles
to the circulatory system following pulmonary exposure224,225, for direct interaction between
particle and platelets225. Some recent studies have shown platelet activation may occur in a
nanoparticle-specific way, with pulmonary exposure to carbon-based nanomaterials inducing a
different type or severity of platelet response than nano-metal oxides226. In the present study, we
showed that all particle treatments induced acute platelet activation, and the identification of
specific biomarkers would allow for a less-invasive test to evaluate potential exposure in humans.
The present study showed a clear, albeit modest, size-dependent toxicity of nCeO2 using
chemically identical particles, generated using the Harvard VEGNES-FSP system, which maintains
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chemical structure but alters particle size via changes in oxygen dispersion flow rate227. Size
dependent differences in particle-induced adverse outcomes observed in the present study were
likely related to corresponding changes in surface area and particle deposition. Small nCeO 2 had a
surface area which was roughly 13 times larger than that of the large sized nCeO2 (Table 1). Particle
size/surface area may also affect how and where a particle is deposited in the lung, which can in
turn impact the subsequent response. In fact, surface area has been previously shown to play the
most critical role in severity of particle-induced adverse outcomes228 as compared to other particle
characteristics. Although histopathology showed that all particle exposures induced physical
changes in the lung, only about half of treated mice were observed to have particle present in the
deep lung (Figure 4-6), and a majority of mice were observed to have blocked airways/upper
respiratory tracts. Generally, a critical concern has been particle-size dependent deposition into the
deep lung. Previous studies have shown upper airway deposition of particle is more likely to induce
acute health effects, whereas deep lung particle deposition is more likely to contribute to chronic
adverse health effects, such as fibrosis229.
4-5. Conclusion:
The present results showed a modest size dependent factor to nCeO2 induced pulmonary
inflammation. The small size nCeO2 (9.5 nm), which had a surface area roughly 13 times greater
than that of the largest sized nCeO2 used (119 nm), induced a more robust inflammatory response.
Mice exposed to small nCeO2 had neutrophil infiltration, macrophage activation, and the upregulation of inflammatory and pro-fibrotic cytokines in the lung, which was sustained through 28
days post exposure, while both medium (23.7 nm) and large (119 nm) nCeO2 induced a milder
inflammatory response. However, issues with blocked airways, which was observed for a majority
of exposed animals, may have obscured actual size dependent toxicity of this particle.
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Overall, our results clearly indicate the significant role particle physicochemical properties,
such as size, may play in particle-induced adverse outcomes. If these properties are better
understood, they may be used to inform future particle design, and ultimately protect those who
may be at risk of exposure.
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Table 4-1: Colloidal/physicochemical characterization of dispersed nanoparticles. Primary particle size as determined by X Ray
diffraction (dXRD), surface area (SSA), hydrodynamic diameter (dH), zeta potentials (ζ), iron/iron oxide content, polydispersity index
(PDI), raw material density (ρENM), and agglomerate effective density (ρEV) of all particle treatments in complete cell culture media
(BEGM). nd: no data. dBET for nTiO2 determined previously230.

Small
nCeO2
Medium
nCeO2
Large
nCeO2
TiO2

dXRD (nm)

dBET (nm)

SSA (m2/g)

9.5

13.8

144

23.7

33.6

59

dH (nm,
water)

371.6

PDI
(water)
0.5

180

11

23

29.3

nd

dH (nm,
FGM)

218.2
344.2

0.12
0.46

ζ potential
(mV, FGM)
[pH]

17.4 [6.09]

591.8

32.8 [6.52]

373.2

-9.5 [7.42]
-10.4
[7.42]

12.5 [6.53]
11.8 [7.12]

311.6
448.4

-10.7 [7.5]
-9.3 [7.48]

0.57
274.3

119

ζ potential
(mV,
water)
[pH]

PDI (FGM)

0.64
0.50
0.09
0.41

117 | K o r n b e r g

Figure 4-1: Lactic acid dehydrogenase (LDH) activity measured from bronchioalveolar lavage fluid collected at 1, 7, 28, and 84 days
continuous exposure. Error bars indicate mean ± SE (n=6).
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Figure 4-2: Cell composition/differentials of bronchioalveolar lavage fluid collected at 1, 7, 28, and 84 days post exposure. Error bars
indicate mean ± SE (n=6). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 from H2O Control group at same time point.
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Figure 4-3: Alveolar Macrophage Polarization from bronchioalveolar lavage fluid collected at 1, 7,
28, and 84 days post exposure. Error bars indicate mean ± SE (n=6). *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 from H2O Control group at same time point. Polarization markers used
were: A) MHC II, B) CD80, and C) CD86.
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A.

B.
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C.

D.

Figure 4-4: Cytokine analysis and hierarchical clustering of bronchioalveolar lavage fluid collected at A) 1, B) 7, C) 28, and D) 84 days
post exposure. Blank well indicates values were too low to be detected. TGFβ on Day 1 was too low to be detected for all treatment
groups. *p<0.05 from H2O Control group at same time point (n=6).
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Figure 4-5: Platelet activation with nCeO2 treatment at 1, 7, 28, and 84 days post exposure. Platelet activity was measured using
bleed times/time to clot (upper panel), and platelet counts from collected serum (bottom panel). Error bars indicate mean ± SE (n=6).
*p<0.05, **p<0.01, ***p<0.001 from H2O Control group at same time point.
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Figure 4-6: Representative histopathology images from 70ug dose of A) small CeO2 B) medium
CeO2, C) large CeO2, and D) TiO2 at 1 day post exposure. Particles were observed as golden brown,
within alveolar macrophages. TB: terminal bronchioles, AD: alveolar ducts.
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Figure 4-7: In vitro fibroblast nodule formation and fibroblast proliferation with 0.014 or 0.14
ug/cm2 (comparable doses to in vivo exposure high and low dose). Error bars indicate mean ± SE
(n=6). *p<0.05, **p<0.01, ***p<0.001 from H2O Control group at same time point.
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Chapter 5: Mechanism Underlying IONP-Induced Cell Transformation – Future
Directions and Preliminary Data
5-1. Introduction:
Iron oxide nanoparticles (IONP), which measure 100 nm or less in diameter, have recently
surged in development and use for a wide variety of applications. Their unique paramagnetic
properties at these small sizes allow for utilization in MRI imaging techniques, targeted drug
delivery systems, and as environmental catalysts for waste water cleanup4,16. However, despite
the known risk of exposure for workers involved in their manufacture and production20,21, there is
very little understood about the potential for IONP to induce toxicity. Recent evidence suggests
that IONP have the potential to induce cancer-related adverse outcomes, including genotoxicity
69,98,99,

neoplastic-like cell transformation231, and in vivo tumor formation232.
Our previous research showed that a specific IONP (nFe2O3) could induce a neoplastic-like

cell transformation with low dose/long term exposure, which was ablated with the addition of an
amorphous silica coating. Previous literature suggested the underlying mechanism was likely
related to particle dissolution, iron homeostasis disruption, oxidative stress, and resulting DNA
damage. However, our study showed nFe2O3 exposure induced decreases in intracellular iron and
minimal changes in ROS production, but still caused double stranded DNA damage and increased
attachment independent colony formation. There were also no significant differences in particle
dissolution between the uncoated and coated nFe2O3. However, we still observed a clear reduction
in these adverse outcomes with the amorphous silica coated nFe2O3 particle. Therefore,
alternative mechanisms were likely involved in the observed nFe2O3-induced cell transformation,
which we have done some preliminary investigation into.
nFe2O3-induced cell transformation and response was roughly similar to that induced by
GMA-MS exposure. Welding Fumes, in general, have been recently re-classified as a Group 1
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(known human) carcinogen, and GMA-MS are composed of roughly 80% insoluble iron. In our
study, they served as a positive control for transformation, although there may have a different
mechanism underlying the observed cell changes. The mechanism underlying GMA-MS-induced
cell transformation is also currently unknown. Further exploration of this mechanism may
support previously published GMA-MS studies, as well.
5-2. Preliminary Results and Discussion:
In our previous study, we observed cell transformation at 132 days continuous exposure.
Non-treated, nFe2O3-treated, SiO2-nFe2O3-treated, and GMA-MS-treated cells from this time point
had their RNA isolated and sequenced. Next generation sequencing (NGS), done by ArrayStar, was
used to assess this. NGS allows for a better understanding of the relationship between transcript
changes and observed phenotype, without requiring prior knowledge of which pathways may be
important. NGS is a more robust method than previous techniques, and has a lower false positive
rate than microarrays.
As our previous study revealed discrepancies between the hypothesized mechanism
underlying IONP-induced transformation, and what was actually observed, we wanted to utilize a
technique which would not potential biases in place. Our results were used in conjunction with
existing literature to identify potentially critical pathways which may be involved in this
transformation, as supporting evidence for any likely critical pathways.
mRNA sequencing data, which showed changes in transcript levels, was used in
conjunction with Core Analysis in Ingenuity Pathway Analysis (IPA). IPA compares changes in
differentially expressed genes/transcripts to previously published literature, and matches them to
common pathways and molecular functions.
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In the present study, IPA was used to identify key canonical pathways, critical genes, and
related biomolecular functions, which were up- or down-regulated in nFe2O3 or GMA-MS exposed
cells. First, principle component analysis of the cells sent for RNA sequencing revealed some
differences in gene expression profile between biological replicates (Figure 5-1). This indicated
that each biological replicate of the nFe2O3-transformed cells underwent transformation at
different rates, and that these differences were especially apparent around the 132 day time
point233.
The variability between replicates in some cell activity assays further indicated this
potential, as is shown in our previous data. By the end of the exposure period (202 days
continuous exposure), however, most biological replicates of the same treatment group were
relatively similar in behavior, and therefore were also likely similar in mRNA sequence, although
this has not yet been assessed. The variability observed in cells at 132 days continuous exposure
did not automatically exclude any RNA sequencing results, but it was critical that any
interpretation of potential mechanisms underlying cell transformation were done with this in
mind.
IPA was used to identify canonical pathways which might be critical to IONP- or GMA-MSinduced cell transformation (Table 5-1).
For nFe2O3-exposed cells, some of the most common pathways identified were related to
DNA damage repair (3 instances), as well as methionine degradation, cell junction signaling, and
hypoxia. For GMA-MS exposed cells, DNA damage repair and methionine degradation were also
highlighted as common pathways, as well as EIF2 signaling, PPAR signaling, and mitochondrial
dysfunction. Some of the key genes identified in the top ranked networks (Table 5-2) for nFe2O3exposed cells included: fibronectin, NFkB, Hsp70, and several proteins known to be involved in
cancer development (Akt234, P53235, and Jnk236). GMA-MS-exposed cells also showed changes in
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some of these same key genes (NFkB, Hsp70), as well as other genes also associated with cancer
development (BRCA1237 and ERK1/2238). Changes in these canonical pathways and critical genes
were linked to several potentially critical biomolecular functions (Table 5-3). Both nFe2O3- and
GMA-MS-exposed cells showed changes in canonical pathways and critical genes related to:
cancer, cell death, necrosis, apoptosis, and DNA or protein metabolism. In addition, nFe2O3exposed cells had changes linked to autophagy and nuclear morphology. For the present study, we
used IPA results which matched previously published literature to identify key pathways which
may be important to explore for our initial investigation.
Manipulations in DNA damage repair response and autophagy have both been linked to
carcinogenic outcomes in previous literature165,239. Observed changes in intracellular iron in our
previous study indicated that changes in iron homeostasis, which have also been linked to cancerrelated adverse outcomes240, may also be a critical pathway involved, but is not a fully recognized
function in IPA, and therefore did not show up in the NGS analysis. None of these pathways have
been well-studied with respect to IONP, or within the context of a low dose/long term model. We
studied these potential changes at key points in the cell transformation – during the critical point
of transformation (day 132-145) and the end of the transformation (day 202). Future studies will
also include time points prior to transformation (day 91).
Therefore, we first investigated potential changes or dysfunctionality in DNA damage
repair pathways with sub chronic nFe2O3 or GMA-MS treatment. Changes in this pathway have
been previously implicated in heavy metal-induced cell transformation (chromium241 and
arsenic182), but has not been studied with long term IONP or GMA-MS exposure. Our previous
study showed that both nFe2O3 and GMA-MS induced double stranded DNA breaks but without
corresponding changes in ROS production. Typically, oxidative stress has been suggested as a key
mechanism to induce DNA damage242, but our results indicated alternative pathways may be
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involved in the induction of this. A typical cell response to DNA damage, regardless of its source,
involves the identification and repair of any non-intact DNA. There are three main types of DNA
damage repair: non-homologous end joining, mismatch repair, and homologous recombination243.
For these processes, key protein components of them are: Ku70 (which complexes with Ku80),
MSH2, and Rad51244. nFe2O3 transformed cells had a significant increase in transcripts of MSH2,
and IPA identified increases in both MSH2 and Rad51 for these cells, as well (Table 5-4). Ku70 was
not indicated in the mRNA sequencing results, but was still considered for this study. Although
mRNA and transcript levels may give an idea as to which pathways may be critically important,
protein expression is an even better indicator of these potential changes. Therefore, we assessed
cells at both Day 145 and 202 of continuous exposure to identify potential changes in protein
expression for MSH2, Ku70, or Rad51. Day 145 cells showed no significant changes in protein
expression of MSH2 or Ku70 between treatment groups (Figure 5-2). At 202 days continuous
exposure, there was a trend of decreased expression for both of these proteins in nFe2O3- and
GMA-MS exposed cells as compared to non-treated control cells, but this was also not significant.
Rad51 was not able to be identified using immunoblotting techniques (data not shown).
MSH2 and Ku70 protein expression did not match changes in mRNA transcript levels as
indicated by either ArrayStar or IPA analysis. These discrepancies may have been due to the
difference in exposure time between the RNA collected from cells (132 days) and the cells tested
for protein expression (145 days). However, we also hypothesized that these discrepancies may
actually have been an indication of these proteins (and connected pathways) being dysfunctional,
and therefore would be unable to adequately repair DNA damage.
Cells with dysfunctional DNA damage repair proteins – particularly MSH2 – are known to
be more resistant to cisplatin245. To assess this, cells collected at 145 days continuous exposure
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were treated with cisplatin at a range of doses to assess changes in viability (Figure 5-3). However,
there were no significant differences between treatment groups for this parameter, either.
Even though mRNA sequencing identified DNA damage repair as being a critical
mechanism underlying nFe2O3- and GMA-MS induced transformation, our other preliminary data
did not show a similar trend. Although it is likely that nFe2O3- and GMA-MS exposed cells had
changes in DNA damage repair pathways, either the proteins we tested were not affected by this
treatment, or perturbations in these pathways were corrected by the cell before we could observe
it in the presented experiments. In fact, in our previous study, doubled stranded DNA damage was
not observed until the end of the exposure period. Late/delayed detection of double stranded DNA
damage and perturbations in MSH2 and KU70 expression suggested this damage may be an effect
rather than a cause of the observed nFe2O3-induced cell transformation. These discrepancies
between protein expression and mRNA sequences revealed potential issues with our mRNA
sequencing data, especially that the difficulty in clustering treatment groups prevented us from
using this dataset to identify any kind of trend of important pathway from this data set. The
freeze/thaw cycle undergone by these cells before RNA collection may have also contributed to
this difficulty.
We are continuing to pursue alternative clustering methods which may allow for a more
accurate analysis of mRNA sequences, and in the future could also utilize cells which had not gone
through a freeze/thaw cycle, to correct for these issues.
Based on these issues, however, we opted to expand our preliminary investigation of
potential mechanisms which may underlie nFe2O3-induced cell transformation to those suggested
by previous literature using relevant dose, cell type, and exposure parameters. Although many
researchers suggest that nFe2O3 exposure may induce oxidative stress, which has the potential to
induce DNA damage and impact other pathways related to cancer development, there have also
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been several studies which looked at the potential for IONP or other heavy metal compounds to
impact other pathways which have also been linked to carcinogenesis.
Autophagy was identified by IPA as being significantly decreased in nFe2O3-exposed cells
(Table 5-3), and Beclin1 as a key autophagy protein had decreased transcripts in these cells as
compared to non-treated control cells (Table 5-5). In general, autophagy can serve in either a
protective capacity against tumor development, or can contribute to uncontrolled tumor cell
proliferation246. In non-cancerous cells, autophagy allows for the recycling of
dysfunctional/damage organelles and proteins247. In cancer cells, however, autophagy recycling of
cell components can allow for continued growth by providing metabolites to aid with this248. In
the literature, oxidative stress is known to be a trigger for autophagy249, to potentially reduce
abnormal development of healthy cells. In our study, however, extended nFe2O3 or GMA-MS
exposure actually led to reduced/suppressed ROS production, which may have prevented
autophagic cell cycling in response to chronic cell injury, abnormal cell growth, ultimately leading
to the observed cell transformation. It is also a possibility that increased autophagy may
reduced/suppressed ROS production instead, although the sequence of these events is still
unclear.
Beclin1 protein expression was therefore assessed at key time points during the cell
transformation (Figure 5-4). At 145 days continuous exposure, nFe2O3-exposed cells had a trend
of elevated Beclin1 expression, indicating increased autophagy250, whereas GMA-MS exposed cells
had decreased Beclin1, indicating the inhibition of autophagy. By the end of the exposure period,
however, Beclin1 protein expression had resolved to be similar to that of non-treated passage
control cells for both nFe2O3 and GMA-MS exposed cells. Although the exact role of autophagy in
cancer is somewhat unclear246, it has been shown that changes and/or dysfunction in autophagic
networks can contribute to cancer-related adverse outcomes. The high variability and changes in
133 | K o r n b e r g

Beclin1 observed here suggested autophagic pathways may be critically impacted with long
term/low dose nFe2O3 or GMA-MS exposure. Further exploration into these potential pathways
are still ongoing.
If there was dysfunction in autophagic recycling processes, it may also be likely that
endocytosed particle may have been able to disrupt critical cell processes. Several studies have
shown iron homeostasis disruption to be related to cancer development or other chronic disease
states 251. Even though both the nFe2O3 and GMA-MS particles used to induce cell transformation
were relatively insoluble, it was still likely that direct surface interaction of the endocytosed
particle with key cell receptors or proteins may have disrupted this pathway.
Iron homeostasis is a complex process which involves a highly complex network of ironrelated proteins. However, one of the most common methods to investigate potential changes in
this pathway is to focus on Ferritin, a key iron storage protein. Furthermore, Ferritin was
identified in IPA as being down-regulated in GMA-MS exposed cells (Table 5-6). Therefore, we
evaluated protein expression of ferritin at key time points (Figure 5-5). Our results showed a
trend of increased ferritin expression in IONP-exposed cells, and a trend of decreased ferritin
expression in GMA-MS exposed cells at 145 days continuous exposure, both of which were
resolved by the end of the exposure period. Again, this indicated that changes in iron homeostasis
were likely occurring throughout the exposure period, but that by the end of the exposure period,
chronic cell exposure/injury caused semi-permanent cell adaptation in these parameters. We are
planning future investigations into this pathway, as well.
Overall, our process of investigating the potential mechanism underlying nFe2O3 and GMAMS induced cell transformation revealed both autophagy and iron homeostasis related pathways
to play potentially critical roles in this. However, our preliminary research has been largely
inconclusive, and therefore represents a key area of research which needs to be further explored.
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It is likely that time points prior to the point of transformation may show greater change in
protein expression for these key pathways, as they may have been a cause of the cell
transformation, rather than an effect. Therefore, another key aspect to future studies would be to
incorporate earlier time points.
5-3. Conclusions and Future Directions:
Both nFe2O3 and GMA-MS sub chronic exposure induced a neoplastic-like cell
transformation in Beas-2B cells. However, the mechanism(s) underlying this transformation
remain unclear. RNA sequencing of exposed cells at the pivotal moment of transformation (132
days continuous exposure) indicated alterations in DNA damage repair, autophagy, and iron
homeostasis may play a critical role. Previous literature also suggested these pathways may be
impacted by continuous long-term exposure to iron containing particles. Our preliminary results
showed some trends of changes in protein expression related to iron homeostasis and autophagy,
but these were not conclusive. In the future, we plan to continue investigating these likely critical
pathways, as well as identify additional pathways or networks which may also be critical to IONPor GMA-MS-induced cell transformation.
5-4. Methods:
5-4a. Continuous Exposure:
Naïve Beas-2B cells (ATCC) were cultured in serum-free BEGM (basal medium with 1%
penicillin/streptomycin, 0.4% bovine pituitary extract, 0.1% hydrocortisone, human epithelial
growth factor, epinephrine, transferrin, insulin, retinoic acid, and triiodothyronine) from Lonza
(Walkersville, MD) for a minimum of two passages before beginning exposures. Cells were
passaged according to the ATCC guidelines, as previously described233.
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Beas-2B (passage 3) were seeded at 50,000 cells/well in six-well plates (Corning), with four
biological replicates per treatment group. At 24 hours post-seeding, the medium was aspirated out
and replaced with specific particle treatments, prepared as previously described. All particle
treatments were administered at 0.6 µg/cm2 (2.88 µg/mL). Particle-free vehicle exposed cells
served as passage controls. Medium with particle treatments was replaced every three to four days.
When cells were approximately 80-90% confluent (roughly once a week), cells were washed,
trypsin/EDTA released from plate, and random selection of cells were re-plated at seeding density
of 50,000 cells/well in 75% of total volume. Particle treatments were added directly to these wells
approximately 3 hours later in the remaining 25% volume.
5-4b. RNA collection:
At 132 days continuous exposure, the critical time point for cell-transformation, cells that
were not re-plated were frozen back for future use. Approximately 6 months after collection, these
cells were thawed, passaged a maximum of three times, and had RNA isolated for sequencing. RNA
was isolated using the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. RNA
samples were frozen until sequencing, which was done by ArrayStar. mRNA data was sequenced
using Illumina HiSeq 4000, and gene and transcript levels were calculated using R package
Ballgown, done by ArrayStar (Rockville, MD).
5-4c. RNA sequencing
ArrayStar conducted all NGS mRNA sequencing. Total RNA from each sample sent to
ArrayStar was quantified by them using a NanoDrop ND-1000 instrument. 1-2 µg total RNA was
used to prepare the sequencing library by enriching total RNA with oligo magnetic beads, and
preparing the RNA-seq library using KAPA Stranded RNA-Seq Library Prep Kit (Illumina). The
completed libraries were qualified with Agilent 2100 Bioanalyzer and quantified by absolute
quantification qPCR method. To sequence the libraries on the Illumina HiSeq 4000 instrument, the
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barcoded libraries were mixed, denatured to single stranded DNA in NaOH, captured on Illumina
flow cell, amplified in situ, and subsequently sequenced for 150 cycles for both ends on Illumina
HiSeq instrument.
Image analysis and base calling were performed using Solexa pipeline v1.8 (Off-Line Base
Caller software, v1.8). Sequence quality was examined using the FastQC software. The trimmed
reads were aligned to reference genome using Hisat2 software. The transcript abundances for
each sample was estimated with StringTie, and the FPKM value for gene and transcript level were
calculated with R package Ballgown. The differentially expressed genes and transcripts were
filtered using R package Ballgown. The novel genes and transcripts were predicted from
assembled results by comparing to the reference annotation using StringTie and Ballgown, then
use CPAT to assess the coding potential of those sequences. Principle Component Analysis (PCA)
and correlation analysis were based on gene expression level, Hierarchical Clustering, Gene
Ontology, Pathway analysis, scatter plots and volcano plots were performed with the differentially
expressed genes in R, Python or shell environment for statistical computing and graphics.
Differentially expressed transcripts (1.5 fold cutoff) were uploaded into the Ingenuity
Pathway Analysis program, and key analysis was condensed and presented here. The number of
differentially expressed genes was very low (<10), so transcripts were used for all subsequent IPA
analysis.
5-4d. SimpleWes.
At 145 and 202 days continuous exposure, time points at the mid-point and end of cell
transformation, cells that were not re-plated were frozen back for future use (10% DMSO in 80°C). Approximately 6 months after collection, these cells were thawed, passaged a maximum of
three times, and were lysed for western blots. Cells were lysed in RIPA buffer (Millipore-Sigma)
with 1X protease inhibitors, 1 mM PMSF, and 1 mM sodium orthovonadate (Millipore-Sigma) on
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ice for 10 minutes. Cell scraper was used to agitate lysates, and collect in microcentrifuge tubes.
Lysates were sonicated using a cup horn sonicator for 5 seconds, pelleted at 13,000 x g for 10
minutes (4 °C), and supernatant was collected and stored. Amount of protein was quantified using
BCA assay (Pierce).
Immunoblotting was performed using the ProteinSimple (Wes), a gel filled capillary
system, with total protein used as a loading control for normalization, according to manufacturer’s
instructions. All antibodies used were purchased from Cell Signaling (FTH, MSH2, Ku70, NQO1) or
Novus Biologics (Bcl1, p53, phos-p53).
5-4e. Cisplatin Treatment:
At 145 days continuous exposure, cells that were not re-plated were frozen back for future
use. Approximately 6 months after collection, these cells were thawed, passaged a maximum of
three times, and evaluated for cisplatin resistance. Cells were plated at 10,000 cells/well in a 96
well plate and allowed to attach. 24 hours later, media was aspirated and replaced with appropriate
cisplatin dilution (1.56-50uM, prepared in 0.9% NaCl), and incubated for 24 hours. Following which,
WST reagent was added (1:10) for 2 hours, and absorbance was read on a spectrophotometer
(Absorbance: 450/650 nm).
5-4f. Statistical Analyses
Data represents mean ± SE from three or more biological replicates and four or more
technical replicates per biological replicate. Samples were normalized to non-treated control for
each biological replicate, then combined for all figures. Following normalization, samples were
analyzed using a two-way ANOVA with Tukey’s post-hoc test for multiple comparisons to determine
significance. When treatment groups had different degrees of variance, a Wilcoxon Chi-squared test was
used instead. Statistical significance is indicated in each figure as *p < 0.05, **p < 0.01, ***p < 0.001,
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and ****p<0.0001. All statistical analyses were performed using GraphPad Prism Software (La Jolla,
CA).
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Figure 5-1: Principle Component Analysis (PCA) of day 132 Non-Treated, nFe2O3, SiO2-nFe2O3,
and GMA-MS exposed cells.
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Table 5-1: Top Canonical Pathways as Identified by Ingenuity Pathway Analysis. Z-score:
deviations from standard deviation using bell curve distribution. Only Z scores > 2 or < -2 indicate
activation or inhibition predictions. Ratio: number of genes from dataset in pathway to total
number of genes in pathway.
nFe2O3-Exposed Cells
Ingenuity Canonical Pathways
Hypoxia Signaling in the Cardiovascular System
Mismatch Repair in Eukaryotes
DNA Double-Strand Break Repair by Non-Homologous
End Joining
Protein Ubiquitination Pathway
Colanic Acid Building Blocks Biosynthesis
Germ Cell-Sertoli Cell Junction Signaling
Circadian Rhythm Signaling
Role of BRCA1 in DNA Damage Response
Methionine Degradation I (to Homocysteine)
Role of PKR in Interferon Induction and Antiviral
Response
GMA-MS-Exposed Cells
Ingenuity Canonical Pathways
Mitochondrial Dysfunction
Aryl Hydrocarbon Receptor Signaling
EIF2 Signaling
PPAR Signaling
Role of BRCA1 in DNA Damage Response
Superpathway of Methionine Degradation
Granzyme B Signaling
Hereditary Breast Cancer Signaling
Cell Cycle: G2/M DNA Damage Checkpoint Regulation

-log(p-value)
5.26
4.75
3.72

Ratio
0.133
0.312
0.286

z-score
1.342
0
0

3.57
2.5
2.3
2.2
2.08
1.93
1.91

0.0604
0.214
0.0578
0.118
0.075
0.136
0.0976

0
0
0
0
0.447
0
0

-log(p-value)
3.72
3.51
3.45
3.27
3.21
3.14
2.97
2.89
2.49

Ratio
0.0877
0.0922
0.0769
0.105
0.113
0.162
0.25
0.0833
0.122

z-score
0
0
0
0
0
0
0
0
0
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Table 5-2: Top Ranked Networks and Hub Genes as identified by Ingenuity Pathway Analysis.
Score of 2 indicates p value of 0.001. Focus Molecules indicates number of molecules in pathway
which are up- or down- regulated as compared to non-treated control cells.
nFe2O3-Exposed Cells
Hub Genes

Score

CSNK1E - Casein Kinase I

56

KIF22 - Kinesin-Like Protein 56

Focus
Top Diseases and Functions
Molecules
33
Cell Cycle, Connective Tissue Disorders,
Developmental Disorder
33
Cellular Assembly and Organization, DNA Replication,
Recombination, and Repair, Cell Morphology
30
Post-Translational Modification, Amino Acid
Metabolism, Small Molecule Biochemistry
29
Tissue Morphology, Cellular Assembly and
Organization, Cellular Function and Maintenance
28
Post-Translational Modification, Cellular Assembly
and Organization, Cellular Compromise
28
Cancer, Cardiac Congestive Cardiac Failure,
Cardiovascular Disease

FN1 - Fibronectin

48

Akt

45

NFkB

43

CCT3 – maintains cellular
proteostasis

43

TP53
Histone H3

40
32

27
23

Hsp70

30

22

Jnk

22

18

GMA-MS-Exposed Cells
Hub Genes

Score

NFkB

49

TADA2A - chromatin
organization
PCM1 - centriolar satellite
components
LIMA1 - inhibits cancer cell
invasion
NOP56 - ribonucleo protein

49

BRCA1

Cancer, Gastrointestinal Disease, Hereditary Disorder
Cellular Compromise, Tissue Development, Cellular
Development
Developmental Disorder, Embryonic Development,
Organismal Development
Cell Cycle, Connective Tissue Development and
Function, DNA Replication, Recombination, and
Repair

46

Focus
Top Diseases and Functions
Molecules
32
RNA Post-Transcriptional Modification, Cellular
Compromise, Cardiovascular System Development
and Function
32
RNA Post-Transcriptional Modification, Embryonic
Development, Organismal Development
31
Cell Cycle, Cell Morphology, Auditory Disease

46

31

41

29

41

29

Cellular Assembly and Organization, Cancer,
Gastrointestinal Disease
Cancer, Cell Death and Survival, Organismal Injury
and Abnormalities
Post-Translational Modification, Infectious Diseases,
Antimicrobial Response
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IKBKB - NFkB inhibitor

37

27

Ck2 - Casein Kinase II

35

26

Hsp70

33

25

ERK1/2

31

24

Dermatological Diseases and Conditions,
Immunological Disease, Inflammatory Disease
Cell Cycle, Cellular Assembly and Organization,
Connective Tissue Development and Function
Hereditary Disorder, Neurological Disease,
Organismal Injury and Abnormalities
Developmental Disorder, Hereditary Disorder,
Ophthalmic Disease
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Table 5-3: Top Biomolecular Functions as identified by Ingenuity Pathway Analysis. Z-score:
deviations from standard deviation using bell curve distribution. Top functions/networks were
ranked using p value.
nFe2O3-Exposed Cells
Disease or Molecular Function
Cancer
Cell Death
Cell Assembly/Organization
Apoptosis
Radiosensitivity of cells
Autophagy
Nuclear Morphology
DNA Metabolism
Necrosis

p-Value
9.43E-18
1.25E-06
3.39E-06
3.65E-06
5.34E-06
9.3E-06
1.12E-05
1.21E-05
1.96E-05

Activation z-score
-0.437
1.088
1.195
0.113
-0.447
-1.436
0
-0.586
1.002

# Molecules
455
85
39
127
8
31
17
28
124

GMA-MS-Exposed Cells
Diseases or Functions Annotation
Cancer
Cell Death
RNA Expression
Protein Metabolism
Necrosis
Cell Cycle Progression
Apoptosis
Spindle Apparatus Formation
DNA Damage Response

p-value
7.31E-17
1.15E-08
2.79E-08
3.64E-08
4.35E-08
1.28E-07
1.52E-07
1.55E-07
2.29E-07

Activation z-score
0.603
0.795
0.116
-0.114
1.271
-0.98
0.136
0.243
0

# Molecules
578
216
154
80
174
83
171
15
28
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Table 5-4: Changes in DNA damage repair proteins of nFe2O3-exposed cells (132 days) indicated
by A) MSH2 mRNA transcript levels in nFe2O3 exposed cells (from ArrayStar analysis) and B) IPA
analysis of transcript levels. FPKM: fragments per kilobase million; FC: fold change; Ratio: number
of genes from dataset in pathway to total number of genes in pathway.
A)
MSH2

Non-Treated FPKM
1.3061487

nFe2O3 FPKM
4.8738359

log2FC
3.5676872

p value
0.0364641

B)
MSH2
Rad51

Expr Log Ratio
3.568
1.207

Expr p value
3.65E-.02
4.10E-.02

Table 5-5: Change in autophagy-related protein (Beclin1) transcript levels in nFe2O3-exposed
cells (132 days) as indicated by IPA analysis. Ratio: number of genes from dataset in pathway to
total number of genes in pathway.
Beclin

Expr Log Ratio
-1.055

Expr p value
1.36E-.02

Table 5-6: Change in iron homeostasis-related protein (Ferritin, FTH) transcript levels in GMA-MS
exposed cells (132 days) as indicated by IPA analysis. Ratio: number of genes from dataset in
pathway to total number of genes in pathway.
FTH

Expr Log Ratio
-1.035

Expr p value
2.41E-.02
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Figure 5-2: Expression of DNA damage repair proteins MSH2 and Ku70 at 145 and 202 days
continuous exposure for non-treated, nFe2O3-treated, and GMA-MS-treated Beas-2B. Expression
was normalized to total protein levels. Error bars indicate mean ± SE (n=4).
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Figure 5-3: Percent Viability of sub chronic (145 days exposure) non-treated, nFe2O3-treated, and
GMA-MS-treated Beas-2B cells with 24hr cisplatin exposure (0-50 µM). Error bars indicate mean ±
SE (n=4).
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Figure 5-4: Expression of autophagy protein Beclin1 at 145 and 202 days continuous exposure for
non-treated, nFe2O3-treated, and GMA-MS-treated Beas-2B. Expression was normalized to total
protein levels. Error bars indicate mean ± SE (n=4).

148 | K o r n b e r g

Figure 5-5: Expression of iron storage protein ferritin (FTH) at 145 and 202 days continuous
exposure for non-treated, nFe2O3-treated, and GMA-MS-treated Beas-2B. Expression was
normalized to total protein levels. Error bars indicate mean ± SE (n=4).
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Chapter 6: Conclusions
The overall goal of my dissertation project was to assess toxicity for two nano-metal oxides
(nFe2O3 and nCeO2), which had unclear toxicity profiles, within the context of physiologically
relevant in vitro and in vivo model systems, as well as how the alteration of specific
physicochemical properties which may impact their toxicity. The underlying concept of my work
was to illustrate how the integration of in vivo and in vitro techniques may be used to gain a better
understanding of potential adverse outcomes, while addressing the need for more rapid and costeffective methods to evaluate new and emerging materials with similarly unknown/unclear
toxicity.
To address this, I first conducted a survey of what is known about IONP toxicity based on
the current literature, and how critical issues with assay and model development may obscure
actual IONP-induced adverse outcomes. I then utilized these concepts in a low dose/long term in
vitro exposure model, to look at the impact of nFe2O3 on neoplastic-like cell transformation as a
precursor to cancer-related adverse outcomes, as well as the use of an amorphous silica coating to
alter particle surface chemistry, and how that may affect its toxicity. Through this, I was able to
show nFe2O3 (as well as GMA-MS) could induce a neoplastic-like cell transformation, which
matched recently published in vivo results with nearly identical particles. For this study, I used an
alteration in particle chemistry/surface interaction (an amorphous silica coating) to demonstrate
how changes in this physicochemical property may impact overall toxicity; and the addition of this
coating was able to ablate nearly all nFe2O3- or GMA-MS- induced cell changes. The direct impact
of this study was to show the potential carcinogenic capacity of nFe2O3, the utility of a sub chronic
in vitro study to assess this, and the value of using the known impact of specific physicochemical
property changes to inform particle design and affect overall toxicity.
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Next, I showed size dependent toxicity of nCeO2 using chemically identical particles within
an occupationally relevant in vivo exposure model. Through this study, I demonstrated correlation
between size/surface area with nCeO2-induced pulmonary inflammation and pro-fibrosis. The
initial goal was to match inflammation to fibrosis development in vivo with fibrotic markers in
vitro. However, the minimal pro-fibrotic markers in vivo, likely due to issues with particle
dispersion and blocked airways in exposed animals, may have obscured actual in vitro to in vivo
translational results. Overall, this study shows how the alteration of a different physicochemical
property – size – may have a critical impact on observed adverse outcomes, and that these may
also be used to inform particle design to overall reduce risk for those who may be exposed. The
confounding issues in this particular study – including particle dispersion and penetration
inconsistencies – show the critical need for well informed particle characterization and study
design before particle toxicity assessment.
Finally, I focused on the potential mechanism underlying nFe2O3-induced cell
transformation using GNS sequencing and pathway analysis in conjunction with supporting
literature, to show how properly designed in vitro studies may be used to glean information on
underlying mechanisms of particle-induced toxicity. Our results showed that DNA damage,
autophagy, and iron homeostasis may play critical roles in the observed neoplastic-like cell
transformation, none of which have been well explored in the current literature for either nFe2O3
or GMA-MS. A better understanding of pathways which might impact nFe2O3 or GMA-MS
transformation would allow for more informed study design, and could even lead to the use of
some of these critical pathways as potential biomarkers for worker exposure or likely potential for
cancer-related adverse outcomes.
The key objective of my dissertation work was to clearly show how the better integration
of in vitro and in vivo techniques is critical both for a more clear understanding of particle-induced
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toxicity. A better integration of these techniques could help address the rapid surge in production
and use for new and emerging particles with unknown toxicity profiles, having a critical impact on
future particle toxicity methods. Without clear toxicity assessment methods in place to evaluate
these particles, there is clear risk of exposure for workers and the general population. Better
integration of cell culture and whole animal model-based techniques would allow for better
assessment of particle toxicity at a pace in concordance with the recent surge in production and
use of nanoparticles in general.
For my research, I focused on two chronic disease outcomes – pulmonary fibrosis and
carcinogenesis. Both of these disease outcomes are understudied in the current literature, likely
due to the extended length of time and high resource cost for these types of studies. By
incorporating in vitro screening methods to assess these outcomes, there are clear applications to
utilize this for other types of materials, and overall protect those at risk of development of these
diseases due to recurring/chronic exposure.
As the production and use of new nanomaterials continues to increase, we need better ways to
assess their potential toxicity and protect at risk workers. Current methods take too long, are too
expensive, and may not accurately represent a human response. By better integrating in vitro and
in vivo model systems, we can address these issues. However, this is reliant on the accuracy and
predictiveness of the model systems used, and how those can translate to an animal or human
toxicity response, especially for chronic disease states. Overall, my dissertation shows the critical
nature of careful model design for nanoparticle toxicity studies. Without considering parameters
such as particle agglomeration, deposition, exposure cell type, duration, particle interference, and
others, it is impossible to make conclusions about particle toxicity which are useful to those who
may be at risk of exposure. My dissertation project highlights unique ways in which these issues
can be addressed, as well as additional factors which should be considered in the future. Overall,
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my dissertation project may have a critical impact on the future of nanotoxicology. The better
integration of in vitro and in vivo techniques would allow for more rapid, accurate, and predictive
toxicity testing for new and emerging particles. This would allow researchers to address critical
knowledge gaps in nanoparticle toxicity, while protecting those who may be at risk of exposure to
these materials. Through my dissertation work, I showed the potential for these types of strategies
using two different nano-metal oxides (nCeO2 and nFe2O3) within the context of physiologically
relevant in vitro and in vivo models, and looked at their potential to induce chronic disease
outcomes. The ultimate goal would be to utilize these ideas for materials with unclear/unknown
toxicity profiles, to protect those who may be at risk of exposure, and positively impact
nanoparticle design, development, and use in the workplace.
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